,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,179,1,1,,406777,5578,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
1,248,1,1,,406777,5578,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,330,1,1,,406777,5578,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
3,357,2,1,,11111923,5578,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
4,357,2,1,,11111924,5578,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
5,360,1,3,,857743,5578,Inactive,66360678.0,,,,Glucocerebrosidase,Confirmatory,,
6,361,1,2,,857743,5578,Inactive,285623.0,,,,Pyruvate Kinase,Confirmatory,,
7,368,2,3,,857743,5578,Inactive,4757950.0,994.0,,,Cdc25B Catalytic Domain protein tyrosine phosphatase  HTS,Screening,,
8,373,1,4,,857743,5578,Inactive,38788193.0,1903.0,,,S1P3 Agonist Primary HTS and Confirmation Assays,Screening,,
9,374,2,3,,857743,5578,Inactive,4758204.0,1843.0,,,In vitro Primary HTS Assay for MKP-1,Screening,,
10,377,1,3,,10321479,5578,Inconclusive,42741659.0,5243.0,,,MDR-1,Other,,
11,410,1,5,,11111923,5578,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
12,410,1,5,,11111924,5578,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
13,410,1,5,,11113621,5578,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
14,411,2,1,,857743,5578,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
15,411,2,1,,11111923,5578,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
16,411,2,1,,11111924,5578,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
17,411,2,1,,11113621,5578,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
18,421,1,3,,17389524,5578,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
19,422,1,5,,857743,5578,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
20,422,1,5,,17405825,5578,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
21,425,3,2,,857743,5578,Inactive,16758752.0,116663.0,,IC50,MKP-3 in vitro HTS assay,Confirmatory,,
22,426,1,2,,17389524,5578,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
23,427,1,1,,17389524,5578,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
24,429,1,5,,857743,5578,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
25,429,1,5,,857743,5578,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
26,429,1,5,,17405825,5578,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
27,429,1,5,,17405825,5578,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
28,432,2,4,,857743,5578,Inactive,11024684.0,12044.0,,IC50,HTS discovery of chemical inhibitors of anti-apoptotic protein Bfl-1,Confirmatory,,
29,433,1,1,,17389524,5578,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
30,434,1,2,,17389524,5578,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
31,435,1,2,,17389524,5578,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
32,436,2,1,,857743,5578,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
33,436,2,1,,17405825,5578,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
34,444,1,1,,11111923,5578,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
35,444,1,1,,11111924,5578,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
36,445,3,1,,857743,5578,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
37,445,3,1,,11111923,5578,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
38,445,3,1,,11111924,5578,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
39,445,3,1,,11113621,5578,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
40,445,3,1,,17389524,5578,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
41,446,1,1,,11111923,5578,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
42,446,1,1,,11111924,5578,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
43,447,1,1,,857743,5578,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
44,447,1,1,,11111923,5578,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
45,447,1,1,,11111924,5578,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
46,447,1,1,,11113621,5578,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
47,448,1,2,,857743,5578,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
48,448,1,2,,11111923,5578,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
49,448,1,2,,11111924,5578,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
50,448,1,2,,11113621,5578,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
51,449,1,5,,857743,5578,Inactive,13027636.0,1901.0,,,Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators,Screening,,
52,450,1,2,,11111923,5578,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
53,450,1,2,,11111924,5578,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
54,450,1,2,,11113621,5578,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
55,451,1,2,,11111923,5578,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
56,451,1,2,,11111924,5578,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
57,451,1,2,,11113621,5578,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
58,453,2,2,,857743,5578,Inactive,63102437.0,1508.0,,,Cathepsin B,Screening,,
59,460,2,2,,857743,5578,Inactive,4503155.0,1514.0,,,Cathepsin L,Screening,,
60,463,1,5,,857743,5578,Inactive,,,,,Cell Proliferation & Viability (Cytotoxicity) Primary Assay 60K MLSMR,Screening,,
61,465,1,7,,857743,5578,Inactive,,,,,Primary HTS assay for chemical inhibitors of antigen receptor-induced NF-kappaB activation,Screening,,
62,485,1,8,,857743,5578,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
63,488,2,1,,857743,5578,Inactive,63102437.0,1508.0,,,Cathepsin B compound mixture screening,Screening,,
64,501,2,2,,857743,5578,Inactive,23110962.0,1520.0,,,Cathepsin S,Screening,,
65,518,2,6,,857743,5578,Inactive,116734717.0,249.0,,IC50,TNAP luminescent HTS assay,Confirmatory,,
66,521,2,5,,857743,5578,Inactive,18375660.0,5778.0,,IC50,"HTS Discovery of Chemical Inhibitors of HePTP, a Leukemia Target",Confirmatory,,
67,522,1,2,,857743,5578,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
68,524,1,3,,857743,5578,Inactive,4506055.0,5566.0,,,Primary biochemical high-throughput screening assay for inhibitors of protein kinase A (PKA) activity,Screening,,
69,525,1,3,,857743,5578,Inactive,20070193.0,2516.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1),Screening,,
70,526,1,1,,857743,5578,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
71,526,1,1,,11111923,5578,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
72,526,1,1,,11111924,5578,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
73,526,1,1,,11113621,5578,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
74,530,1,1,,11111923,5578,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
75,530,1,1,,11111924,5578,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
76,530,1,1,,11113621,5578,Inconclusive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
77,530,1,1,,17389524,5578,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
78,538,2,2,,857743,5578,Inactive,4502495.0,716.0,,,Complement factor C1s,Screening,,
79,539,1,2,,857743,5578,Inactive,116077694.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - PMK,Screening,,
80,540,1,1,,17389524,5578,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
81,541,1,1,,17389524,5578,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
82,542,1,1,,17389524,5578,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
83,543,1,1,,17389524,5578,Inconclusive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
84,544,2,1,,17389524,5578,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
85,545,1,1,,17389524,5578,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
86,546,1,1,,17389524,5578,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
87,547,1,4,,17405825,5578,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
88,555,1,2,,857743,5578,Inactive,116516899.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK,Screening,,
89,556,1,3,,857743,5578,Inactive,116076351.0,,,,Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - DPM-DC,Screening,,
90,559,2,2,,857743,5578,Inactive,147728.0,,,,RNA polymerase,Screening,,
91,560,1,2,,857743,5578,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
92,561,1,3,,857743,5578,Inactive,548814.0,6095.0,,,Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA),Screening,,
93,565,1,4,,857743,5578,Inactive,1431733.0,,,,HIV-1 RT-RNase H  MLSCN HTS MH077605,Screening,,
94,567,1,4,,857743,5578,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists,Screening,,
95,568,1,7,,857743,5578,Inactive,5729877.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
96,568,1,7,,857743,5578,Inactive,24234686.0,3312.0,,IC50,High Throughput Screening Assay for Hsc70 Inhibitors,Confirmatory,,
97,570,1,4,,857743,5578,Inactive,4505209.0,4322.0,,,Primary biochemical high-throughput screening assay for inhibitors of Matrix Metalloproteinase 13 (MMP13) activity,Screening,,
98,571,1,4,,857743,5578,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
99,573,1,4,,857743,5578,Active,,,,,Primary Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan Protocol for 384-well HTS,Screening,,
100,574,1,3,,857743,5578,Inactive,112822.0,3354.0,,,Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E),Screening,,
101,577,1,1,,857743,5578,Inactive,11528014.0,912267.0,,,HTS to identify Inhibitors of West Nile Virus NS2bNS3 Proteinase,Screening,,
102,581,2,2,,857743,5578,Inactive,15680217.0,1511.0,,,Cathepsin G,Screening,,
103,583,2,6,,857743,5578,Inactive,123271505.0,,,IC50,High Throughput Screening Assay for Hsp70 Inhibitors,Confirmatory,,
104,584,1,3,,857743,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
105,584,1,3,,11111923,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
106,584,1,3,,11111924,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
107,584,1,3,,11113621,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
108,584,1,3,,17389524,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
109,585,1,4,,857743,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
110,585,1,4,,11111923,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
111,585,1,4,,11111924,5578,Active,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
112,585,1,4,,11113621,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
113,585,1,4,,17389524,5578,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
114,587,1,5,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
115,587,1,5,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
116,587,1,5,,11111924,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
117,588,1,4,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
118,588,1,4,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
119,588,1,4,,11111924,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
120,589,1,3,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
121,589,1,3,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
122,589,1,3,,11111924,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
123,590,1,3,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
124,590,1,3,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
125,590,1,3,,11111924,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
126,591,1,4,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
127,591,1,4,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
128,591,1,4,,11111924,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
129,592,1,6,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
130,592,1,6,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
131,592,1,6,,11111924,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
132,593,1,4,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
133,593,1,4,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
134,593,1,4,,11111924,5578,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
135,594,1,4,,857743,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
136,594,1,4,,11111923,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
137,594,1,4,,11111924,5578,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
138,595,1,3,,857743,5578,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
139,595,1,3,,11111923,5578,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
140,595,1,3,,11111924,5578,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
141,595,1,3,,11113621,5578,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
142,595,1,3,,17389524,5578,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
143,596,1,2,,857743,5578,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
144,596,1,2,,11111923,5578,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
145,596,1,2,,11111924,5578,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
146,596,1,2,,11113621,5578,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
147,596,1,2,,17389524,5578,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
148,597,1,3,,857743,5578,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
149,597,1,3,,11111923,5578,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
150,597,1,3,,11111924,5578,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
151,597,1,3,,11113621,5578,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
152,598,1,4,,857743,5578,Inactive,,,,,Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen,Screening,,
153,602,1,4,,857743,5578,Inactive,,,,,Identification of Molecular Probes that Reverse MRP-Mediated Drug Resistance,Screening,,
154,603,1,2,,857743,5578,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
155,603,1,2,,11111923,5578,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
156,603,1,2,,11111924,5578,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
157,603,1,2,,11113621,5578,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
158,603,1,2,,17389524,5578,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
159,604,1,3,,857743,5578,Inactive,41872583.0,9475.0,,,Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2),Screening,,
160,605,1,2,,857743,5578,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
161,605,1,2,,11111923,5578,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
162,605,1,2,,11111924,5578,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
163,605,1,2,,11113621,5578,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
164,605,1,2,,17389524,5578,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
165,606,1,3,,857743,5578,Inactive,224586929.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
166,606,1,3,,857743,5578,Inactive,301171662.0,26191.0,,,HTS for LYP Inhibitors-an Autoimmunity Target - Primary screen,Confirmatory,,
167,607,1,3,,11111923,5578,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
168,607,1,3,,11111924,5578,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
169,607,1,3,,11113621,5578,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
170,612,1,2,,857743,5578,Inactive,55956923.0,3350.0,,,Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists,Screening,,
171,614,1,6,,857743,5578,Inactive,116734717.0,249.0,,,HTS colorimetric detection of phosphate released in TNAP reaction,Screening,,
172,615,1,6,,857743,5578,Inactive,116734717.0,249.0,,,HTS colorimetric detection of p-nitrophenol released in TNAP reaction,Screening,,
173,617,1,2,,857743,5578,Active,,,,,Antimicrobial Assay for E. coli BW25113 &#8710;tolC::kan - Dose Response,Confirmatory,,
174,618,2,6,,857743,5578,Inactive,6690534.0,4323.0,,EC50,Luminescent HTS for small molecule inhibitors of MT1-MMP transcription,Confirmatory,,
175,619,1,2,,857743,5578,Inactive,21359873.0,5347.0,,,Fluorescence polarization assay for PLK1 inhibitors,Screening,,
176,620,2,5,,857743,5578,Inactive,,,,EC50,Fluorescent HTS Cytotoxicity/Cell viability assay (HT1080 cells),Confirmatory,,
177,626,1,3,,857743,5578,Inactive,,,,,Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist  Primary Screen,Screening,,
178,628,2,4,,857743,5578,Inactive,113121.0,25229.0,,,Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen,Screening,,
179,629,1,3,,857743,5578,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors,Screening,,
180,630,1,1,,857743,5578,Inactive,5174513.0,4088.0,,,HTS of Smad transcription factor inhibitors,Screening,,
181,631,1,4,,857743,5578,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
182,631,1,4,,857743,5578,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
183,633,1,3,,857743,5578,Inactive,10835013.0,2100.0,,,HTS for Estrogen Receptor-beta Coactivator Binding inhibitors,Screening,,
184,635,1,2,,857743,5578,Active,,,,,Antimicrobial Assay for E. coli BW25113 (wild type) mutant pool - DR,Confirmatory,,
185,638,1,3,,857743,5578,Active,,,,,Antimicrobial Assay for E. coli BW25113 (wild type) - DR,Confirmatory,,
186,639,1,2,,857743,5578,Inactive,118764400.0,2099.0,,,HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators,Screening,,
187,640,1,3,,857743,5578,Inactive,224586929.0,26191.0,,,LYP Inhibitors-an Autoimmunity Target - Primary screen,Screening,,
188,640,1,3,,857743,5578,Inactive,301171662.0,26191.0,,,LYP Inhibitors-an Autoimmunity Target - Primary screen,Screening,,
189,641,1,4,,857743,5578,Inactive,,,,,Allosteric Modulators of D1 Receptors: Primary Screen,Screening,,
190,645,1,4,,857743,5578,Inactive,,,,,Isolation of Inhibitors of Her-Kinase Expression - 66K library screen,Screening,,
191,648,1,3,,857743,5578,Inactive,,,,,Human Endothelial Cell Proliferation Assay in 384-well format,Screening,,
192,654,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
193,655,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
194,656,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
195,657,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
196,658,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
197,659,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
198,660,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
199,661,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
200,662,1,1,,857743,5578,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
201,662,1,1,,11111923,5578,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
202,662,1,1,,11111924,5578,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
203,662,1,1,,11113621,5578,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
204,662,1,1,,17389524,5578,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
205,663,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
206,664,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
207,665,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
208,666,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
209,667,1,1,,17389524,5578,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
210,680,1,10,,857743,5578,Inactive,180352.0,,,,Factor XIa Mixture HTS,Screening,,
211,684,1,12,,857743,5578,Inactive,317373446.0,2161.0,,,Factor XIIa Mixture HTS,Screening,,
212,685,1,3,,857743,5578,Inactive,,,,,Yeast Toxicity Assay.,Screening,,
213,688,1,4,,857743,5578,Inactive,6320417.0,851797.0,,,Yeast eIF2B assay,Screening,,
214,690,1,5,,857743,5578,Inactive,157266296.0,251.0,,IC50,Luminescent assay for HTS discovery of chemical inhibitors of placental alkaline phosphatase,Confirmatory,,
215,693,1,1,,857743,5578,Inactive,21359873.0,5347.0,,,High throughput fluorescence polarization-based assay to screen for small molecule inhibitors of the Polo box domain (PBD) of Plk1.,Screening,,
216,694,1,1,,17405825,5578,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
217,696,1,4,,857743,5578,Inactive,157266296.0,251.0,,IC50,Luminescent assay for HTS discovery of chemical activators of placental alkaline phosphatase,Confirmatory,,
218,697,1,3,,857743,5578,Inactive,224586929.0,26191.0,,,LYP Activators-an Autoimmunity Target - Primary screen,Screening,,
219,697,1,3,,857743,5578,Inactive,301171662.0,26191.0,,,LYP Activators-an Autoimmunity Target - Primary screen,Screening,,
220,704,1,5,,857743,5578,Inactive,253722402.0,,,,Primary biochemical high-throughput screening assay for inhibitors of the HIV Rev RRE RNA interaction (disruption of protein-RNA interaction),Screening,,
221,707,1,1,,857743,5578,Inactive,27597073.0,2053.0,,,Novel sEH inhibitors for the therapeutic treatment of hypertension and inflammation,Screening,,
222,708,1,4,,857743,5578,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Absorbance at 340 nm,Screening,,
223,709,1,2,,857743,5578,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm,Screening,,
224,710,1,2,,857743,5578,Active,,,,,Antimicrobial HTS Assay for E. coli BW25113 (wild type) - Expanded Screen,Screening,,
225,717,1,1,,857743,5578,Inactive,27597073.0,2053.0,,,Novel sEH activators for the therapeutic treatment of hypertension and inflammation,Screening,,
226,719,1,3,,857743,5578,Inactive,,,,,Human Lung Fibroblast Proliferation Assay,Screening,,
227,720,1,2,,857743,5578,Inactive,19860819.0,2050.0,,,Primary biochemical high-throughput screening assay for antagonists of the interaction between the Eph receptor B4 (EphB4) and its ligand ephrin-B2 via TNYL-RAW peptide probe,Screening,,
228,727,1,2,,857743,5578,Inactive,3183518.0,5747.0,,,Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK),Screening,,
229,729,1,5,,857743,5578,Inactive,134244587.0,9294.0,,,Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2),Screening,,
230,731,1,5,,857743,5578,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
231,731,1,5,,857743,5578,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
232,732,1,2,,17405825,5578,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
233,736,1,2,,857743,5578,Inactive,134244587.0,9294.0,,,Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2),Screening,,
234,738,1,4,,857743,5578,Inactive,,,,,"Screening for Modulators of Post-Golgi Transport, Control Strain",Screening,,
235,739,1,4,,857743,5578,Inactive,,,,,Modulators of Post-Golgi Transport,Screening,,
236,740,1,2,,857743,5578,Inactive,,,,,Inhibitors of Highly Pathogenic Avian Influenza (H5N1) Infection,Screening,,
237,746,1,1,,857743,5578,Inactive,2507196.0,5602.0,,,Primary biochemical high-throughput screening assay for inhibitors of the c-Jun N-Terminal Kinase 3 (JNK3),Screening,,
238,748,2,5,,857743,5578,Inactive,27894344.0,3164.0,,IC50,High Throughput Fluorescence Polarization Screen for Bcl-B Phenotype Converters,Confirmatory,,
239,750,1,3,,857743,5578,Inactive,,,,,Luminescent HTS for small molecule activators of MT1-MMP transcription,Screening,,
240,757,1,4,,857743,5578,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype,Screening,,
241,758,1,4,,857743,5578,Inactive,164058.0,404007.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab7 wildtype,Screening,,
242,759,1,4,,857743,5578,Inactive,190938.0,3265.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype,Screening,,
243,760,1,4,,857743,5578,Inactive,46577642.0,404009.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rab2 wildtype,Screening,,
244,761,1,4,,857743,5578,Inactive,56202836.0,,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Cdc42 wildtype,Screening,,
245,764,1,4,,857743,5578,Inactive,8574038.0,5879.0,,,HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant,Screening,,
246,774,1,2,,857743,5578,Inactive,,,,,Profiling the NIH Molecular Libraries Small Molecule Repository: Inhibition of Enzymes Frequently Used to reach a NAD/NADH Endpoint,Other,,
247,775,1,3,,857743,5578,Inactive,,,,,Screen for Chemicals that Extend Yeast Lifespan,Screening,,
248,777,1,4,,857743,5578,Inactive,13699818.0,1559.0,,,CYP2C9 Assay,Screening,,
249,778,1,3,,857743,5578,Inactive,4503219.0,1557.0,,,CYP2C19 Assay,Screening,,
250,781,1,1,,857743,5578,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
251,782,1,2,,857743,5578,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
252,782,1,2,,857743,5578,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
253,793,1,2,,857743,5578,Inactive,4505447.0,4887.0,,,Primary cell based high-throughput screening assay for antagonists of neuropeptide Y receptor Y2 (NPY-Y2),Screening,,
254,796,1,2,,857743,5578,Inactive,,,,,IL-1B Induced NFkB Translocation - Primary Screen,Screening,,
255,797,1,1,,857743,5578,Inactive,115529463.0,5587.0,,,Fluorescence polarization assay for PKD inhibitors,Screening,,
256,798,2,12,,857743,5578,Inactive,180352.0,,,,Factor XIa 1536 HTS,Screening,,
257,799,1,5,,857743,5578,Inactive,134142337.0,4363.0,,,Identification of Molecular Probes that Activate MRP-1,Screening,,
258,800,2,11,,857743,5578,Inactive,317373446.0,2161.0,,,Factor XIIa 1536 HTS,Screening,,
259,802,1,3,,857743,5578,Inactive,,,,,Primary HTS assay for chemical inhibitors of TNF alpha stimulated VCAM1 expression,Screening,,
260,803,1,4,,857743,5578,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify agonists of Galanin Receptor 2 (GALR2),Screening,,
261,804,1,3,,857743,5578,Inactive,,,,,Screen for Chemicals that Shorten Yeast Lifespan,Screening,,
262,808,1,3,,857743,5578,Inactive,,,,,Primary HTS assay for chemical potentiators of TNFalpha stimulated VCAM1 expression,Screening,,
263,813,1,4,,857743,5578,Inactive,116734717.0,249.0,,,HTS identification of compounds activating TNAP at intermediate concentration of phosphate acceptor detected in luminescent assay,Screening,,
264,817,1,1,,857743,5578,Inactive,1360328.0,,,,Identification and characterization of compounds for addressing human bone marrow failure,Other,,
265,818,1,2,,857743,5578,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression,Screening,,
266,819,1,2,,857743,5578,Inactive,,,,,Primary HTS assay for chemical potentiators of IL-1B stimulated NFkB nuclear translocation,Screening,,
267,827,1,2,,857743,5578,Inactive,,,,,High Throughput Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor,Screening,,
268,828,1,5,,857743,5578,Inactive,6016094.0,8811.0,,,Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2),Screening,,
269,834,1,3,,857743,5578,Inactive,,,,,C. albicans biofilm killing,Screening,,
270,836,1,1,,857743,5578,Inactive,,,,,Primary HTS assay for chemical modifiers of cytoskeleton assembly,Screening,,
271,841,1,1,,857743,5578,Inactive,,,,,Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library),Screening,,
272,845,1,2,,857743,5578,Inactive,,,,,Primary HTS assay to asses cytotoxicity for IL-1B stimulated NFkB expression.,Other,,
273,847,1,2,,857743,5578,Inactive,,,,,Human SK-BR-3 Breast Tumor Cell Growth Inhibition In a 24- Hour Assay,Screening,,
274,848,1,1,,857743,5578,Inactive,4507875.0,7412.0,,,Primary HTS assay during TNFalpha stimulated VCAM1 expression to assess cytotoxicity.,Other,,
275,853,1,2,,857743,5578,Inactive,296434520.0,3064.0,,,Primary HTS for Clearance of Mutant Huntintin Protein.,Screening,,
276,861,1,1,,857743,5578,Inactive,55662034.0,,,,Primary cell-based high-throughput screening assay for inhibitors of TLR4-MyD88 binding,Screening,,
277,862,1,2,,857743,5578,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 inhibition,Screening,,
278,868,1,3,,857743,5578,Inactive,,,,,Screen for Chemicals that Inhibit the RAM Network,Screening,,
279,871,1,2,,857743,5578,Inactive,13272532.0,6774.0,,,Primary cell-based high throughput screening assay to measure STAT3 activation,Screening,,
280,873,1,13,,857743,5578,Inactive,6912644.0,25818.0,,,Kallikrein 5 1536 HTS,Screening,,
281,875,1,2,,857743,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
282,875,1,2,,11111924,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
283,875,1,2,,11113621,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
284,875,1,2,,17389524,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
285,878,1,2,,857743,5578,Inactive,,,,,NIH Compound Library Profiling: Compound and DTT Dependent Redox Cycling H2O2 Generation.,Screening,,
286,879,1,2,,17389524,5578,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
287,879,1,2,,17389524,5578,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
288,880,2,1,,857743,5578,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
289,880,2,1,,857743,5578,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
290,880,2,1,,11111924,5578,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
291,880,2,1,,11111924,5578,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
292,880,2,1,,11113621,5578,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
293,880,2,1,,11113621,5578,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
294,880,2,1,,17389524,5578,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
295,880,2,1,,17389524,5578,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
296,880,2,1,,26747124,5578,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
297,880,2,1,,26747124,5578,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
298,880,2,1,,26751820,5578,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
299,880,2,1,,26751820,5578,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
300,880,2,1,,50104512,5578,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
301,880,2,1,,50104512,5578,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
302,881,2,2,,857743,5578,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
303,881,2,2,,11111924,5578,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
304,881,2,2,,11113621,5578,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
305,881,2,2,,17389524,5578,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
306,881,2,2,,26751820,5578,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
307,883,1,3,,11111923,5578,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
308,883,1,3,,11111924,5578,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
309,883,1,3,,11113621,5578,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
310,884,1,2,,11111924,5578,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
311,884,1,2,,11113621,5578,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
312,884,1,2,,17389524,5578,Active,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
313,885,1,2,,11111924,5578,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
314,885,1,2,,11113621,5578,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
315,885,1,2,,17389524,5578,Inactive,13435386.0,1576.0,12.5893,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
316,886,1,2,,857743,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
317,886,1,2,,857743,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
318,886,1,2,,11111923,5578,Inconclusive,122921310.0,,0.0063,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
319,886,1,2,,11111923,5578,Inconclusive,122921311.0,,0.0063,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
320,886,1,2,,11111924,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
321,886,1,2,,11111924,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
322,886,1,2,,11113621,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
323,886,1,2,,11113621,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
324,886,1,2,,17389524,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
325,886,1,2,,17389524,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
326,887,1,2,,857743,5578,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
327,887,1,2,,11111924,5578,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
328,887,1,2,,11113621,5578,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
329,887,1,2,,17389524,5578,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
330,889,1,3,,857743,5578,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
331,889,1,3,,11111924,5578,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
332,889,1,3,,11113621,5578,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
333,889,1,3,,17389524,5578,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
334,891,1,2,,11111923,5578,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
335,891,1,2,,11111924,5578,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
336,891,1,2,,11113621,5578,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
337,892,1,2,,857743,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
338,892,1,2,,11111924,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
339,892,1,2,,11113621,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
340,892,1,2,,17389524,5578,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
341,893,1,2,,857743,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
342,893,1,2,,857743,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
343,893,1,2,,11111924,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
344,893,1,2,,11111924,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
345,893,1,2,,11113621,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
346,893,1,2,,11113621,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
347,893,1,2,,17389524,5578,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
348,893,1,2,,17389524,5578,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
349,894,2,1,,857743,5578,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
350,894,2,1,,11111924,5578,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
351,894,2,1,,11113621,5578,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
352,894,2,1,,17389524,5578,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
353,894,2,1,,26747124,5578,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
354,894,2,1,,26751820,5578,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
355,894,2,1,,50104512,5578,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
356,895,1,2,,17389524,5578,Inconclusive,21620132.0,4790.0,0.2512,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
357,898,1,1,,857743,5578,Inactive,28373018.0,1239205.0,,,YopH  HTS,Screening,,
358,899,1,2,,11111923,5578,Inactive,4503219.0,1557.0,39.8107,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
359,899,1,2,,11111924,5578,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
360,899,1,2,,11113621,5578,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
361,900,1,3,,857743,5578,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
362,900,1,3,,11111924,5578,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
363,900,1,3,,11113621,5578,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
364,900,1,3,,17389524,5578,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
365,901,1,2,,857743,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
366,901,1,2,,11111924,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
367,901,1,2,,11113621,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
368,901,1,2,,17389524,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
369,902,1,2,,857743,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
370,902,1,2,,11111924,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
371,902,1,2,,11113621,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
372,902,1,2,,17389524,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
373,910,1,2,,17389524,5578,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
374,912,1,2,,857743,5578,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
375,912,1,2,,11111923,5578,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
376,912,1,2,,11111924,5578,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
377,912,1,2,,11113621,5578,Inconclusive,21392848.0,,12.5893,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
378,912,1,2,,17389524,5578,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
379,914,1,3,,11111923,5578,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
380,914,1,3,,11111924,5578,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
381,915,1,3,,11111923,5578,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
382,915,1,3,,11111924,5578,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
383,917,1,3,,17389524,5578,Inactive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
384,918,1,3,,17389524,5578,Inconclusive,120660324.0,7066.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
385,920,1,2,,857743,5578,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 inhibition,Screening,,
386,921,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-001,Confirmatory,,
387,923,1,2,,857743,5578,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
388,923,1,2,,11111924,5578,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
389,923,1,2,,11113621,5578,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
390,923,1,2,,17389524,5578,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
391,924,1,2,,857743,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
392,924,1,2,,11111924,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
393,924,1,2,,11113621,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
394,924,1,2,,17389524,5578,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
395,925,1,2,,857743,5578,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
396,925,1,2,,11111923,5578,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
397,925,1,2,,11111924,5578,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
398,925,1,2,,17389524,5578,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
399,926,1,2,,857743,5578,Inconclusive,38016895.0,7253.0,5.0119,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
400,926,1,2,,11111923,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
401,926,1,2,,11111924,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
402,926,1,2,,11113621,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
403,926,1,2,,17389524,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
404,927,1,3,,857743,5578,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
405,927,1,3,,11111924,5578,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
406,927,1,3,,17389524,5578,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
407,928,1,2,,17389524,5578,Inconclusive,21620132.0,4790.0,0.2512,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
408,930,1,2,,17389524,5578,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
409,932,1,4,,857743,5578,Inactive,6274552.0,6772.0,,,Primary cell-based high throughput screening assay to measure STAT1 activation,Screening,,
410,938,1,2,,857743,5578,Inconclusive,38016895.0,7253.0,5.0119,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
411,938,1,2,,11111923,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
412,938,1,2,,11111924,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
413,938,1,2,,11113621,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
414,938,1,2,,17389524,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
415,940,1,2,,857743,5578,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
416,940,1,2,,17405825,5578,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
417,940,1,2,,26611964,5578,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
418,943,1,2,,17389524,5578,Inconclusive,18249941.0,25229.0,14.1254,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
419,944,1,2,,17389524,5578,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
420,945,1,4,,17389524,5578,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
421,946,1,2,,17389524,5578,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
422,947,1,2,,17389524,5578,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
423,948,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
424,950,1,1,,857743,5578,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
425,951,1,1,,857743,5578,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
426,952,1,1,,857743,5578,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
427,954,1,2,,17389524,5578,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
428,955,1,2,,17389524,5578,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
429,957,1,2,,17389524,5578,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
430,958,1,2,,17389524,5578,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
431,959,1,4,,17389524,5578,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
432,960,1,2,,17389524,5578,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
433,961,1,2,,17389524,5578,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
434,962,1,2,,17389524,5578,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
435,963,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
436,964,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
437,965,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
438,966,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
439,967,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-005,Confirmatory,,
440,968,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
441,969,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
442,970,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
443,971,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
444,972,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
445,973,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-019,Confirmatory,,
446,974,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-021,Confirmatory,,
447,975,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
448,976,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
449,977,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
450,978,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
451,979,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
452,980,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
453,981,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-010,Confirmatory,,
454,982,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
455,983,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
456,984,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
457,985,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
458,986,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
459,987,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-022,Confirmatory,,
460,988,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-024,Confirmatory,,
461,989,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
462,992,1,3,,17389524,5578,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
463,993,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
464,994,1,2,,17389524,5578,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
465,995,1,2,,857743,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
466,995,1,2,,11111924,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
467,995,1,2,,11113621,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
468,995,1,2,,17389524,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
469,997,1,2,,17389524,5578,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
470,998,1,2,,17389524,5578,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
471,999,1,1,,46487917,5578,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
472,1001,2,2,,857743,5578,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
473,1004,1,1,,46487917,5578,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
474,1006,1,6,,857743,5578,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
475,1007,1,1,,857743,5578,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
476,1008,1,2,,857743,5578,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
477,1009,1,2,,857743,5578,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
478,1012,1,4,,857743,5578,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
479,1016,1,4,,857743,5578,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
480,1018,2,5,,857743,5578,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
481,1019,1,4,,857743,5578,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
482,1020,1,5,,857743,5578,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
483,1021,1,1,,857743,5578,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
484,1022,1,1,,857743,5578,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
485,1024,1,3,,857743,5578,Inactive,13699818.0,1559.0,,,HTS Assay for Activators of Cytochrome P450 2A9,Screening,,
486,1025,1,3,,857743,5578,Inactive,4503219.0,1557.0,,,HTS Assay for Activators of Cytochrome P450 2A19,Screening,,
487,1027,1,3,,857743,5578,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
488,1029,1,3,,857743,5578,Inactive,,,,,Image-based Screening Assay for Inhibitors of Phagocytosis,Screening,,
489,1030,2,1,,857743,5578,Inactive,30582681.0,216.0,28.1838,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
490,1030,2,1,,11111924,5578,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
491,1030,2,1,,11113621,5578,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
492,1030,2,1,,17389524,5578,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
493,1030,2,1,,26747124,5578,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
494,1030,2,1,,26751820,5578,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
495,1030,2,1,,50104512,5578,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
496,1032,1,2,,857743,5578,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
497,1032,1,2,,857743,5578,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
498,1040,1,2,,857743,5578,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
499,1046,1,6,,857743,5578,Inactive,339641.0,2147.0,,,Thrombin 1536 HTS,Screening,,
500,1049,1,1,,857743,5578,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
501,1049,1,1,,857743,5578,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
502,1063,1,1,,857743,5578,Inactive,,,,,Leishmania major promastigote HTS,Screening,,
503,1066,1,2,,857743,5578,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
504,1085,1,1,,857743,5578,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
505,1135,1,3,,857743,5578,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
506,1136,1,3,,857743,5578,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
507,1195,1,2,,48416671,5578,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
508,1203,1,3,,857743,5578,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
509,1209,2,2,,857743,5578,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
510,1214,1,4,,857743,5578,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
511,1216,1,5,,857743,5578,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
512,1217,1,4,,857743,5578,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
513,1220,2,2,,857743,5578,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
514,1222,1,6,,857743,5578,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
515,1229,1,3,,857743,5578,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
516,1230,1,3,,857743,5578,Inactive,89993689.0,4193.0,,,E3 Ligase HTS_1536,Screening,,
517,1235,1,2,,857743,5578,Inactive,,,,,Alternative Pathway ELISA_orthogonal screening,Screening,,
518,1236,1,1,,857743,5578,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
519,1239,1,3,,857743,5578,Inactive,34577122.0,4790.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
520,1239,1,3,,857743,5578,Inactive,223468676.0,5970.0,,,High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen,Screening,,
521,1246,1,2,,857743,5578,Inactive,56417702.0,,,,Primary HTS assay for chemical inhibitors of TNF alpha stimulated E-Selectin expression,Screening,,
522,1251,1,1,,857743,5578,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
523,1273,1,1,,857743,5578,Inactive,59036749.0,3630.0,,,Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells,Screening,,
524,1274,1,2,,857743,5578,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
525,1276,1,1,,857743,5578,Inactive,257380.0,351.0,,,Primary screen for compounds that activate Alzheimer's amyloid precursor,Screening,,
526,1285,1,1,,857743,5578,Inactive,257380.0,351.0,,,Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation,Screening,,
527,1296,1,1,,857743,5578,Inactive,59036749.0,3630.0,,,Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells,Screening,,
528,1304,1,2,,857743,5578,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
529,1321,1,2,,857743,5578,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
530,1325,1,2,,857743,5578,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
531,1326,1,4,,857743,5578,Inactive,42741659.0,5243.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen",Screening,,
532,1332,1,1,,49698744,5578,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
533,1359,1,4,,857743,5578,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
534,1362,1,2,,857743,5578,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
535,1376,1,2,,857743,5578,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
536,1377,1,1,,857743,5578,Inactive,,,,,HTS to identify inhibitors of zVAD Induced Cell Death in L929 Cells.,Screening,,
537,1379,1,2,,857743,5578,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
538,1379,1,2,,11111924,5578,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
539,1379,1,2,,11113621,5578,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
540,1379,1,2,,26747124,5578,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
541,1379,1,2,,26751820,5578,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
542,1379,1,2,,50104512,5578,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
543,1381,1,1,,857743,5578,Inactive,,,,,HCS to Identify Inhibitors of Dynein Mediated Cargo Transport on Microtubules.,Screening,,
544,1385,2,2,,857743,5578,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
545,1415,1,2,,857743,5578,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
546,1415,1,2,,857743,5578,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
547,1416,1,2,,857743,5578,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
548,1422,1,1,,857743,5578,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
549,1422,1,1,,17405825,5578,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
550,1422,1,1,,26611964,5578,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
551,1423,1,2,,857743,5578,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
552,1423,1,2,,857743,5578,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
553,1424,1,1,,857743,5578,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
554,1430,1,1,,857743,5578,Inactive,70832125.0,3663016.0,,,HTS assay for inhibitors of Trypanosoma brucei hexokinase 1,Screening,,
555,1434,2,3,,857743,5578,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
556,1434,2,3,,857743,5578,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
557,1439,1,1,,857743,5578,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
558,1439,1,1,,857743,5578,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
559,1440,1,1,,857743,5578,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
560,1440,1,1,,857743,5578,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
561,1441,1,1,,857743,5578,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
562,1441,1,1,,857743,5578,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
563,1443,1,3,,857743,5578,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
564,1445,1,1,,857743,5578,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
565,1446,1,3,,857743,5578,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
566,1448,1,3,,857743,5578,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
567,1452,1,1,,857743,5578,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
568,1452,1,1,,11111924,5578,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
569,1452,1,1,,11113621,5578,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
570,1452,1,1,,17389524,5578,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
571,1452,1,1,,26751820,5578,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
572,1454,1,1,,857743,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
573,1454,1,1,,11111924,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
574,1454,1,1,,11113621,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
575,1454,1,1,,26747124,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
576,1454,1,1,,50104512,5578,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
577,1456,1,1,,857743,5578,Inactive,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
578,1457,1,1,,857743,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
579,1457,1,1,,11111924,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
580,1457,1,1,,11113621,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
581,1457,1,1,,17389524,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
582,1457,1,1,,26747124,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
583,1457,1,1,,26751820,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
584,1457,1,1,,50104512,5578,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
585,1458,1,1,,857743,5578,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
586,1458,1,1,,11111924,5578,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
587,1458,1,1,,17389524,5578,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
588,1458,1,1,,26747124,5578,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
589,1458,1,1,,50104512,5578,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
590,1459,1,1,,50104512,5578,Inactive,27436948.0,4000.0,,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
591,1460,1,3,,857743,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
592,1460,1,3,,11113621,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
593,1460,1,3,,26747124,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
594,1460,1,3,,26751820,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
595,1460,1,3,,50104512,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
596,1461,1,2,,857743,5578,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
597,1461,1,2,,50104512,5578,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
598,1463,1,1,,857743,5578,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
599,1463,1,1,,11113621,5578,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
600,1463,1,1,,26747124,5578,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
601,1463,1,1,,26751820,5578,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
602,1463,1,1,,50104512,5578,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
603,1465,1,1,,857743,5578,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
604,1466,1,2,,857743,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
605,1467,1,3,,857743,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
606,1467,1,3,,11111924,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
607,1467,1,3,,11113621,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
608,1467,1,3,,26747124,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
609,1467,1,3,,26751820,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
610,1467,1,3,,50104512,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
611,1468,1,1,,857743,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
612,1468,1,1,,11113621,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
613,1468,1,1,,26747124,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
614,1468,1,1,,26751820,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
615,1468,1,1,,50104512,5578,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
616,1469,1,1,,857743,5578,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
617,1469,1,1,,11111924,5578,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
618,1469,1,1,,11113621,5578,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
619,1469,1,1,,17389524,5578,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
620,1469,1,1,,26747124,5578,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
621,1469,1,1,,26751820,5578,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
622,1469,1,1,,50104512,5578,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
623,1471,2,1,,857743,5578,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
624,1471,2,1,,11111923,5578,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
625,1471,2,1,,11111924,5578,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
626,1471,2,1,,11113621,5578,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
627,1471,2,1,,17389524,5578,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
628,1471,2,1,,26747124,5578,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
629,1471,2,1,,26751820,5578,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
630,1476,2,1,,857743,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
631,1476,2,1,,11111924,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
632,1476,2,1,,11113621,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
633,1476,2,1,,17389524,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
634,1476,2,1,,26747124,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
635,1476,2,1,,26751820,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
636,1476,2,1,,50104512,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
637,1477,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
638,1477,1,1,,11111924,5578,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
639,1477,1,1,,11113621,5578,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
640,1477,1,1,,17389524,5578,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
641,1477,1,1,,26747124,5578,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
642,1477,1,1,,26751820,5578,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
643,1477,1,1,,50104512,5578,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
644,1478,2,1,,857743,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
645,1478,2,1,,11111924,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
646,1478,2,1,,11113621,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
647,1478,2,1,,17389524,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
648,1478,2,1,,26747124,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
649,1478,2,1,,26751820,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
650,1478,2,1,,50104512,5578,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
651,1479,1,2,,857743,5578,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
652,1479,1,2,,11111924,5578,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
653,1479,1,2,,11113621,5578,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
654,1479,1,2,,17389524,5578,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
655,1479,1,2,,26747124,5578,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
656,1479,1,2,,26751820,5578,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
657,1479,1,2,,50104512,5578,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
658,1481,1,2,,857743,5578,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
659,1486,1,3,,857743,5578,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
660,1487,1,1,,857743,5578,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
661,1487,1,1,,11111924,5578,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
662,1487,1,1,,17389524,5578,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
663,1487,1,1,,50104512,5578,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
664,1490,2,1,,857743,5578,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
665,1490,2,1,,11111924,5578,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
666,1490,2,1,,11113621,5578,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
667,1490,2,1,,17389524,5578,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
668,1490,2,1,,26747124,5578,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
669,1490,2,1,,26751820,5578,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
670,1496,1,4,,857743,5578,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
671,1496,1,4,,857743,5578,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
672,1497,1,4,,857743,5578,Inactive,88501734.0,3684.0,,,HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.,Screening,,
673,1497,1,4,,857743,5578,Inactive,89191865.0,3689.0,,,HTS identification of compounds inhibiting the binding of CD11b/CD18 to fibrinogen via a luminescence assay.,Screening,,
674,1499,1,4,,857743,5578,Inactive,88501734.0,3684.0,,,HTS identification of compounds that enhance the binding of CD11b/CD18 to fibrinogen via a luminescence assay.,Screening,,
675,1499,1,4,,857743,5578,Inactive,89191865.0,3689.0,,,HTS identification of compounds that enhance the binding of CD11b/CD18 to fibrinogen via a luminescence assay.,Screening,,
676,1509,1,2,,857743,5578,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
677,1510,1,3,,857743,5578,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
678,1511,1,3,,857743,5578,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
679,1515,1,2,,857743,5578,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
680,1519,1,3,,11111924,5578,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
681,1519,1,3,,11113621,5578,Inconclusive,,,0.7079,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
682,1519,1,3,,26747124,5578,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
683,1519,1,3,,50104512,5578,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
684,1527,1,3,,857743,5578,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
685,1529,1,1,,857743,5578,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
686,1530,1,1,,857743,5578,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
687,1531,1,1,,857743,5578,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
688,1532,1,1,,857743,5578,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
689,1554,1,1,,857743,5578,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
690,1556,1,4,,857743,5578,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
691,1565,2,2,,857743,5578,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
692,1566,2,3,,857743,5578,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
693,1578,3,2,,857743,5578,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
694,1580,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
695,1581,1,1,,8149571,5578,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
696,1582,1,1,,8149571,5578,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
697,1583,1,1,,8149571,5578,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
698,1584,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
699,1585,1,1,,8149571,5578,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
700,1586,1,1,,8149571,5578,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
701,1587,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
702,1588,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
703,1589,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
704,1590,1,1,,8149571,5578,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
705,1593,1,1,,8149571,5578,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
706,1594,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
707,1595,1,1,,8149571,5578,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
708,1596,1,1,,8149571,5578,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
709,1597,1,1,,8149571,5578,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
710,1598,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
711,1599,1,1,,8149571,5578,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
712,1600,1,1,,8149571,5578,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
713,1601,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
714,1602,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
715,1603,1,1,,8149571,5578,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
716,1604,1,1,,8149571,5578,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
717,1605,1,1,,8149571,5578,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
718,1606,1,1,,8149571,5578,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
719,1607,1,1,,8149571,5578,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
720,1608,1,1,,8149571,5578,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
721,1609,1,1,,8149571,5578,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
722,1610,1,1,,8149571,5578,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
723,1612,1,1,,8149571,5578,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
724,1613,1,1,,8149571,5578,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
725,1614,1,1,,8149571,5578,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
726,1616,1,1,,8149571,5578,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
727,1619,1,2,,857743,5578,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
728,1621,1,2,,857743,5578,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
729,1625,2,2,,857743,5578,Inactive,,,,EC50,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
730,1626,1,2,,857743,5578,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
731,1628,2,2,,857743,5578,Inactive,,,,IC50,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
732,1631,3,1,,857743,5578,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
733,1634,3,1,,857743,5578,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
734,1654,2,2,,857743,5578,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
735,1656,2,2,,857743,5578,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
736,1662,1,2,,857743,5578,Active,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
737,1663,1,2,,857743,5578,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
738,1672,1,3,,857743,5578,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
739,1688,1,1,,857743,5578,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
740,1700,1,2,,857743,5578,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
741,1705,1,2,,50104512,5578,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
742,1706,1,2,,857743,5578,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
743,1707,1,3,,50104512,5578,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
744,1708,1,3,,50104512,5578,Inactive,405898.0,,0.8913,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
745,1721,1,2,,857743,5578,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
746,1722,1,2,,857743,5578,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
747,1766,1,1,,857743,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
748,1766,1,1,,857743,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
749,1766,1,1,,11111924,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
750,1766,1,1,,11111924,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
751,1766,1,1,,11113621,5578,Inconclusive,18860839.0,4221.0,35.4813,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
752,1766,1,1,,11113621,5578,Inconclusive,56550039.0,4297.0,35.4813,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
753,1766,1,1,,17389524,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
754,1766,1,1,,17389524,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
755,1766,1,1,,26747124,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
756,1766,1,1,,26747124,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
757,1766,1,1,,26751820,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
758,1766,1,1,,26751820,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
759,1766,1,1,,50104512,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
760,1766,1,1,,50104512,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
761,1768,1,1,,857743,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
762,1768,1,1,,857743,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
763,1768,1,1,,11111924,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
764,1768,1,1,,11111924,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
765,1768,1,1,,11113621,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
766,1768,1,1,,11113621,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
767,1768,1,1,,17389524,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
768,1768,1,1,,17389524,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
769,1768,1,1,,26747124,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
770,1768,1,1,,26747124,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
771,1768,1,1,,26751820,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
772,1768,1,1,,26751820,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
773,1768,1,1,,50104512,5578,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
774,1768,1,1,,50104512,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
775,1775,1,2,,857743,5578,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
776,1776,1,2,,857743,5578,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
777,1777,3,2,,857743,5578,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
778,1778,3,3,,857743,5578,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
779,1779,2,2,,857743,5578,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
780,1789,1,2,,857743,5578,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
781,1800,1,2,,857743,5578,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
782,1813,1,2,,857743,5578,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
783,1814,1,2,,857743,5578,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
784,1815,1,1,,50104512,5578,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
785,1816,1,1,,50104512,5578,Active,,,1.122,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
786,1817,2,2,,857743,5578,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
787,1822,1,3,,857743,5578,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
788,1825,1,1,,857743,5578,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
789,1828,2,1,,50104512,5578,Active,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
790,1832,2,1,,857743,5578,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
791,1845,1,2,,857743,5578,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
792,1850,2,1,,857743,5578,Active,,,3.41,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
793,1851,1,2,,11111924,5578,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
794,1851,1,2,,11113621,5578,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
795,1851,1,2,1.0,11111924,5578,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
796,1851,1,2,1.0,11113621,5578,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
797,1851,1,2,2.0,11111924,5578,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
798,1851,1,2,2.0,11113621,5578,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
799,1851,1,2,3.0,11111924,5578,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
800,1851,1,2,3.0,11113621,5578,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
801,1851,1,2,4.0,11111924,5578,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
802,1851,1,2,4.0,11113621,5578,Inactive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
803,1851,1,2,5.0,11111924,5578,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
804,1851,1,2,5.0,11113621,5578,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
805,1861,2,1,,857743,5578,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
806,1862,1,4,,857743,5578,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_RPL19A,Screening,,
807,1863,2,1,,857743,5578,Active,,,4.13,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
808,1865,1,1,,857743,5578,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
809,1865,1,1,,11111924,5578,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
810,1865,1,1,,11113621,5578,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
811,1865,1,1,,26747124,5578,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
812,1865,1,1,,26751820,5578,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
813,1865,1,1,,50104512,5578,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
814,1867,1,4,,857743,5578,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_MEP2,Screening,,
815,1868,1,4,,857743,5578,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
816,1870,1,4,,857743,5578,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_CIT2,Screening,,
817,1873,1,4,,857743,5578,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_LAP4,Screening,,
818,1875,2,1,,857743,5578,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
819,1876,1,1,,50104512,5578,Active,,,1.122,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
820,1877,1,1,,50104512,5578,Active,,,3.1623,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
821,1882,1,1,,50104512,5578,Inactive,,,,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
822,1883,1,1,,50104512,5578,Inconclusive,,,17.7828,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
823,1885,2,1,,857743,5578,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
824,1886,1,1,,50104512,5578,Active,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
825,1887,1,4,,857743,5578,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_AGP1,Screening,,
826,1899,1,3,,857743,5578,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
827,1903,2,3,,857743,5578,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
828,1906,1,3,,857743,5578,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
829,1910,1,2,,857743,5578,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
830,1947,1,2,,857743,5578,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
831,1948,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
832,1948,1,1,,11111924,5578,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
833,1948,1,1,,11113621,5578,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
834,1948,1,1,,17389524,5578,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
835,1948,1,1,,26747124,5578,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
836,1948,1,1,,26751820,5578,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
837,1948,1,1,,50104512,5578,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
838,1950,1,3,,857743,5578,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
839,1956,1,1,,857743,5578,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
840,1961,2,2,,857743,5578,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
841,1962,1,2,,857743,5578,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
842,1967,1,1,,85231275,5578,Inactive,4505907.0,5376.0,,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
843,1974,1,2,,857743,5578,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
844,1981,2,1,,857743,5578,Active,,,0.87,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhimurium using a modified counterscreen.,Confirmatory,,
845,1984,1,3,,857743,5578,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
846,1985,2,1,,857743,5578,Active,,,0.675,IC50,A screen for inhibitors of the PhoP regulon in Salmonella Typhi using a modified counterscreen,Confirmatory,,
847,1986,1,2,,857743,5578,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
848,1987,1,2,,857743,5578,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
849,2006,3,2,,857743,5578,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
850,2006,3,2,,857743,5578,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
851,2006,3,2,,857743,5578,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
852,2012,3,2,,857743,5578,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
853,2013,2,2,,857743,5578,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
854,2014,3,2,,857743,5578,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
855,2016,1,3,,857743,5578,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
856,2023,1,3,,857743,5578,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
857,2025,1,3,,857743,5578,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
858,2029,1,3,,857743,5578,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
859,2052,2,1,,857743,5578,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
860,2057,1,2,,857743,5578,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
861,2058,3,2,,857743,5578,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
862,2066,1,4,,857743,5578,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
863,2071,2,2,,857743,5578,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
864,2073,2,3,,857743,5578,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
865,2073,2,3,,857743,5578,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
866,2094,1,2,,857743,5578,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
867,2094,1,2,,857743,5578,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
868,2094,1,2,,857743,5578,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
869,2097,1,2,,857743,5578,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
870,2098,1,1,,857743,5578,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
871,2099,1,1,,857743,5578,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
872,2100,1,1,,857743,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
873,2101,1,1,,857743,5578,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
874,2101,1,1,,11111924,5578,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
875,2101,1,1,,11113621,5578,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
876,2101,1,1,,17389524,5578,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
877,2101,1,1,,26747124,5578,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
878,2101,1,1,,26751820,5578,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
879,2101,1,1,,50104512,5578,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
880,2107,1,1,,857743,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
881,2107,1,1,,11111924,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
882,2107,1,1,,11113621,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
883,2107,1,1,,17389524,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
884,2107,1,1,,26747124,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
885,2107,1,1,,26751820,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
886,2107,1,1,,50104512,5578,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
887,2112,1,1,,857743,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
888,2112,1,1,,11111924,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
889,2112,1,1,,11113621,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
890,2112,1,1,,17389524,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
891,2112,1,1,,26747124,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
892,2112,1,1,,26751820,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
893,2112,1,1,,50104512,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
894,2120,1,1,,17389524,5578,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
895,2129,1,2,,857743,5578,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
896,2130,1,3,,857743,5578,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
897,2147,1,1,,857743,5578,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
898,2147,1,1,,11111924,5578,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
899,2147,1,1,,11113621,5578,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
900,2147,1,1,,26747124,5578,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
901,2147,1,1,,50104512,5578,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
902,2156,2,2,,857743,5578,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
903,2174,1,3,,857743,5578,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
904,2177,1,3,,857743,5578,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
905,2205,1,1,,857743,5578,Inactive,29788785.0,203068.0,,,HCS assay for microtubule stabilizers,Screening,,
906,2216,1,3,,857743,5578,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
907,2221,1,2,,857743,5578,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
908,2227,1,2,,857743,5578,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
909,2234,1,2,,857743,5578,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
910,2235,1,2,,857743,5578,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
911,2237,1,2,,857743,5578,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
912,2239,1,2,,857743,5578,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
913,2240,1,1,,85788427,5578,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
914,2241,1,1,,85788427,5578,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
915,2242,1,1,,857743,5578,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
916,2247,1,2,,857743,5578,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
917,2252,1,1,,857743,5578,Inactive,,,,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhi identified in the primary screen,Confirmatory,,
918,2253,1,1,,857743,5578,Inactive,,,,EC50,A cytotoxicity screen of small molecule inhibitors of the PhoP regulon in Salmonella typhimurium identified in the primary screen,Confirmatory,,
919,2275,1,1,,85788427,5578,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
920,2280,2,3,,857743,5578,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
921,2288,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
922,2289,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
923,2297,1,2,,85859995,5578,Unspecified,,,,,Inhibition Frequency Index,Other,,
924,2300,1,3,,857743,5578,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
925,2302,1,2,,85859995,5578,Inactive,111034851.0,,,,Inhibition of P. falciparum Dd2,Screening,,
926,2303,1,2,,85859995,5578,Inactive,,,,,Inhibition of HepG2 cell line,Screening,,
927,2304,1,2,,85859995,5578,Inactive,111034851.0,,,,Inhibition of P. falciparum LDH,Screening,,
928,2305,1,2,,85859995,5578,Unspecified,,,0.75,XC50_3D7,XC50 for P. falciparum 3D7,Confirmatory,,
929,2306,1,2,,85859995,5578,Active,124513266.0,814112.0,,,Inhibition of P. falciparum 3D7,Screening,,
930,2313,1,1,,85788427,5578,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
931,2314,1,2,,857743,5578,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
932,2314,1,2,,857743,5578,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
933,2315,1,2,,857743,5578,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
934,2315,1,2,,857743,5578,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
935,2322,1,1,,85788427,5578,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
936,2323,1,1,,50104512,5578,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
937,2326,1,1,,857743,5578,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
938,2326,1,1,,50104512,5578,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
939,2330,1,1,,85788427,5578,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
940,2353,1,3,,50104512,5578,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
941,2364,1,2,,50104512,5578,Inconclusive,4557365.0,641.0,0.0032,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
942,2380,1,2,,50085866,5578,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
943,2384,1,1,,857743,5578,Active,,,0.82,IC50,A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
944,2391,1,1,,857743,5578,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
945,2401,1,2,,857743,5578,Active,,,0.56,IC50,A Counter Screen to identiry small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
946,2417,1,1,,857743,5578,Inactive,4506243.0,5725.0,,,High Content Assay for Compounds that inhibit the Assembly of the Perinucleolar Compartment,Screening,,
947,2435,1,2,,857743,5578,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
948,2445,1,2,,857743,5578,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
949,2451,1,2,,857743,5578,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
950,2451,1,2,,11111924,5578,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
951,2451,1,2,,11113621,5578,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
952,2451,1,2,,26747124,5578,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
953,2451,1,2,,26751820,5578,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
954,2451,1,2,,50104512,5578,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
955,2462,1,1,,857743,5578,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
956,2462,1,1,,857743,5578,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
957,2472,1,2,,857743,5578,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
958,2472,1,2,,11111924,5578,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
959,2472,1,2,,11113621,5578,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
960,2472,1,2,,26747124,5578,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
961,2472,1,2,,26751820,5578,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
962,2517,2,1,,857743,5578,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
963,2517,2,1,,11111924,5578,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
964,2517,2,1,,11113621,5578,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
965,2517,2,1,,17389524,5578,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
966,2517,2,1,,26747124,5578,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
967,2517,2,1,,26751820,5578,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
968,2517,2,1,,50104512,5578,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
969,2520,1,4,,50085866,5578,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
970,2521,1,3,,50085866,5578,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
971,2523,1,1,,857743,5578,Inactive,124486680.0,16408.0,,,HTS of MLPCN Validation Compound Set for developing T Cell Immune Modulators,Screening,,
972,2524,1,2,,50085866,5578,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
973,2528,1,2,,857743,5578,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
974,2528,1,2,,11111924,5578,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
975,2528,1,2,,11113621,5578,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
976,2528,1,2,,17389524,5578,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
977,2528,1,2,,26747124,5578,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
978,2528,1,2,,26751820,5578,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
979,2528,1,2,,50104512,5578,Inconclusive,4557365.0,641.0,0.0032,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
980,2540,1,2,,50085866,5578,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
981,2544,1,2,,50085866,5578,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
982,2546,1,1,,857743,5578,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
983,2546,1,1,,11111924,5578,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
984,2546,1,1,,11113621,5578,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
985,2546,1,1,,17389524,5578,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
986,2546,1,1,,26747124,5578,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
987,2546,1,1,,26751820,5578,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
988,2549,1,1,,857743,5578,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
989,2549,1,1,,11111924,5578,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
990,2549,1,1,,11113621,5578,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
991,2549,1,1,,17389524,5578,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
992,2549,1,1,,26747124,5578,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
993,2549,1,1,,26751820,5578,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
994,2549,1,1,,50104512,5578,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
995,2550,1,3,,857743,5578,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
996,2551,1,1,,857743,5578,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
997,2551,1,1,,11111924,5578,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
998,2551,1,1,,11113621,5578,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
999,2551,1,1,,17389524,5578,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
1000,2551,1,1,,26747124,5578,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
1001,2551,1,1,,26751820,5578,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
1002,2553,1,2,,857743,5578,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
1003,2557,1,3,,857743,5578,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
1004,2563,1,1,,857743,5578,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
1005,2599,1,2,,50085866,5578,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
1006,2606,1,2,,857743,5578,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
1007,2629,1,1,,857743,5578,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
1008,2629,1,1,,50085866,5578,Active,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
1009,2642,1,2,,857743,5578,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
1010,2648,1,2,,857743,5578,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
1011,2650,2,1,,857743,5578,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
1012,2660,1,1,,90340764,5578,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
1013,2661,1,1,,857743,5578,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
1014,2662,2,1,,857743,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
1015,2662,2,1,,85231275,5578,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
1016,2666,1,1,,90340764,5578,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
1017,2667,1,1,,90340764,5578,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
1018,2668,1,1,,90340764,5578,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
1019,2669,1,1,,17389524,5578,Inactive,90903231.0,3064.0,,Potency,qHTS Assay Multiplex Screening to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (Protease relase),Confirmatory,,
1020,2673,1,1,,17389524,5578,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection confirmation (ATP),Confirmatory,,
1021,2674,1,1,,857743,5578,Inactive,34810098.0,,,,HTS for Identification of VLA-4 Allosteric Modulators from Validation Compound Set.,Screening,,
1022,2675,1,1,,857743,5578,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
1023,2675,1,1,,50104512,5578,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
1024,2676,1,2,,857743,5578,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
1025,2685,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
1026,2690,1,2,,857743,5578,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
1027,2706,1,1,,857743,5578,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide for Validation Compound Set,Screening,,
1028,2716,1,1,,857743,5578,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
1029,2716,1,1,,50085866,5578,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
1030,2717,1,2,,857743,5578,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
1031,2718,1,1,,857743,5578,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
1032,2732,1,1,,857743,5578,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
1033,2732,1,1,,17405825,5578,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
1034,2751,2,2,,857743,5578,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
1035,2774,1,3,,92303160,5578,Inactive,,,,,LOPAC Circadian Assay,Screening,,
1036,2796,1,4,,857743,5578,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
1037,2797,1,2,,857743,5578,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
1038,2805,2,2,,50085866,5578,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
1039,2806,2,2,,50085866,5578,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
1040,2825,1,2,,50085866,5578,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
1041,2831,1,3,,85747719,5578,Active,,,4.62,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium (2) using purified and synthesized compounds,Confirmatory,,
1042,2834,1,2,,85747719,5578,Active,,,125.0,IC50,A counter screen for small molecule inhibitors of the PhoP regulon in Salmonella Typhimurium (2) using purified and synthesized compounds,Confirmatory,,
1043,2839,1,2,,85747719,5578,Active,,,25.04,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi (2) using purified and synthesized compounds,Confirmatory,,
1044,2840,1,2,,85747719,5578,Active,,,0.15,IC50,A counter screen for small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi (2) using purified and synthesized compounds,Confirmatory,,
1045,7783,3,4,,103164817,5578,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
1046,8002,5,2,,103164817,5578,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
1047,17266,4,1,,103164817,5578,Unspecified,,,,,Affinity constant KD value was derived from TMP,Other,6754932.0,
1048,19424,3,4,,103164817,5578,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
1049,22293,4,4,,103164817,5578,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
1050,23227,3,3,,103164817,5578,Unspecified,,,,,Partition coefficient (logP),Other,3312605.0,
1051,23492,3,3,,103164817,5578,Unspecified,,,,,Partition coefficient (logP),Other,7086836.0,
1052,23493,3,4,,103164817,5578,Unspecified,,,,,Partition coefficient was evaluated for the protinated form (acidic pH ),Other,7086836.0,
1053,23497,3,4,,103164817,5578,Unspecified,,,,,Partition coefficient (logD) (aqueous phase 0.1 N HCl),Other,3701780.0,
1054,23701,3,4,,103164817,5578,Unspecified,,,,,Partition coefficient (logD) (0.1 N NaOH),Other,6699880.0,
1055,24429,3,5,,103164817,5578,Unspecified,,,,,Partition coefficient (logD) (0.1 N HCl/octanol),Other,1899453.0,
1056,26304,4,4,,103164817,5578,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
1057,26362,4,3,,103164817,5578,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
1058,26776,3,4,,103164817,5578,Unspecified,,,,,Compound was evaluated for the partition coefficients probably at the pH >> 7.2 at the aqueous phase 0.1 N HCl,Other,7005446.0,
1059,26777,3,4,,103164817,5578,Unspecified,,,,,Compound was evaluated for the partition coefficients probably at the pH >> 7.2 at the aqueous phase 0.1 N NaOH,Other,7005446.0,
1060,26815,4,3,,103164817,5578,Unspecified,,,,,Calculated partition coefficient (clogP),Other,8941396.0,
1061,27417,3,3,,103164817,5578,Unspecified,,,,,Half-life in dogs Plasma,Other,2754716.0,
1062,27590,3,4,,103164817,5578,Unspecified,,,,,Partition coefficient (logD) (aqueous phase 0.1 N HCl),Other,2502631.0,
1063,28233,3,3,,103164817,5578,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
1064,28235,3,3,,103164817,5578,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
1065,28236,3,3,,103164817,5578,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
1066,29337,3,3,,103164817,5578,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
1067,29359,3,3,,103164817,5578,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
1068,29423,3,4,,103164817,5578,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
1069,29647,5,2,,103164817,5578,Unspecified,,,,,Oral bioavailability in dog,Other,2754716.0,
1070,29811,4,3,,103164817,5578,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
1071,29925,5,2,,103164817,5578,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
1072,40352,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Bacillus fragilis) activities compared to that of trimethoprim and metronidazole,Other,2754716.0,
1073,41219,6,2,,103164817,5578,Unspecified,,,250.0,IC50,Cytotoxicity against human breast cancer cells.,Confirmatory,11881993.0,
1074,41432,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Bacteroides thetaiotaomicron) activities compared to that of trimethoprim and metronidazole,Other,2754716.0,
1075,41563,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Bacteroides vulgatus) activities compared to that of trimethoprim and metronidazole,Other,2754716.0,
1076,43581,3,7,,103164817,5578,Unspecified,,,,,Inhibition of beta-lactamase at 100 uM,Other,14521410.0,
1077,48922,6,2,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration required to inhibit Candida albicans (in vitro),Other,7658448.0,
1078,50852,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Clostridium difficile) activities compared to that of trimethoprim and metronidazole,Other,2754716.0,
1079,51011,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Clostridium perfringens) activities compared to that of trimethoprim and metronidazole,Other,2754716.0,
1080,52790,3,7,,103164817,5578,Unspecified,,,,,Inhibition of chymotrypsin at 250 uM,Other,14521410.0,
1081,53760,11,2,,103164817,5578,Active,165971782.0,,0.006,IC50,In vitro inhibition of dihydrofolate reductase of Escherichia coli,Confirmatory,2754716.0,
1082,53761,11,1,,103164817,5578,Active,,,0.12,IC50,In vitro inhibition of dihydrofolate reductase of Plasmodium berghei,Confirmatory,2754716.0,
1083,53762,8,5,,103164817,5578,Active,60392215.0,31214198.0,0.0051,Ki,Antibacterial activity against Staphylococcus aureus,Confirmatory,2754716.0,
1084,53763,7,3,,103164817,5578,Unspecified,,,260.0,IC50,In vitro inhibition of dihydrofolate reductase enzymes in rat liver,Confirmatory,2754716.0,
1085,55683,10,5,,103164817,5578,Active,165971782.0,,12.0,IC50,In vitro inhibition of Pneumocystis carinii (Pc) dihydrofolate reductase.,Confirmatory,11754594.0,
1086,55686,12,2,,103164817,5578,Active,118998.0,,43.0,IC50,Inhibition of Pneumocystis carinii dihydrofolate reductase (DHFR) enzyme by Iclaprim,Confirmatory,14623005.0,
1087,55688,10,2,,103164817,5578,Active,118998.0,,40.0,IC50,Inhibitory concentration against Pneumocystis carinii dihydrofolate reductases (DHFR),Confirmatory,8230134.0,
1088,55689,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Pneumocystis carinii (pc) Dihydrofolate reductase,Confirmatory,7783147.0,
1089,55692,8,5,,103164817,5578,Active,118998.0,,12.0,IC50,The compound was tested for inhibition of dihydrofolate reductase(DHFR) from Pneumocystis carinii(pc),Confirmatory,10395486.0,
1090,55694,9,5,,103164817,5578,Active,118998.0,,15.0,IC50,Inhibitory activity against pneumocystis carinii Dihydrofolate reductase,Confirmatory,12408727.0,
1091,55696,9,2,,103164817,5578,Active,,,12.0,IC50,Inhibitory activity against Pneumocystis carinii dihydrofolate reductase.,Confirmatory,8627607.0,
1092,55697,12,2,,103164817,5578,Active,118998.0,,12.0,IC50,Compound was tested for inhibition activity against Dihydrofolate reductase in pneumocystis carinii (Pneumocystis carinii).,Confirmatory,9526565.0,
1093,55700,12,2,,103164817,5578,Active,118998.0,,12.0,IC50,Concentration inhibiting Pneumocystis carinii dihydrofolate reductase.,Confirmatory,7629801.0,
1094,55703,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition against Dihydrofolate reductase in Pneumocystis carinii,Confirmatory,9089339.0,
1095,55704,10,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Pneumocystis carinii Dihydrofolate Reductase,Confirmatory,9357537.0,
1096,55705,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Dihydrofolate reductase of Pneumocystis carinii,Confirmatory,7799402.0,
1097,55708,9,2,,103164817,5578,Active,729370.0,,2.8,IC50,Concentration required to inhibit the Toxoplasma gondii Dihydrofolate reductase by 50% was determined; Range: 2400-3300,Confirmatory,15115391.0,
1098,55714,7,2,,103164817,5578,Active,,,2.7,IC50,Inhibition of dihydrofolate reductase from Toxoplasma gondii.,Confirmatory,14584957.0,
1099,55820,8,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii,Confirmatory,7752201.0,
1100,55821,10,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against Dihydrofolate reductase from Pneumocystis carinii (pcDHFR),Confirmatory,9719595.0,
1101,55823,9,5,,103164817,5578,Active,118998.0,,13.0,IC50,Inhibition of Dihydrohydrofolate reductase(DHFR) of Pneumocystis carinii,Confirmatory,12699390.0,
1102,55825,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Dihydrofolate Reductase of Pneumocystis carinii.,Confirmatory,9046338.0,
1103,55827,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) from Pneumocystis carinii,Confirmatory,9804692.0,
1104,55831,10,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against DHFR (Dihydrofolate reductase) from Pneumocystis carinii.,Confirmatory,10579848.0,
1105,55832,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against Pneumocystis carinii Dihydrofolate reductase,Confirmatory,7877140.0,
1106,55833,10,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against Pneumocystis carinii dihydrofolate reductase,Confirmatory,8632434.0,
1107,55836,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against dihydrofolate reductase in Pneumocystis carinii at 37 centigrade.,Confirmatory,7490723.0,
1108,55838,10,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory concentration against Dihydrofolate reductase from Pneumocystis carinii (pc),Confirmatory,9046337.0,
1109,55841,10,5,,103164817,5578,Active,118998.0,,26.8,IC50,Inhibitory concentration against dihydrofolate reductase dihydrofolate reductase from Pneumocystis carinii.,Confirmatory,11448221.0,
1110,55843,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,The ability to inhibit Pneumocystis carinii Dihydrofolate reductase was tested,Confirmatory,10090784.0,
1111,55845,8,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against purified DHFR (Dihydrofolate reductase) from Pneumocystis carinii.,Confirmatory,7658454.0,
1112,55851,8,5,,103164817,5578,Active,118998.0,,0.152,Ki,Binding affinity was reported with purified recombinant Pneumocystis carinii Dihydrofolate reductase,Confirmatory,7490723.0,
1113,55853,8,5,,103164817,5578,Active,118998.0,,0.15136,Ki,Inhibition of dihydrofolate reductase (DHFR) from Pneumocystis carinii.,Confirmatory,7699713.0,
1114,55855,8,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against Pneumocystis carinii dihydrofolate reductase (in 90 uM dihydrofolic acid),Confirmatory,8691474.0,
1115,55858,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Pneumocystis carinii dihydrofolate reductase,Confirmatory,9554874.0,
1116,55989,10,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory activity against dihydrofolate reductase from pneumocystis carinii,Confirmatory,9548816.0,
1117,55991,3,8,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Proteus mirabilis S 2409,Other,7035668.0,
1118,55992,3,8,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Proteus vulgaris CN 329,Other,7035668.0,
1119,55993,3,8,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Salmonella typhi CN 512,Other,7035668.0,
1120,55994,3,8,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Shigella dysentariae CN 1513,Other,7035668.0,
1121,55996,12,2,,103164817,5578,Active,60392215.0,31214198.0,0.027000000000000003,IC50,Antibacterial activity against TMP-Resistant Dihydrofolate reductase from Staphylococcus aureus 157/4696,Confirmatory,12773035.0,
1122,55997,12,2,,103164817,5578,Active,60392215.0,31214198.0,0.006999999999999999,IC50,Inhibition of Staphylococcus aureus dihydrofolate reductase (DHFR) enzyme by Iclaprim,Confirmatory,14623005.0,
1123,56000,12,2,,103164817,5578,Active,60392215.0,31214198.0,19.0,IC50,Tested for inhibition of TMP-Resistant Dihydrofolate reductase from Staphylococcus aureus 157/4696.,Confirmatory,12773035.0,
1124,56004,6,7,,103164817,5578,Unspecified,60392215.0,31214198.0,,,Tested for inhibition of TMP-Resistant Dihydrofolate reductase from Staphylococcus pneumoniae 1/1.,Other,12773035.0,
1125,56006,3,11,,103164817,5578,Unspecified,60392215.0,31214198.0,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Staphylococcus aureus CN 491,Other,7035668.0,
1126,56007,4,1,,103164817,5578,Unspecified,,,15848.9,IC50,In vitro inhibition of Staphylococcus aureus (NTCT6571A) Dihydrofolate reductase.,Confirmatory,2404122.0,
1127,56010,9,2,,103164817,5578,Active,,,3.0,IC50,Antibacterial activity against TMP-susceptible Dihydrofolate reductase from Staphylococcus pneumoniae ATCC 49619,Confirmatory,12773035.0,
1128,56013,11,1,,103164817,5578,Active,,,0.075,IC50,Inhibitory activity against TMP-susceptible DHFR from Staphylococcus pneumoniae ATCC 49619,Confirmatory,12773035.0,
1129,56014,9,2,,103164817,5578,Active,,,34.0,IC50,Inhibitory activity against TMP-susceptible Dihydrofolate reductase from Staphylococcus pneumoniae ATCC 49619,Confirmatory,12773035.0,
1130,56016,6,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against TMP-Resistance DHFR from Staphylococcus pneumoniae 1/1,Other,12773035.0,
1131,56017,6,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against TMP-Resistance Dihydrofolate reductase from Staphylococcus pneumoniae 1/1,Other,12773035.0,
1132,56021,6,4,,103164817,5578,Unspecified,,,,,Inhibitory activity against TMP-Resistance Dihydrofolate reductase from Staphylococcus aureus 157/4696,Other,12773035.0,
1133,56024,6,4,,103164817,5578,Unspecified,,,,,Tested for inhibition of TMP-Resistant Dihydrofolate reductase from Staphylococcus pneumoniae 1/1.,Other,12773035.0,
1134,56157,11,1,,103164817,5578,Active,,,0.075,IC50,Inhibition of Streptococcus pneumoniae dihydrofolate reductase (DHFR) enzyme by Iclaprim,Confirmatory,14623005.0,
1135,56162,9,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition of partially purified dihydrofolate reductase (DHFR) from Toxoplasma gondii (Tg),Confirmatory,11754594.0,
1136,56164,9,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition of Toxoplasma gondii Dihydrofolate Reductase,Confirmatory,9357537.0,
1137,56166,9,2,,103164817,5578,Active,729370.0,,10.0,IC50,Inhibitory concentration against Toxoplasma gondii dihydrofolate reductases (DHFR),Confirmatory,8230134.0,
1138,56167,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition of Toxoplasma gondii (tc) Dihydrofolate reductase,Confirmatory,7783147.0,
1139,56170,7,5,,103164817,5578,Active,729370.0,,2.7,IC50,The compound was tested for inhibition of dihydrofolate reductase(DHFR) from Toxoplasma gondii(tg),Confirmatory,10395486.0,
1140,56171,10,5,,103164817,5578,Active,729370.0,,3.4,IC50,Inhibitory activity against Toxoplasma gondii (tg) Dihydrofolate reductase (DHFR),Confirmatory,12408727.0,
1141,56172,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase.,Confirmatory,8627607.0,
1142,56173,11,2,,103164817,5578,Active,729370.0,,2.7,IC50,Compound was tested for inhibition activity against Dihydrofolate reductase in Toxoplasma gondii (Toxoplasma gondii),Confirmatory,9526565.0,
1143,56175,9,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against dihydrofolate reductase from Toxoplasma gondii,Confirmatory,9548816.0,
1144,56177,11,2,,103164817,5578,Active,729370.0,,2.7,IC50,Concentration inhibiting Toxoplasma gondii dihydrofolate reductase.,Confirmatory,7629801.0,
1145,56180,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition against Dihydrofolate reductase in Toxoplasma gondii,Confirmatory,9089339.0,
1146,56182,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition of Dihydrofolate reductase of Toxoplasma gondii,Confirmatory,7799402.0,
1147,56183,7,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii,Confirmatory,7752201.0,
1148,56184,9,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against Dihydrofolate reductase from Toxoplasma gondii (tgDHFR),Confirmatory,9719595.0,
1149,56186,10,5,,103164817,5578,Active,729370.0,,2.8,IC50,Inhibitory activity against Dihydrohydrofolate reductase(DHFR) of Toxoplasma gondii,Confirmatory,12699390.0,
1150,56187,10,5,,103164817,5578,Active,729370.0,,3.7,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase,Confirmatory,11384244.0,
1151,56188,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition of Dihydrofolate Reductase of Toxoplasma gondii.,Confirmatory,9046338.0,
1152,56310,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) from Toxoplasma gondii,Confirmatory,9804692.0,
1153,56313,9,5,,103164817,5578,Active,729370.0,,0.0072,IC50,Inhibitory activity against recombinant Dihydrofolate reductase from Toxoplasma gondii (tgDHFR),Confirmatory,9719595.0,
1154,56316,11,2,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against DHFR (Dihydrofolate reductase) from Toxoplasma gondii.,Confirmatory,10579848.0,
1155,56317,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against Toxoplasma gondii Dihydrofolate reductase,Confirmatory,7877140.0,
1156,56318,9,5,,103164817,5578,Active,729370.0,,2.73,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase,Confirmatory,8632434.0,
1157,56319,9,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory concentration against Dihydrofolate reductase from Toxoplasma gondii (tg),Confirmatory,9046337.0,
1158,56325,9,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory concentration against dihydrofolate reductase DHFR from Toxoplasma gondii,Confirmatory,11448221.0,
1159,56326,7,5,,103164817,5578,Active,729370.0,,2.8,IC50,Inhibitory concentration against dihydrofolate reductase of Toxoplasma gondii,Confirmatory,14998335.0,
1160,56329,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition of Toxoplasma gondii Dihydrofolate reductase,Confirmatory,9554874.0,
1161,56330,10,5,,103164817,5578,Active,729370.0,,2.7,IC50,The ability to inhibit Toxoplasma gondii Dihydrofolate reductase was tested,Confirmatory,10090784.0,
1162,56331,8,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against purified DHFR (Dihydrofolate reductase) from Toxoplasma gondii,Confirmatory,7658454.0,
1163,56345,8,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibitory activity against Toxoplasma gondii dihydrofolate reductase (in 90 uM dihydrofolic acid),Confirmatory,8691474.0,
1164,56350,7,2,,103164817,5578,Active,,,0.01,Ki,Inhibition of recombinant Dihydrofolate reductase from humans.,Confirmatory,10543874.0,
1165,56459,7,2,,103164817,5578,Active,,,1.0,Ki,Inhibition of recombinant Dihydrofolate reductase from Trypanosoma cruzi.,Confirmatory,10543874.0,
1166,56461,4,10,,103164817,5578,Unspecified,118985.0,427317.0,,,Inhibition of chicken liver dihydrofolate reductase,Other,3701780.0,
1167,56462,8,6,,103164817,5578,Unspecified,118985.0,427317.0,750.0,IC50,Binding affinity against Dihydrofolate reductase of chicken liver,Confirmatory,3973902.0,
1168,56464,10,5,,103164817,5578,Active,118985.0,427317.0,7.6e-06,IC50,Inhibitory activity against Dihydrofolate reductase in chicken,Confirmatory,2666668.0,
1169,56467,8,5,,103164817,5578,Unspecified,118985.0,427317.0,104.713,Ki,Inhibitory activity against chicken liver dihydrofolate reductase,Confirmatory,2502631.0,
1170,56471,4,11,,103164817,5578,Unspecified,118985.0,427317.0,,,Inhibitory activity against chicken dihydrofolate reductase at pH 7.2.,Other,7069722.0,
1171,56473,9,5,,103164817,5578,Unspecified,118985.0,427317.0,730.0,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from chicken liver,Confirmatory,3312605.0,
1172,56483,5,2,,103164817,5578,Unspecified,118985.0,427317.0,104.713,Ki,Compound was evaluated for inhibitory activity against chicken dihydrofolate reductase,Confirmatory,1899453.0,
1173,56485,3,9,,103164817,5578,Unspecified,118985.0,427317.0,,,Inhibition of chicken liver Dihydrofolate reductase (dihydrofolate reductase),Other,9784101.0,
1174,56780,4,2,,103164817,5578,Unspecified,109940075.0,508809.0,158489000.0,IC50,In vitro inhibition of Bovine liver dihydrofolate reductase.,Confirmatory,2404122.0,
1175,56784,4,11,,103164817,5578,Unspecified,109940075.0,508809.0,,,Inhibitory activity against bovine liver dihydrofolate reductase at pH 7.2.,Other,7069722.0,
1176,56792,3,11,,103164817,5578,Unspecified,109940075.0,508809.0,,,Inhibition of bovine liver dehydrofolate reductase.,Other,7005446.0,
1177,56794,3,11,,103164817,5578,Unspecified,109940075.0,508809.0,,,Inhibition of bovine liver dihydrofolate reductase.,Other,6345782.0,
1178,56795,3,11,,103164817,5578,Unspecified,109940075.0,508809.0,,,Inhibition of bovine liver Dihydrofolate reductase.,Other,7277386.0,
1179,56796,3,11,,103164817,5578,Unspecified,109940075.0,508809.0,,,Inhibition of dihydrofolate reductase from bovine liver,Other,7017146.0,
1180,56807,9,2,,103164817,5578,Unspecified,,,490.0,IC50,In vitro inhibition of human dihydrofolate reductase,Confirmatory,7658448.0,
1181,56945,9,2,,103164817,5578,Active,,,3.4,IC50,Compound was evaluated as inhibitor of human Dihydrofolate reductase,Confirmatory,12570380.0,
1182,56953,10,1,,103164817,5578,Active,,,0.9,IC50,Concentration required to inhibit the human Dihydrofolate reductase by 50% was determined (reported by workers at Hoffman-LaRoche),Confirmatory,15115391.0,
1183,56954,6,4,,103164817,5578,Unspecified,,,300.0,IC50,Inhibition of Human dihydrofolate reductase (DHFR) enzyme by Iclaprim,Confirmatory,14623005.0,
1184,56959,9,2,,103164817,5578,Active,,,0.054000000000000006,IC50,Inhibitory activity against Dihydrofolate reductase from recombinant human (hDHFR),Confirmatory,9719595.0,
1185,56963,9,2,,103164817,5578,Unspecified,,,340.0,IC50,Inhibitory activity against recombinant human Dihydrofolate reductase,Confirmatory,12408727.0,
1186,56964,9,5,,103164817,5578,Unspecified,118992.0,1719.0,200.0,IC50,Inhibitory activity against human dihydrofolate reductase,Confirmatory,11384244.0,
1187,56964,9,5,,103164817,5578,Unspecified,118992.0,573971.0,200.0,IC50,Inhibitory activity against human dihydrofolate reductase,Confirmatory,11384244.0,
1188,56968,6,4,,103164817,5578,Unspecified,,,900.0,IC50,Inhibitory activity against TMP-Resistance DHFR from human,Confirmatory,12773035.0,
1189,56971,5,5,,103164817,5578,Unspecified,,,300.0,IC50,Inhibitory concentration against dihydrofolate reductace enzyme of human,Confirmatory,14998335.0,
1190,57072,8,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibitory concentration against dihydrofolate reductace enzyme of Pneumocystis carinii,Confirmatory,14998335.0,
1191,57074,9,5,,103164817,5578,Unspecified,1169444.0,,50.0,IC50,Inhibition of dihydrofolate reductase in Candida albicans (in vitro).,Confirmatory,7658448.0,
1192,57075,10,5,,103164817,5578,Active,1169444.0,,30.3,IC50,Inhibitory activity against cell free dihydrofolate reductase (DHFR) from Candida albicans,Confirmatory,14695838.0,
1193,57080,9,1,,103164817,5578,Active,,,2.0,IC50,Inhibitory concentration against dihydrofolate reductace enzyme of Cryptosporidium parvum of bovine origin,Confirmatory,14998335.0,
1194,57081,11,1,,103164817,5578,Active,,,5.0,IC50,Inhibitory concentration against dihydrofolate reductace enzyme of Cryptosporidium parvum of human origin,Confirmatory,14998335.0,
1195,57082,3,8,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Enterobacter aerogenes 2200/86,Other,7035668.0,
1196,57083,3,10,,103164817,5578,Unspecified,165971782.0,,,,Inhibitory activity against dihydrofolate reductase,Other,11495588.0,
1197,57084,4,8,,103164817,5578,Unspecified,,,,,Inhibition of Escherichia coli dihydrofolate reductase.,Other,7277386.0,
1198,57093,9,5,,103164817,5578,Active,165971782.0,,0.006999999999999999,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) from Escherichia coli,Confirmatory,3100802.0,
1199,57094,9,5,,103164817,5578,Active,165971782.0,,0.005,IC50,Inhibitory activity against Dihydrofolate reductase of Escherichia coli,Confirmatory,7035668.0,
1200,57096,9,5,,103164817,5578,Active,165971782.0,,0.005,IC50,Inhibition against dihydrofolate reductase enzyme of Escherichia coli,Confirmatory,6991695.0,
1201,57097,9,5,,103164817,5578,Active,165971782.0,,0.005,IC50,In vitro inhibition of Escherichia coli dihydrofolate reductase.,Confirmatory,2754716.0,
1202,57100,10,5,,103164817,5578,Active,165971782.0,,0.005,IC50,Inhibitory activity against Dihydrofolate reductase enzyme purified from Escherichia coli,Confirmatory,6991692.0,
1203,57101,9,2,,103164817,5578,Active,,,0.5,IC50,Inhibitory activity to dihydrofolate reductase in Escherichia coli,Confirmatory,2502632.0,
1204,57102,9,5,,103164817,5578,Active,165971782.0,,0.005,IC50,Inhibitory activity against Dihydrofolate reductase in Escherichia coli,Confirmatory,2502633.0,
1205,57103,9,2,,103164817,5578,Active,,,5e-11,IC50,Inhibitory activity against Dihydrofolate reductase in Escherichia coli,Confirmatory,2666668.0,
1206,57105,12,2,,103164817,5578,Active,165971782.0,,0.005,IC50,Inhibitory activity against Dihydrofolate reductase obtained from E. coli; Range 0.005-0.007,Confirmatory,2016714.0,
1207,57106,9,5,,103164817,5578,Active,165971782.0,,0.005,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from Escherichia coli,Confirmatory,3312605.0,
1208,57107,11,5,,103164817,5578,Active,1169444.0,,0.0022,IC50,Inhibitory activity against cell free dihydrofolate reductase (DHFR) from Escherichia coli,Confirmatory,14695838.0,
1209,57141,7,2,,103164817,5578,Active,,,1.38,Ki,Inhibition of recombinant Dihydrofolate reductase from humans.,Confirmatory,10543874.0,
1210,57143,7,2,,103164817,5578,Active,,,0.19498,Ki,Inhibition of human dihydrofolate reductase (DHFR) enzyme,Confirmatory,7699713.0,
1211,57148,3,7,,103164817,5578,Inactive,,,,,Cytotoxicity by selective inhibition against human dihydrofolate reductase (DHFR); NI=no inhibition,Other,11881993.0,
1212,57235,10,5,,103164817,5578,Active,165971782.0,,0.015,IC50,Compound was evaluated as inhibitor of Escherichia coli Dihydrofolate reductase,Confirmatory,12570380.0,
1213,57237,12,2,,103164817,5578,Active,165971782.0,,0.006999999999999999,IC50,Inhibition of Escherichia coli dihydrofolate reductase (DHFR) enzyme by Iclaprim,Confirmatory,14623005.0,
1214,57239,10,5,,103164817,5578,Active,165971782.0,,0.018000000000000002,IC50,Inhibitory activity against recombinant Dihydrofolate reductase from Escherichia coli (ecDHFR),Confirmatory,9719595.0,
1215,57240,10,5,,103164817,5578,Active,165971782.0,,1.0,IC50,Inhibitory activity against recombinant Escherichia coli dihydrofolate reductase,Confirmatory,11384244.0,
1216,57244,9,5,,103164817,5578,Active,165971782.0,,0.037000000000000005,IC50,Inhibition of Escherichia coli Dihydrofolate reductase in presence of 100 uM Dihydrofolate reductase,Confirmatory,12852950.0,
1217,57245,8,5,,103164817,5578,Active,165971782.0,,0.018000000000000002,IC50,Inhibition of Escherichia coli Dihydrofolate reductase in presence of 30 uM Dihydrofolate reductase,Confirmatory,12852950.0,
1218,57249,5,3,,103164817,5578,Unspecified,165971782.0,,,,Relative Binding affinity against Dihydrofolate reductase of Escherichia coli,Other,3973902.0,
1219,57274,8,5,,103164817,5578,Active,165971782.0,,0.0013,Ki,Antibacterial activity against Escherichia coli,Confirmatory,2754716.0,
1220,57395,12,2,,103164817,5578,Active,165971782.0,,0.0013,Ki,Binding affinity against Dihydrofolate reductase of Escherichia coli,Confirmatory,3973902.0,
1221,57396,8,5,,103164817,5578,Active,165971782.0,,0.0013,Ki,Binding affinity for Escherichia coli Dihydrofolate reductase,Confirmatory,6754932.0,
1222,57403,8,5,,103164817,5578,Active,165971782.0,,0.0038,Ki,Inhibition constant against Dihydrofolate reductase,Confirmatory,12852950.0,
1223,57410,8,5,,103164817,5578,Active,165971782.0,,0.0013,Ki,Apparent binding affinity against Dihydrofolate reductase in Escherichia coli,Confirmatory,2666668.0,
1224,57435,3,11,,103164817,5578,Unspecified,165971782.0,,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Escherichia coli CN 314,Other,7035668.0,
1225,57470,4,6,,103164817,5578,Unspecified,,,,,Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate,Other,6699880.0,
1226,57573,4,11,,103164817,5578,Unspecified,165971782.0,,,,Ratio of IC50 in presence of 100 uM Dihydrofolate reductase,Other,12852950.0,
1227,57574,3,10,,103164817,5578,Unspecified,165971782.0,,,,Activity against dihydrofolate reductase of Escherichia coli strain MB 1428,Other,1507206.0,
1228,57578,5,2,,103164817,5578,Active,165971782.0,,0.00589,IC50,Compound was tested for inhibition of Escherichia coli Dihydrofolate reductase.,Confirmatory,8941396.0,
1229,57579,5,2,,103164817,5578,Active,,,0.008320000000000001,Ki,Inhibitory activity against Escherichia coli dihydrofolate reductase,Confirmatory,1899453.0,
1230,57580,4,2,,103164817,5578,Unspecified,165971782.0,,10000.0,IC50,In vitro inhibition of Escherichia coli (B41) Dihydrofolate reductase.,Confirmatory,2404122.0,
1231,57582,3,11,,103164817,5578,Unspecified,165971782.0,,,,In vitro inhibition of E. Coli dihydrofolate reductase.,Other,7005446.0,
1232,57583,4,7,,103164817,5578,Unspecified,,,,,Inhibition of dihydrofolate reductase (DHFR) from Escherichia coli.,Other,3882967.0,
1233,57584,3,10,,103164817,5578,Unspecified,165971782.0,,,,Apparent inhibitory (log 1/Ki) activity against Escherichia coli dihydrofolate reductase,Other,3276891.0,
1234,57585,3,11,,103164817,5578,Unspecified,165971782.0,,,,Inhibitory activity against dihydrofolate reductase (DHFR) from Escherichia coli (expressed as log 1/Kiapp),Other,6809941.0,
1235,57586,3,11,,103164817,5578,Unspecified,165971782.0,,,,Compound is evaluated for the inhibition of dihydrofolate reductase from Escherichia coli,Other,7017146.0,
1236,57588,4,1,,103164817,5578,Unspecified,165971782.0,,741310000000000.0,Ki,Inhibition constant against binding of Escherichia coli dihydrofolate reductase,Confirmatory,3290487.0,
1237,57589,11,2,,103164817,5578,Active,165971782.0,,0.45,IC50,Inhibitory activity against Dihydrofolate reductase in Neisseria gonorrhoeae,Confirmatory,2502632.0,
1238,57591,9,5,,103164817,5578,Active,165971782.0,,0.006999999999999999,IC50,Inhibitory activity against Escherichia coli dihydrofolate reductase at 10e8 M,Confirmatory,1995876.0,
1239,57592,10,5,,103164817,5578,Active,165971782.0,,0.02,IC50,Inhibitory activity against Escherichia coli (ec) Dihydrofolate reductase,Confirmatory,12408727.0,
1240,57602,3,8,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration versus trimethoprim against Dihydrofolate Reductase of Klebsiella pneumoniae CN 3632,Other,7035668.0,
1241,57603,8,5,,103164817,5578,Active,7227951.0,,0.10300000000000001,IC50,Inhibitory activity against Dihydrofolate reductase from Lactobacillus casei,Confirmatory,7752201.0,
1242,57604,3,7,,103164817,5578,Unspecified,,,,,Binding affinity for dihydrofolate reductase from Lactobacillus casei,Other,9379435.0,
1243,57612,10,2,,103164817,5578,Active,75426075.0,,0.3,IC50,Concentration required to inhibit the Mycobacterium avium Dihydrofolate reductase by 50% was determined; Range: 260-350,Confirmatory,15115391.0,
1244,57618,10,2,,103164817,5578,Active,118998.0,,0.046,IC50,Concentration required to inhibit the Pneumocystis carinii Dihydrofolate reductase by 50% was determined (reported by workers at Hoffman-LaRoche),Confirmatory,15115391.0,
1245,57621,10,2,,103164817,5578,Active,118998.0,,13.0,IC50,Concentration required to inhibit the Pneumocystis carinii Dihydrofolate reductase by 50% was determined; Range: 10000-16000,Confirmatory,15115391.0,
1246,57630,7,2,,103164817,5578,Active,,,12.0,IC50,Inhibition of dihydrofolate reductase from pneumocystis carinii.,Confirmatory,14584957.0,
1247,57637,9,1,,103164817,5578,Unspecified,,,340.0,IC50,Binding affinity against Dihydrofolate reductase of rat liver,Confirmatory,3973902.0,
1248,57638,9,1,,103164817,5578,Unspecified,,,370.0,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) from rat liver,Confirmatory,3100802.0,
1249,57641,9,1,,103164817,5578,Unspecified,,,260.0,IC50,Inhibition of rat liver Dihydrofolate reductase.,Confirmatory,7035668.0,
1250,57642,7,3,,103164817,5578,Unspecified,,,260.0,IC50,Inhibition against dihydrofolate reductase enzyme of rat liver,Confirmatory,6991695.0,
1251,57644,9,1,,103164817,5578,Unspecified,,,300.0,IC50,In vitro inhibition of rat liver dihydrofolate reductase.,Confirmatory,2754716.0,
1252,57647,9,1,,103164817,5578,Active,,,34.0,IC50,Inhibition of Rat liver Dihydrofolate reductase(DHFR),Confirmatory,3121854.0,
1253,57648,9,1,,103164817,5578,Unspecified,,,260.0,IC50,Inhibitory activity against Dihydrofolate reductase enzyme purified from rat liver.,Confirmatory,6991692.0,
1254,57739,9,5,,103164817,5578,Active,7227951.0,,0.62,IC50,Compound was evaluated as inhibitor of Lactobacillus casei Dihydrofolate reductase,Confirmatory,12570380.0,
1255,57753,10,5,,103164817,5578,Active,7227951.0,,0.054000000000000006,IC50,Inhibitory activity against Dihydrofolate reductase from Lactobacillus casei (lcDHFR),Confirmatory,9719595.0,
1256,57779,8,5,,103164817,5578,Active,7227951.0,,0.13183,Ki,Inhibitory activity against Lactobacillus casei dihydrofolate reductase,Confirmatory,2502631.0,
1257,57780,9,1,,103164817,5578,Unspecified,,,340.0,IC50,Inhibitory activity against dihydrofolate reductase in rat liver,Confirmatory,2502632.0,
1258,57781,9,1,,103164817,5578,Unspecified,,,340.0,IC50,Inhibitory activity against Dihydrofolate reductase in rat liver,Confirmatory,2502633.0,
1259,57782,9,1,,103164817,5578,Active,,,2.6e-06,IC50,Inhibitory activity against Dihydrofolate reductase in rat liver,Confirmatory,2666668.0,
1260,57784,6,3,,103164817,5578,Unspecified,,,260.0,IC50,Inhibitory activity against Dihydrofolate reductase obtained from rat liver; Range 260-370,Confirmatory,2016714.0,
1261,57785,9,1,,103164817,5578,Unspecified,,,260.0,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from rat liver,Confirmatory,3312605.0,
1262,57788,9,1,,103164817,5578,Unspecified,,,370.0,IC50,Inhibitory activity against rat liver dihydrofolate reductase at 10e8 M,Confirmatory,1995876.0,
1263,57789,10,2,,103164817,5578,Unspecified,,,190.0,IC50,Inhibitory activity against cell free dihydrofolate reductase (DHFR) from rat,Confirmatory,14695838.0,
1264,57796,10,5,,103164817,5578,Unspecified,81871579.0,24312.0,130.0,IC50,Inhibition of partially purified dihydrofolate reductase (DHFR) from rat liver,Confirmatory,11754594.0,
1265,57797,9,1,,103164817,5578,Unspecified,,,130.0,IC50,Compound was tested for inhibition activity against rat liver lipophilic Dihydrofolate reductase (DHFR).,Confirmatory,9526565.0,
1266,57798,9,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory activity against dihydrofolate reductase from rat liver,Confirmatory,9548816.0,
1267,57799,9,1,,103164817,5578,Unspecified,,,130.0,IC50,Concentration inhibiting rat liver dihydrofolate reductase.,Confirmatory,7629801.0,
1268,57810,5,4,,103164817,5578,Unspecified,,,180.0,IC50,Concentration required to inhibit the rat liver Dihydrofolate reductase by 50% was determined; Range: 160000-210000,Confirmatory,15115391.0,
1269,57814,9,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibition against Dihydrofolate reductase in rat liver,Confirmatory,9089339.0,
1270,57817,9,1,,103164817,5578,Unspecified,,,130.0,IC50,Inhibition of rat liver Dihydrofolate Reductase,Confirmatory,9357537.0,
1271,57819,9,5,,103164817,5578,Unspecified,81871579.0,24312.0,130.0,IC50,Inhibition of Dihydrofolate reductase (DHFR) of in rat liver,Confirmatory,7799402.0,
1272,57820,8,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory activity against Dihydrofolate reductase from rat liver,Confirmatory,7752201.0,
1273,57821,6,3,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory activity against Dihydrofolate reductase from rat liver ( rlDHFR),Confirmatory,9719595.0,
1274,57824,9,5,,103164817,5578,Unspecified,81871579.0,24312.0,180.0,IC50,Inhibition Dihydrohydrofolate reductase(DHFR) of rat liver,Confirmatory,12699390.0,
1275,57825,9,5,,103164817,5578,Unspecified,81871579.0,24312.0,133.0,IC50,Inhibition of Dihydrofolate Reductase of Rat Liver.,Confirmatory,9046338.0,
1276,57925,3,11,,103164817,5578,Unspecified,7227951.0,,,,Inhibitory activity against dihydrofolate reductase (DHFR) from Lactobacillus casei (expressed as log 1/Kiapp),Other,6809941.0,
1277,57926,3,9,,103164817,5578,Unspecified,7227951.0,,,,Inhibition of Dihydrofolate reductase from Lactobacillus casei,Other,9784101.0,
1278,57948,7,2,,103164817,5578,Active,,,0.12,Ki,Inhibition of recombinant Dihydrofolate reductase from Leishmania major.,Confirmatory,10543874.0,
1279,57951,10,5,,103164817,5578,Active,75426075.0,,0.19,IC50,Inhibition of partially purified dihydrofolate reductase (DHFR) from Mycobacterium avium (Ma),Confirmatory,11754594.0,
1280,57956,9,5,,103164817,5578,Active,75426075.0,,0.3,IC50,Inhibition of Dihydrohydrofolate reductase(DHFR) of Mycobacterium avium,Confirmatory,12699390.0,
1281,57959,12,2,,103164817,5578,Active,75426075.0,,0.19,IC50,Inhibitory activity against DHFR (Dihydrofolate reductase) from Mycobacterium avium,Confirmatory,10579848.0,
1282,57960,8,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibition of dihydrofolate reductase from rat liver.,Confirmatory,14584957.0,
1283,57961,9,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) from rat liver,Confirmatory,9804692.0,
1284,57967,6,3,,103164817,5578,Unspecified,,,130.0,IC50,Inhibitory activity against DHFR (Dihydrofolate reductase) from Rat liver.,Confirmatory,10579848.0,
1285,57968,9,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory activity against rat liver dihydrofolate reductase,Confirmatory,8632434.0,
1286,57969,9,1,,103164817,5578,Unspecified,,,130.0,IC50,Inhibitory activity against rat liver dihydrofolate reductase.,Confirmatory,8627607.0,
1287,57970,8,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory activity against rat liver dihydrofolate reductase (in 90 uM dihydrofolic acid),Confirmatory,8691474.0,
1288,57972,9,1,,103164817,5578,Unspecified,,,130.0,IC50,Inhibitory activity against rat liver Dihydrofolate reductase,Confirmatory,7877140.0,
1289,57977,9,1,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory concentration against Dihydrofolate reductase from Rat liver (rl),Confirmatory,9046337.0,
1290,57979,9,1,,103164817,5578,Unspecified,,,121.0,IC50,Inhibitory concentration against dihydrofolate reductase DHFR from rat liver.,Confirmatory,11448221.0,
1291,57980,8,1,,103164817,5578,Unspecified,,,180.0,IC50,Inhibitory concentration against dihydrofolate reductase of rat liver,Confirmatory,14998335.0,
1292,57981,9,1,,103164817,5578,Active,,,40.0,IC50,Inhibitory concentration against rat liver (RL) dihydrofolate reductases (DHFR),Confirmatory,8230134.0,
1293,57984,10,5,,103164817,5578,Unspecified,81871579.0,24312.0,133.0,IC50,Inhibition of rat liver Dihydrofolate reductase,Confirmatory,7783147.0,
1294,57985,9,5,,103164817,5578,Unspecified,81871579.0,24312.0,133.0,IC50,Inhibition of Dihydrofolate reductase of rat liver,Confirmatory,9554874.0,
1295,57989,9,1,,103164817,5578,Unspecified,,,130.0,IC50,The ability to inhibit rat liver Dihydrofolate reductase was tested,Confirmatory,10090784.0,
1296,57991,8,1,,103164817,5578,Unspecified,,,133.0,IC50,The compound was tested for inhibition of dihydrofolate reductase(DHFR) from rat liver (rl),Confirmatory,10395486.0,
1297,57992,8,2,,103164817,5578,Unspecified,,,133.0,IC50,Inhibitory activity against purified DHFR (Dihydrofolate reductase) from rat,Confirmatory,7658454.0,
1298,58091,8,5,,103164817,5578,Active,75426075.0,,0.3,IC50,Inhibitory concentration against dihydrofolate reductase of Mycobacterium avium,Confirmatory,14998335.0,
1299,58100,10,5,,103164817,5578,Active,1169444.0,,0.27,IC50,Inhibitory activity against cell free dihydrofolate reductase (DHFR) from Mycobacterium lufu,Confirmatory,14695838.0,
1300,58101,9,5,,103164817,5578,Active,118996.0,,0.45,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) of Neisseria gonorrhoea,Confirmatory,3100802.0,
1301,58102,9,2,,103164817,5578,Active,,,0.45,IC50,In vitro inhibition of dihydrofolate reductase enzymes in Neisseria gonorrhoeae,Confirmatory,2754716.0,
1302,58103,9,2,,103164817,5578,Active,,,0.45,IC50,In vitro inhibition of dihydrofolate reductase of Neisseria gonorrhoeae,Confirmatory,2754716.0,
1303,58104,9,2,,103164817,5578,Active,,,0.45,IC50,Inhibition of Neisseria gonorrhoeae Dihydrofolate reductase(DHFR),Confirmatory,3121854.0,
1304,58105,9,2,,103164817,5578,Active,,,0.45,IC50,Inhibitory activity against Dihydrofolate reductase in Neisseria gonorrhoeae,Confirmatory,2502633.0,
1305,58106,9,2,,103164817,5578,Active,,,0.45,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from Neisseria gonorrhoeae,Confirmatory,3312605.0,
1306,58108,9,5,,103164817,5578,Active,118996.0,,0.45,IC50,Inhibitory activity against Neisseria gonorrhoeae dihydrofolate reductase at 10e8 M,Confirmatory,1995876.0,
1307,58109,9,2,,103164817,5578,Active,,,0.12,IC50,Inhibitory activity against Dihydrofolate reductase enzyme purified from Plasmodium berghei.,Confirmatory,6991692.0,
1308,58110,9,2,,103164817,5578,Active,,,0.12,IC50,Compound was tested for its inhibition against dihydrofolate reductase enzyme of Plasmodium berghei,Confirmatory,6991695.0,
1309,58112,9,2,,103164817,5578,Active,,,0.12,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) enzyme from Plasmodium berghei,Confirmatory,3312605.0,
1310,58115,9,2,,103164817,5578,Active,,,0.12,IC50,Inhibitory activity against dihydrofolate reductase (DHFR) of Plasmodium berghei,Confirmatory,3100802.0,
1311,58151,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selective index for rat liver and Mycobacterium avium dihydrofolate reductase,Other,11754594.0,
1312,58153,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selective index against dihydrofolate reductase of Rat liver and dihydrofolate reductase of Pneumocystis carinii,Other,11754594.0,
1313,58154,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selective index against dihydrofolate reductase of Rat liver and Toxoplasma gondii,Other,11754594.0,
1314,58155,3,6,,103164817,5578,Unspecified,,,,,Relative affinity for Dihydrofolate reductase of rat liver and Mycobacterium avium,Other,12699390.0,
1315,58156,3,9,,103164817,5578,Unspecified,118998.0,,,,Relative affinity for Dihydrofolate reductase from rat liver and Pneumocystis carinii,Other,12699390.0,
1316,58156,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Relative affinity for Dihydrofolate reductase from rat liver and Pneumocystis carinii,Other,12699390.0,
1317,58157,3,9,,103164817,5578,Unspecified,729370.0,,,,Selective index for Dihydrofolate reductase was determined by IC50(rat liver) / IC50(Toxoplasma gondii),Other,12699390.0,
1318,58157,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selective index for Dihydrofolate reductase was determined by IC50(rat liver) / IC50(Toxoplasma gondii),Other,12699390.0,
1319,58159,3,6,,103164817,5578,Unspecified,,,,,The concentration required to inhibit dihydrofolate reductase in rat liver,Other,6737433.0,
1320,58163,3,8,,103164817,5578,Unspecified,,,,,Inhibition of dihydrofolate reductase,Other,6864738.0,
1321,58253,7,2,,103164817,5578,Active,,,0.2421,Ki,Inhibition of the C59R+S108N mutant of dihydrofolate reductase (DHFR),Confirmatory,11881993.0,
1322,58254,7,2,,103164817,5578,Active,,,0.1323,Ki,Inhibition of the S108N mutant of dihydrofolate reductase (DHFR),Confirmatory,11881993.0,
1323,58255,7,2,,103164817,5578,Active,,,0.0103,Ki,Inhibition of the wild-type dihydrofolate reductase (DHFR),Confirmatory,11881993.0,
1324,58256,7,2,,103164817,5578,Active,,,0.2421,Ki,Inhibitory activity against double mutant dihydrofolate reductase (C59R+S108N DHFR),Confirmatory,14711307.0,
1325,58257,7,2,,103164817,5578,Active,,,6.6645,Ki,Inhibitory activity against quadruple mutant dihydrofolate reductase (N51I C59R S108N I164L DHFR),Confirmatory,14711307.0,
1326,58258,7,2,,103164817,5578,Active,,,5.6887,Ki,Inhibitory activity against triple mutant dihydrofolate reductase (C59R S108 NI164L DHFR),Confirmatory,14711307.0,
1327,58277,3,7,,103164817,5578,Unspecified,,,,,"Inhibitory activity against double mutant dihydrofolate reductase (C59R S108N DHFR), relative to trimethoprim",Other,14711307.0,
1328,58278,3,7,,103164817,5578,Unspecified,,,,,"Inhibitory activity against quadruple mutant dihydrofolate reductase (N51I C59R S108N I164L DHFR), relative to trimethoprim",Other,14711307.0,
1329,58279,3,7,,103164817,5578,Unspecified,,,,,"Inhibitory activity against triple mutant dihydrofolate reductase (C59R S108 NI164L DHFR), relative to trimethoprim",Other,14711307.0,
1330,63877,5,1,,103164817,5578,Unspecified,,,,,Antibacterial activity (10 e-6 log (1/MIC) ) against Escherichia coli,Other,2404122.0,
1331,64568,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial activity against Escherichia coli (CN314),Other,3312605.0,
1332,65039,4,1,,103164817,5578,Unspecified,,,,,Relative in vitro Antibacterial activity against Escherichia coli CN314 strain,Other,3973902.0,
1333,65357,4,3,,103164817,5578,Unspecified,,,,,Inhibition of growth of methotrexate-sensitive (MB1417) strain of Escherichia coli cells.,Other,3934385.0,
1334,65359,4,3,,103164817,5578,Unspecified,,,,,Inhibition of growth of methotrexate-resistant (MB1428) strain of Escherichia coli cells.,Other,3934385.0,
1335,66125,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus species,Other,14623005.0,
1336,67530,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Enterobacter aerogenes 2201/86) activity compared to trimethoprim.,Other,2754716.0,
1337,67696,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial activity against Enterobacter aerogenes (2200/86),Other,3312605.0,
1338,67717,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Enterobacter aerogenes (2200/186) was measured,Other,3121854.0,
1339,67872,6,2,,103164817,5578,Unspecified,,,,,"Ratio of antibacterial (Enterobacter aerogenes, 2201/86) activities of compound and trimethoprim",Other,2754716.0,
1340,68678,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial effect against E. c. Vogel by using gradient plate test,Other,7009868.0,
1341,69024,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Escherichia coli (CN314) was measured,Other,3121854.0,
1342,69791,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Escherichia coli) activity compared to trimethoprim.,Other,2754716.0,
1343,70450,3,3,,103164817,5578,Unspecified,,,,,The logarithm of the inverse of the concentration (log 1/C) for the inhibition of Escherichia coli MB 1428 growth by 80%,Other,3276891.0,
1344,70451,3,3,,103164817,5578,Unspecified,,,,,The logarithm of the inverse of the concentration (log 1/C) for the inhibition of Escherichia coli 1515 (Escherichia coli) growth by 80%,Other,3276891.0,
1345,70634,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Escherichia coli CN314) activities of compound and trimethoprim,Other,2754716.0,
1346,70706,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli CN314.,Other,6991692.0,
1347,70710,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli CN348 in mice in experiment 1,Other,7035668.0,
1348,70711,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli CN348 in mice in experiment 2,Other,7035668.0,
1349,70712,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli CN348 in mice in experiment 3,Other,7035668.0,
1350,72257,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Fusobacterium nucleatum) activities compared to that of trimethoprim and metronidazole,Other,2754716.0,
1351,85783,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Haemophillia influenzae,Other,14623005.0,
1352,91481,4,7,,103164817,5578,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
1353,94235,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Klebsiella pneumoniae CN3632) activity compared to trimethoprim.,Other,2754716.0,
1354,94239,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae CN3632 in mice in experiment 1,Other,7035668.0,
1355,94359,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae CN3632 in mice in experiment 2,Other,7035668.0,
1356,94360,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae CN3632 in mice in experiment 3,Other,7035668.0,
1357,95371,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Klebsiella pneumoniae CN3632) activities of compound and trimethoprim,Other,2754716.0,
1358,95488,6,2,,103164817,5578,Unspecified,,,250.0,IC50,Cytotoxicity against human epidermoid carcinoma KB cell.,Confirmatory,11881993.0,
1359,95763,4,3,,103164817,5578,Active,,,0.10300000000000001,IC50,Inhibitory concentration against Lactobacillus casei,Confirmatory,8230134.0,
1360,96057,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae CN 3632.,Other,6991692.0,
1361,96248,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial activity against Klebsiella pneumoniae (CN 3632),Other,3312605.0,
1362,96432,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Klebsiella pneumoniae (CN3632) was measured,Other,3121854.0,
1363,99653,3,4,,103164817,5578,Unspecified,,,,,Inhibitory activity against murine tumor cells (L5178Y/R),Other,7086836.0,
1364,99656,3,4,,103164817,5578,Unspecified,,,,,Inhibitory activity against murine tumor cells (L5178Y/S),Other,7086836.0,
1365,106806,3,8,,103164817,5578,Unspecified,,,,,Inhibition of malate dehydrogenase (MDH) at 400 uM,Other,14521410.0,
1366,125103,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Moraxella catarrhalis,Other,14623005.0,
1367,132397,6,2,,103164817,5578,Unspecified,,,,,Efficacy of compound to protect the methicillin resistant Staphylococcus aureus infected murine iv administration,Other,14623005.0,
1368,132399,6,2,,103164817,5578,Unspecified,,,,,Efficacy of compound to protect the methicillin resistant Staphylococcus pneumoniae infected murine sc administration,Other,14623005.0,
1369,138421,3,3,,103164817,5578,Unspecified,,,,,Effect on Pneumocystis carinii pneumonia in SCID mice in the presence of SMX,Other,8632413.0,
1370,139500,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 10 min after oral administration of 10 mg dose,Other,7035668.0,
1371,139501,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 10 min after oral administration of 2 mg dose,Other,7035668.0,
1372,139502,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 180 min after oral administration of 10 mg dose,Other,7035668.0,
1373,139503,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 180 min after oral administration of 2 mg dose,Other,7035668.0,
1374,139504,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 30 min after oral administration of 10 mg dose,Other,7035668.0,
1375,139622,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 30 min after oral administration of 2 mg dose,Other,7035668.0,
1376,139623,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 360 min after oral administration of 10 mg dose,Other,7035668.0,
1377,139624,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 360 min after oral administration of 2 mg dose,Other,7035668.0,
1378,139625,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 90 min after oral administration of 10 mg dose,Other,7035668.0,
1379,139626,5,1,,103164817,5578,Unspecified,,,,,Concentration of compound in serum of mouse 90 min after oral administration of 2 mg dose,Other,7035668.0,
1380,139627,3,4,,103164817,5578,Unspecified,,,,,Half-life in serum of mice after oral administration of 10 mg dose,Other,7035668.0,
1381,139628,3,4,,103164817,5578,Unspecified,,,,,Half-life in serum of mice after oral administration of 2 mg dose,Other,7035668.0,
1382,139779,3,3,,103164817,5578,Active,,,,,Number of mice infected to that of total number of mice in the presence of SMX (8/10),Other,8632413.0,
1383,143423,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial effect against M. t. H37Rv by using gradient plate test,Other,7009868.0,
1384,143854,6,2,,103164817,5578,Unspecified,,,,,Minimum inhibitory concentration required against Mycobacterium avium isolate; Not inhibitory,Other,14998335.0,
1385,144372,10,2,,103164817,5578,Unspecified,129288.0,938339.0,1.0,IC50,Inhibitory activity against Bacillus subtilis NAD synthetase,Confirmatory,12852767.0,
1386,144450,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Mycobacterium smegmatis (S3254) was measured,Other,3121854.0,
1387,144570,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Mycobacterium smegmatis S3254) activity compared to trimethoprim.,Other,2754716.0,
1388,147026,8,1,,103164817,5578,Unspecified,,,,,Inhibition of growth of Neisseria gonorrhoeae,Other,3121854.0,
1389,151378,4,1,,103164817,5578,Unspecified,,,,,Relative in vitro Antibacterial activity against Proteus vulgaris CN329 strain,Other,3973902.0,
1390,151983,3,3,,103164817,5578,Unspecified,,,,,Inhibitory concentration against Pneumocystis carinii cells in human embryonic lung fibrobalstic cell culture with MEM at 50 ug/mL,Other,8230134.0,
1391,155929,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Pasteurella multocides ATCC 6587) activity compared to trimethoprim.,Other,2754716.0,
1392,157842,6,3,,103164817,5578,Unspecified,,,136.5,IC50,Antiplasmodial activity IC50 against Plasmodium falciparum K1CB1 DHFR double-mutant (C59R/S10),Confirmatory,11881993.0,
1393,158189,6,2,,103164817,5578,Active,,,6.7,IC50,In vitro antiplasmodial activity (IC50) against Plasmodium falciparum wtTM4/8.2,Confirmatory,11881993.0,
1394,161281,10,5,,103164817,5578,Unspecified,7531135.0,3757.0,239.88299999999998,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
1395,163212,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus vulgaris CN 329.,Other,6991692.0,
1396,163241,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial activity against Proteus vulgaris (CN3296),Other,3312605.0,
1397,163399,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Proteus vulgaris (CN329) was measured,Other,3121854.0,
1398,163574,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Proteus vulgaris CN329) activities of compound and trimethoprim,Other,2754716.0,
1399,163575,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Proteus vulgaris CN329) activity compared to trimethoprim.,Other,2754716.0,
1400,163578,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Proteus vulgaris CN329 in mice in experiment 1,Other,7035668.0,
1401,163579,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Proteus vulgaris CN329 in mice in experiment 2,Other,7035668.0,
1402,163934,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial effect against P.a 28 by using gradient plate test,Other,7009868.0,
1403,197851,5,1,,103164817,5578,Unspecified,,,,,Antibacterial activity (10 e-6 log (1/MIC) ) against Staphylococcus aureus,Other,2404122.0,
1404,198341,4,1,,103164817,5578,Unspecified,,,,,Relative in vitro Antibacterial activity against Salmonella typhi CN512 strain,Other,3973902.0,
1405,200503,8,1,,103164817,5578,Active,,,,,Antibacterial activity by measuring minimal inhibitory concentration against Salmonella enteritidis ATCC 13076,Other,12852767.0,
1406,201272,4,1,,103164817,5578,Unspecified,,,,,Relative in vitro Antibacterial activity against Staphylococcus aureus CN491 strain,Other,3973902.0,
1407,201392,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against typhi CN512.,Other,6991692.0,
1408,201393,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial activity against Salmonella typhi (CN512),Other,3312605.0,
1409,201395,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Salmonella typhi (CN512) was measured,Other,3121854.0,
1410,201535,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Salmonella typhi CN512) activities of compound and trimethoprim,Other,2754716.0,
1411,201536,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Salmonella typhi CN512) activity compared to trimethoprim.,Other,2754716.0,
1412,203035,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against of against Shig dysentariae CN 1523.,Other,6991692.0,
1413,203044,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Shigella dysentariae CN513) activities of compound and trimethoprim,Other,2754716.0,
1414,203150,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Serratia marcescens (CN2398) was measured,Other,3121854.0,
1415,203184,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial activity against Shigella flexneri (CN6007),Other,3312605.0,
1416,203187,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Shigella flexneri (CN6007) was measured,Other,3121854.0,
1417,203195,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Shigella flexneri CN6007) activity compared to trimethoprim.,Other,2754716.0,
1418,203216,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial effect against S. s C-10 by using gradient plate test,Other,7009868.0,
1419,203270,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Staphylococcus pyogenes CN10) activities of compound and trimethoprim,Other,2754716.0,
1420,203271,6,2,,103164817,5578,Unspecified,,,,,Ratio of antibacterial (Staphylococcus aureus CN491) activities of compound and trimethoprim,Other,2754716.0,
1421,203294,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial effect against S. a. S18713 by using gradient plate test,Other,7009868.0,
1422,203295,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial effect against S. a. UC-76 by using gradient plate test,Other,7009868.0,
1423,203314,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Serratia marcescens CN2398) activity compared to trimethoprim.,Other,2754716.0,
1424,205197,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against of against Serr. marcescens CN 398.,Other,6991692.0,
1425,206280,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial activity against Staphylococcus aureus (CN491),Other,3312605.0,
1426,206646,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin resistant Staphylococcus aureus (MRSA),Other,14623005.0,
1427,206647,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin susceptible Staphylococcus aureus (MSSA),Other,14623005.0,
1428,206822,6,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus pyogenes,Other,14623005.0,
1429,207008,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus CN491.,Other,6991692.0,
1430,207387,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Staphylococcus aureus (CN491) was measured,Other,3121854.0,
1431,207577,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Staphylococcus aureus CN491) activity compared to trimethoprim.,Other,2754716.0,
1432,207694,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CN491 in mice in experiment 1,Other,7035668.0,
1433,207695,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CN491 in mice in experiment 2,Other,7035668.0,
1434,207696,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus CN491 in mice in experiment 3,Other,7035668.0,
1435,208623,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus pneumoniae (PEN-R),Other,14623005.0,
1436,208756,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus agalactiae,Other,14623005.0,
1437,209129,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pyogenes CN10,Other,6991692.0,
1438,209414,6,2,,103164817,5578,Unspecified,,,,,In vitro antibacterial effect against S. f MGH-2,Other,7009868.0,
1439,210397,6,2,,103164817,5578,Unspecified,,,,,Antibacterial (Staphylococcus pyogenes CN10) activity compared to trimethoprim.,Other,2754716.0,
1440,215506,6,2,,103164817,5578,Unspecified,,,148.0,IC50,Inhibition of Trypanosoma brucei rhodesiense growth,Confirmatory,10543874.0,
1441,216566,6,2,,103164817,5578,Unspecified,,,,,Inhibition of growth of Vibrio cholera (ATCC 14035) was measured,Other,3121854.0,
1442,218759,5,1,,103164817,5578,Unspecified,,,,,Peak serum concentration reached within 1 hr of administration of 5 mg/kg oral dose,Other,7035668.0,
1443,218760,3,3,,103164817,5578,Unspecified,,,,,Average half-life upon rapid elimination from serum in dog at 5 mg/kg orally on day 1,Other,7035668.0,
1444,219251,7,2,,103164817,5578,Active,,,0.0103,Ki,Inhibitory activity against wild-type dihydrofolate reductase (S108N DHFR),Confirmatory,14711307.0,
1445,219252,3,7,,103164817,5578,Unspecified,,,,,"Inhibitory activity against wild-type dihydrofolate reductase (S108N DHFR), relative to trimethoprim",Other,14711307.0,
1446,227718,7,1,,103164817,5578,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
1447,227866,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against streptococcus pyogenes CN10 in mice in experiment 1,Other,7035668.0,
1448,227867,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against streptococcus pyogenes CN10 in mice in experiment 2,Other,7035668.0,
1449,227868,4,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against streptococcus pyogenes CN10 in mice in experiment 3,Other,7035668.0,
1450,229041,6,2,,103164817,5578,Unspecified,,,50.0,IC50,Cytotoxicity by the selective inhibition against African green monkey kidney fibroblast (vero cells).,Confirmatory,11881993.0,
1451,229432,3,5,,103164817,5578,Unspecified,,,,,Selectivity ratio against human and Staphylococcus pneumoniae ATCC 49619 dihydrofolate reductase,Other,12773035.0,
1452,229443,3,4,,103164817,5578,Unspecified,,,,,Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of Escherichia coli (ec) DHFR.,Other,12408727.0,
1453,229444,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of pneumocystis carinii (pc ) DHFR.,Other,12408727.0,
1454,229445,3,4,,103164817,5578,Unspecified,,,,,Selectivity ratio as the ratio of IC50 value against recombinant human (rh) DHFR to that of Toxoplasma gondii (tg) DHFR.,Other,12408727.0,
1455,229684,3,9,,103164817,5578,Unspecified,118998.0,,,,Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii,Other,7799402.0,
1456,229684,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii,Other,7799402.0,
1457,229685,3,9,,103164817,5578,Unspecified,729370.0,,,,Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii,Other,7799402.0,
1458,229685,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii,Other,7799402.0,
1459,229964,4,3,,103164817,5578,Unspecified,,,,,IC50 ratio against Plasmodium falciparum K1CB1/TM4,Other,11881993.0,
1460,230159,3,5,,103164817,5578,Unspecified,,,,,The compound was tested for ratio of inhibition of dihydrofolate reductase(DHFR) from rat(rl) liver and Pneumocystis carinii(pc),Other,10395486.0,
1461,230160,3,5,,103164817,5578,Unspecified,,,,,The compound was tested for ratio of inhibition of dihydrofolate reductase(DHFR) from rat(rl) liver and Toxoplasma gondii(tg),Other,10395486.0,
1462,231131,3,5,,103164817,5578,Unspecified,,,,,Ratio of the inhibitory concentrations against rat liver DHFR and Pneumocystis carinii DHFR,Other,7752201.0,
1463,231132,3,9,,103164817,5578,Unspecified,729370.0,,,,Ratio of the inhibitory concentrations against rat liver DHFR and Toxoplasma gondii DHFR.,Other,7752201.0,
1464,231132,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Ratio of the inhibitory concentrations against rat liver DHFR and Toxoplasma gondii DHFR.,Other,7752201.0,
1465,232631,3,5,,103164817,5578,Unspecified,,,,,Ratio of inhibitory activity against dihydrofolate reductase of rat liver to pneumocystis carinii,Other,14584957.0,
1466,232632,3,5,,103164817,5578,Unspecified,,,,,Ratio of inhibitory activity against dihydrofolate reductase of rat liver to Toxoplasma gondii,Other,14584957.0,
1467,232772,3,5,,103164817,5578,Unspecified,,,,,Selectivity index as the ratio of Ki value towards Human DHFR to that of Pneumocystis carinii DHFR.,Other,7699713.0,
1468,232804,3,3,,103164817,5578,Unspecified,,,,,Toxic index against Dihydrofolate reductase,Other,2502631.0,
1469,232863,3,3,,103164817,5578,Unspecified,,,,,Safety ratio is cytotoxicity to human breast cancer (BC) cell/IC50 KI,Other,11881993.0,
1470,232864,3,3,,103164817,5578,Unspecified,,,,,Safety ratio is cytotoxicity to human breast cancer (BC) cell/IC50 TM4.,Other,11881993.0,
1471,232865,3,3,,103164817,5578,Unspecified,,,,,Safety ratio is cytotoxicity to human epidermoid carcinoma KB cell/IC50 TM4.,Other,11881993.0,
1472,232868,3,4,,103164817,5578,Unspecified,,,,,Safety ratio is cytotoxicity to vero cells/IC50 KI,Other,11881993.0,
1473,232870,4,3,,103164817,5578,Unspecified,,,,,Safety ratio as cytotoxicity in vero cells relative to IC50 TM4,Other,11881993.0,
1474,232872,3,3,,103164817,5578,Unspecified,,,,,Safety ratio is cytotoxicity to vhuman epidermoid carcinoma KB cell/IC50 KI,Other,11881993.0,
1475,232973,3,3,,103164817,5578,Unspecified,,,,,Ratio of Dihydrofolate reductase inhibitory activity in rat to Mycobacterium avium,Other,10579848.0,
1476,232974,3,3,,103164817,5578,Unspecified,,,,,Ratio of Dihydrofolate reductase inhibitory activity in rat to Pneumocystis carinii,Other,10579848.0,
1477,232975,3,3,,103164817,5578,Unspecified,,,,,Ratio of Dihydrofolate reductase inhibitory activity in rat to Toxoplasma gondii,Other,10579848.0,
1478,232976,3,9,,103164817,5578,Unspecified,118998.0,,,,Ratio of IC50 evaluated towards DHFR of rat liver to Pneumocystis carinii,Other,7658454.0,
1479,232976,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Ratio of IC50 evaluated towards DHFR of rat liver to Pneumocystis carinii,Other,7658454.0,
1480,232977,3,9,,103164817,5578,Unspecified,729370.0,,,,Ratio of IC50 evaluated towards DHFR of rat liver to Toxoplasma gondii,Other,7658454.0,
1481,232977,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Ratio of IC50 evaluated towards DHFR of rat liver to Toxoplasma gondii,Other,7658454.0,
1482,233114,3,5,,103164817,5578,Unspecified,,,,,Ratio of IC50 against rat liver DHFR and Pneumocystis carinii DHFR (IC50rl/IC50pc),Other,7783147.0,
1483,233115,3,5,,103164817,5578,Unspecified,,,,,Ratio of the IC50 against rat liver DHFR and Toxoplasma gondii DHFR (IC50rl/IC50tg),Other,7783147.0,
1484,233134,3,5,,103164817,5578,Unspecified,,,,,Selectivity for dihydrofolate reductase enzyme in rat liver Toxoplasma gondii,Other,9554874.0,
1485,233138,3,5,,103164817,5578,Unspecified,,,,,Selectivity for dihydrofolate reductase enzyme in rat liver and Pneumocystis carinii,Other,9554874.0,
1486,233406,3,5,,103164817,5578,Unspecified,,,,,Ratio for IC50 of mammalian DHFR to IC50 of Pneumocystis carinii DHFR,Other,7490723.0,
1487,233411,5,2,,103164817,5578,Unspecified,118998.0,,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 pcDHFR,Other,8691474.0,
1488,233411,5,2,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 pcDHFR,Other,8691474.0,
1489,233412,5,2,,103164817,5578,Unspecified,729370.0,,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 tgDHFR,Other,8691474.0,
1490,233412,5,2,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio is defined as IC50 rlDHFR/IC50 tgDHFR,Other,8691474.0,
1491,233450,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 (rat liver)/IC50 (Pneumocystis carinii),Other,9357537.0,
1492,233452,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 (rat liver)/IC50 (Toxoplasma gondii,Other,9357537.0,
1493,233638,3,4,,103164817,5578,Unspecified,,,,,Ratio of inhibitory concentration of Rat liver and Pneumocystis carinii DHFR,Other,8627607.0,
1494,233639,3,4,,103164817,5578,Unspecified,,,,,Ratio of inhibitory concentration of Rat liver and Toxoplasma gondii DHFR,Other,8627607.0,
1495,233680,3,5,,103164817,5578,Unspecified,,,,,Selectivity ratio of rat liver(rl) / Pneumocystis carinii (pc),Other,9046337.0,
1496,233681,3,9,,103164817,5578,Unspecified,118998.0,,,,Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii,Other,9046338.0,
1497,233681,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Relative affinity for dihydrofolate reductase of rat liver and Pneumocystis carinii,Other,9046338.0,
1498,233682,3,5,,103164817,5578,Unspecified,,,,,Selectivity ratio of rat liver(rl) / Toxoplasma gondii (tg),Other,9046337.0,
1499,233683,3,9,,103164817,5578,Unspecified,729370.0,,,,Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii,Other,9046338.0,
1500,233683,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Relative affinity for dihydrofolate reductase of rat liver and Toxoplasma gondii,Other,9046338.0,
1501,234269,3,9,,103164817,5578,Unspecified,118998.0,,,,Ratio of IC50 rat liver DHFR vs IC50 of Pneumocystis carinii DHFR,Other,8632434.0,
1502,234269,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Ratio of IC50 rat liver DHFR vs IC50 of Pneumocystis carinii DHFR,Other,8632434.0,
1503,234270,3,5,,103164817,5578,Unspecified,,,,,Ratio of IC50 rat liver DHFR vs IC50 of Toxoplasma gondii DHFR,Other,8632434.0,
1504,234661,3,5,,103164817,5578,Unspecified,,,,,"Selectivity Index is the ratio of the inhibitory concentrations against rat liver(RL) DHFR and P. carinii(Pc) DHFR, IC50(RL) / IC50(Pc).",Other,10090784.0,
1505,234662,3,5,,103164817,5578,Unspecified,,,,,"Selectivity Index is the ratio of the inhibitory concentrations against rat liver(RL) DHFR and T. gondii(Tg) DHFR, IC50(RL) / IC50(Tg).",Other,10090784.0,
1506,234733,3,9,,103164817,5578,Unspecified,118998.0,,,,Selectivity ratio of IC50 value against rat liver DHFR to that of Pneumocystis carinii DHFR,Other,7877140.0,
1507,234733,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio of IC50 value against rat liver DHFR to that of Pneumocystis carinii DHFR,Other,7877140.0,
1508,234735,3,9,,103164817,5578,Unspecified,729370.0,,,,Selectivity ratio of IC50 value against rat liver DHFR and Toxoplasma gondii DHFR,Other,7877140.0,
1509,234735,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio of IC50 value against rat liver DHFR and Toxoplasma gondii DHFR,Other,7877140.0,
1510,235292,3,3,,103164817,5578,Unspecified,,,,,Selectivity index against Escherichia coli DHFR.,Other,1899453.0,
1511,235294,4,3,,103164817,5578,Unspecified,,,,,Selectivity index against Lactobacillus casei DHFR.,Other,1899453.0,
1512,235297,3,3,,103164817,5578,Unspecified,,,,,Ratio of DHFR inhibition of humans to that of Cryptosporidium parvum of human origin,Other,14998335.0,
1513,235298,3,6,,103164817,5578,Unspecified,,,,,Ratio of DHFR inhibition of rat liver to that of Mycobacterium avium,Other,14998335.0,
1514,235299,3,6,,103164817,5578,Unspecified,,,,,Ratio of DHFR inhibition of rat liver to that of Pneumocystis carinii,Other,14998335.0,
1515,235300,3,6,,103164817,5578,Unspecified,,,,,Ratio of DHFR inhibition of rat liver to that of Toxoplasma gondii,Other,14998335.0,
1516,235379,3,9,,103164817,5578,Unspecified,118998.0,,,,Selectivity ratio was measured as IC50 of rlDHFR/IC50 pcDHFR,Other,9804692.0,
1517,235379,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio was measured as IC50 of rlDHFR/IC50 pcDHFR,Other,9804692.0,
1518,235504,3,9,,103164817,5578,Unspecified,729370.0,,,,Selectivity ratio was measured as IC50 of rlDHFR/IC50 tgDHFR,Other,9804692.0,
1519,235504,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio was measured as IC50 of rlDHFR/IC50 tgDHFR,Other,9804692.0,
1520,235550,3,5,,103164817,5578,Unspecified,,,,,Selectivity measured as log[1/Ki(Lactobacillus casei DHFR)]-log[1/Ki(chicken liver DHFR)],Other,9784101.0,
1521,235648,3,5,,103164817,5578,Unspecified,,,,,Selectivity index was determined by the ratio for IC50 of human DHFR to the IC50 of Pneumocystis carinii DHFR,Other,15115391.0,
1522,235659,3,6,,103164817,5578,Unspecified,,,,,Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Mycobacterium avium DHFR; Range: 460-810,Other,15115391.0,
1523,235663,3,5,,103164817,5578,Unspecified,,,,,Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Pneumocystis carinii DHFR; Range: 10-20,Other,15115391.0,
1524,235670,3,5,,103164817,5578,Unspecified,,,,,Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Toxoplasma gondii DHFR,Other,15115391.0,
1525,235677,3,5,,103164817,5578,Unspecified,,,,,Selectivity index was determined by the ratio for IC50 of rat liver DHFR to the IC50 of Toxoplasma gondii DHFR; Range: 48-87,Other,15115391.0,
1526,235732,3,9,,103164817,5578,Unspecified,118998.0,,,,Selectivity ratio between the IC50 values of DHFR from rat liver and DHFR from Pneumocystis carinii,Other,9548816.0,
1527,235732,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio between the IC50 values of DHFR from rat liver and DHFR from Pneumocystis carinii,Other,9548816.0,
1528,235734,4,7,,103164817,5578,Unspecified,729370.0,,,,Selectivity ratio between the IC50 values of DHFR from rat liver and DHFR from Toxoplasma gondii,Other,9548816.0,
1529,235734,4,7,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity ratio between the IC50 values of DHFR from rat liver and DHFR from Toxoplasma gondii,Other,9548816.0,
1530,235849,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio is the ratio between the IC50 values of rat liver and Pneumocystis carinii,Other,9526565.0,
1531,235851,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio is the ratio between the IC50 values of rat liver and Toxoplasma gondii,Other,9526565.0,
1532,235861,3,9,,103164817,5578,Unspecified,118998.0,,,,IC50(rlDHFR)/IC50(pcDHFR) Ratio of the compound,Other,11448221.0,
1533,235861,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,IC50(rlDHFR)/IC50(pcDHFR) Ratio of the compound,Other,11448221.0,
1534,235862,3,6,,103164817,5578,Unspecified,,,,,IC50(rlDHFR)/IC50(tgDHFR) Ratio of the compound,Other,11448221.0,
1535,240573,9,1,,103164817,5578,Unspecified,81871579.0,24312.0,180.0,IC50,Inhibitory concentration against rat DHFR,Confirmatory,15974594.0,
1536,240835,8,5,,103164817,5578,Active,729370.0,,2.8,IC50,Inhibitory concentration against Toxoplasma gondii DHFR,Confirmatory,15974594.0,
1537,240892,8,5,,103164817,5578,Active,75426075.0,,0.3,IC50,Inhibitory concentration against Mycobacterium avium DHFR,Confirmatory,15974594.0,
1538,240926,8,5,,103164817,5578,Active,118998.0,,13.0,IC50,Inhibitory concentration against Pneumocystis carinii DHFR,Confirmatory,15974594.0,
1539,244388,3,6,,103164817,5578,Unspecified,,,,,Selectivity index measured as IC50(Rat)/IC50(Mycobacterium avium),Other,15974594.0,
1540,244389,3,9,,103164817,5578,Unspecified,118998.0,,,,Selectivity index measured as IC50(Rat)/IC50(Pneumocystis carinii),Other,15974594.0,
1541,244389,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity index measured as IC50(Rat)/IC50(Pneumocystis carinii),Other,15974594.0,
1542,244390,3,9,,103164817,5578,Unspecified,729370.0,,,,Selectivity index measured as IC50(Rat)/IC50(Toxoplasma gondii),Other,15974594.0,
1543,244390,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Selectivity index measured as IC50(Rat)/IC50(Toxoplasma gondii),Other,15974594.0,
1544,268782,12,2,,103164817,5578,Active,,,14.0,IC50,Inhibition of Cryptosporidium hominis DHFR,Confirmatory,16750361.0,
1545,268783,9,2,,103164817,5578,Active,,,0.01,IC50,Inhibition of Plasmodium falciparum DHFR,Confirmatory,16750361.0,
1546,268784,9,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Pneumocystis carinii DHFR,Confirmatory,16750361.0,
1547,279961,6,2,,103164817,5578,Active,,,14.0,IC50,Inhibition of Cryptosporidium hominis DHFR-TS expressed in Escherichia coli,Confirmatory,17269758.0,
1548,279962,10,5,,103164817,5578,Active,729370.0,,8.0,IC50,Inhibition of Toxoplasma gondii DHFR-TS,Confirmatory,17269758.0,
1549,279963,3,3,,103164817,5578,Unspecified,,,,,Ligand efficiency at Cryptosporidium hominis DHFR-TS,Other,17269758.0,
1550,279964,3,9,,103164817,5578,Unspecified,729370.0,,,,Ligand efficiency at Toxoplasma gondii DHFR-TS,Other,17269758.0,
1551,283150,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5204 isolate from prosthetic joint infection patient by broth microdilution method,Other,17158933.0,
1552,285156,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Streptococcus pneumoniae ATCC 49619,Other,17210772.0,
1553,285157,3,3,,103164817,5578,Unspecified,,,,,Antimicrobial susceptibility of tetracycline-resistant Streptococcus pneumoniae from respiratory tract disease patient assessed as percent susceptible isolates,Other,17210772.0,
1554,285158,3,3,,103164817,5578,Unspecified,,,,,Antimicrobial susceptibility of tetracycline-resistant Streptococcus pneumoniae from respiratory tract disease patient assessed as percent resistant isolates,Other,17210772.0,
1555,285159,8,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed by relative light units after 7 days,Other,17210775.0,
1556,285160,8,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in aerobic condition assessed as bacterial density after 7 days,Other,17210775.0,
1557,285161,8,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as relative light unit after 11 days by LORA assay,Other,17210775.0,
1558,285162,8,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against non replicating persistence Mycobacterium tuberculosis H37Rv in anaerobic condition assessed as bacterial density after 10 days,Other,17210775.0,
1559,288184,9,1,,103164817,5578,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
1560,288185,7,1,,103164817,5578,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
1561,288192,3,4,,103164817,5578,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
1562,288306,4,9,,103164817,5578,Unspecified,803341899.0,,,,Inhibition of Mycobacterium tuberculosis DHFR expressed in Saccharomyces cerevisiae TB5 assessed as yeast growth inhibition after 3 days by radial spoke assay,Other,17451962.0,
1563,288307,4,9,,103164817,5578,Unspecified,118992.0,1719.0,,,Inhibition of human DHFR expressed in Saccharomyces cerevisiae TB5 assessed as yeast growth inhibition after 3 days by radial spoke assay,Other,17451962.0,
1564,288307,4,9,,103164817,5578,Unspecified,118992.0,573971.0,,,Inhibition of human DHFR expressed in Saccharomyces cerevisiae TB5 assessed as yeast growth inhibition after 3 days by radial spoke assay,Other,17451962.0,
1565,288308,4,9,,103164817,5578,Unspecified,68844666.0,854411.0,,,Inhibition of yeast DHFR expressed in Saccharomyces cerevisiae TB5 assessed as yeast growth inhibition by after 3 days by radial spoke assay,Other,17451962.0,
1566,291229,9,1,,103164817,5578,Active,,,0.02,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,17552508.0,
1567,291230,9,5,,103164817,5578,Unspecified,118992.0,1719.0,680.0,IC50,Inhibition of human DHFR,Confirmatory,17552508.0,
1568,291230,9,5,,103164817,5578,Unspecified,118992.0,573971.0,680.0,IC50,Inhibition of human DHFR,Confirmatory,17552508.0,
1569,291231,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for human DHFR to IC50 for Escherichia coli DHFR,Other,17552508.0,
1570,291232,8,7,,103164817,5578,Unspecified,118998.0,,12000.0,IC50,Inhibition of Pneumocystis carinii DHFR,Confirmatory,17552508.0,
1571,291235,9,6,,103164817,5578,Unspecified,729370.0,,2800.0,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,17552508.0,
1572,291236,9,5,,103164817,5578,Unspecified,75426075.0,,300.0,IC50,Inhibition of Mycobacterium avium DHFR,Confirmatory,17552508.0,
1573,291237,8,7,,103164817,5578,Unspecified,81871579.0,24312.0,180000.0,IC50,Inhibition of rat liver DHFR,Confirmatory,17552508.0,
1574,291238,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR,Other,17552508.0,
1575,291239,4,1,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR,Other,17552508.0,
1576,291240,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR,Other,17552508.0,
1577,291524,7,6,,103164817,5578,Unspecified,81871579.0,24312.0,133.0,IC50,Inhibition of rat liver DHFR,Confirmatory,17569517.0,
1578,291525,11,2,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Pneumocystis carinii DHFR,Confirmatory,17569517.0,
1579,291526,12,2,,103164817,5578,Active,729370.0,,2.73,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,17569517.0,
1580,291527,11,2,,103164817,5578,Active,75426075.0,,0.19,IC50,Inhibition of Mycobacterium avium DHFR,Confirmatory,17569517.0,
1581,291528,11,2,,103164817,5578,Active,7227951.0,,0.62,IC50,Inhibition of Lactobacillus casei DHFR,Confirmatory,17569517.0,
1582,297559,6,2,,103164817,5578,Active,,,45.0,IC50,Inhibition of trimethoprim-resistant Staphylococcus aureus DHFR F98Y mutant,Confirmatory,17696333.0,
1583,297560,6,3,,103164817,5578,Active,,,42.0,IC50,Inhibition of trimethoprim-resistant Streptococcus pneumoniae DHFR I100L mutant,Confirmatory,17696333.0,
1584,311524,4,3,,103164817,5578,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
1585,312253,9,5,,103164817,5578,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human thymidylate synthase,Confirmatory,18072727.0,
1586,312254,10,4,,103164817,5578,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,18072727.0,
1587,312255,6,2,,103164817,5578,Inconclusive,,,,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,18072727.0,
1588,312256,9,5,,103164817,5578,Unspecified,118992.0,1719.0,340.0,IC50,Inhibition of human recombinant DHFR,Confirmatory,18072727.0,
1589,312256,9,5,,103164817,5578,Unspecified,118992.0,573971.0,340.0,IC50,Inhibition of human recombinant DHFR,Confirmatory,18072727.0,
1590,312257,8,2,,103164817,5578,Active,,,0.01,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,18072727.0,
1591,312258,6,2,,103164817,5578,Active,,,6.8,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,18072727.0,
1592,312259,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for Toxoplasma gondii DHFR over IC50 for human recombinant DHFR,Other,18072727.0,
1593,312273,3,9,,103164817,5578,Unspecified,118992.0,1719.0,,,Inhibition of human recombinant DHFR at >340 uM,Other,18072727.0,
1594,312273,3,9,,103164817,5578,Unspecified,118992.0,573971.0,,,Inhibition of human recombinant DHFR at >340 uM,Other,18072727.0,
1595,320706,9,3,,103164817,5578,Unspecified,,,7500.0,IC50,Inhibition of PAD4 by ABPP-based assay,Confirmatory,17964793.0,
1596,322319,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5 alpha isolates by agar dilution method,Other,17371815.0,
1597,322320,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli INSRA5776 isolates expressing CTX-M-14 and TEM-1B enzymes by agar dilution method,Other,17371815.0,
1598,322321,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5 alpha-URA5776 isolates expressing CTX-M-14 enzyme by agar dilution method,Other,17371815.0,
1599,322322,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli INSRA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method,Other,17371815.0,
1600,322323,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5 alpha-URA5905 isolates expressing CTX-M-15 and TEM-1B enzymes by agar dilution method,Other,17371815.0,
1601,322324,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli INSRA5924 isolates expressing CTX-M-32 and TEM-1B enzymes by agar dilution method,Other,17371815.0,
1602,322325,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5 alpha-URA5924 isolates expressing CTX-M-32 by agar dilution method,Other,17371815.0,
1603,323636,8,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli U21 isolate by disk diffusion test,Other,17307981.0,
1604,323637,8,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli U93 isolate by disk diffusion test,Other,17307981.0,
1605,324160,8,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 PhoU wild type W3110 after 16 hrs by serial dilution method,Other,17420206.0,
1606,324161,8,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 after 16 hrs by serial dilution method,Other,17420206.0,
1607,324162,8,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid PhoU after 16 hrs by serial dilution method,Other,17420206.0,
1608,324163,8,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid vector after 16 hrs by serial dilution method,Other,17420206.0,
1609,324180,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 PhoU wild type W3110 at 2 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1610,324181,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 at 2 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1611,324182,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid PhoU at 2 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1612,324183,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid vector at 2 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1613,324184,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 PhoU wild type W3110 at 0.5 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1614,324185,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 at 0.5 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1615,324186,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid PhoU at 0.5 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1616,324187,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid vector at 0.5 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1617,324200,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 PhoU wild type W3110 at 1 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1618,324201,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 at 1 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1619,324202,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid PhoU at 1 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1620,324203,4,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli K12 mutant JHU313 containing plasmid vector at 1 ug/ml after 48 hrs by disc diffusion method,Other,17420206.0,
1621,340858,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against wild type vancomycin-intermediate resistant Staphylococcus aureus Mu50 by microdilution assay,Other,17502406.0,
1622,340859,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 graR mutant microdilution assay,Other,17502406.0,
1623,340860,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 vraG mutant microdilution assay,Other,17502406.0,
1624,341462,9,5,,103164817,5578,Unspecified,118992.0,1719.0,680.0,IC50,Inhibition of human dihydrofolate reductase,Confirmatory,18605720.0,
1625,341462,9,5,,103164817,5578,Unspecified,118992.0,573971.0,680.0,IC50,Inhibition of human dihydrofolate reductase,Confirmatory,18605720.0,
1626,341469,6,2,,103164817,5578,Active,,,0.02,IC50,Inhibition of Escherichia coli dihydrofolate reductase,Confirmatory,18605720.0,
1627,341470,10,5,,103164817,5578,Active,729370.0,,2.9,IC50,Inhibition of Toxoplasma gondii dihydrofolate reductase,Confirmatory,18605720.0,
1628,341471,3,3,,103164817,5578,Unspecified,,,,,Selectivity for Escherichia coli dihydrofolate reductase over human dihydrofolate reductase,Other,18605720.0,
1629,341472,3,3,,103164817,5578,Unspecified,,,,,Selectivity for sToxoplasma gondii dihydrofolate reductase over human dihydrofolate reductase,Other,18605720.0,
1630,341473,6,2,,103164817,5578,Active,,,12.0,IC50,Inhibition of Pneumocystis carinii DHFR using dihydrofolic acid substrate and NADPH cofactor,Confirmatory,18605720.0,
1631,341476,9,5,,103164817,5578,Unspecified,81871579.0,24312.0,180.0,IC50,Inhibition of rat liver DHFR using dihydrofolic acid substrate and NADPH cofactor,Confirmatory,18605720.0,
1632,341477,3,3,,103164817,5578,Unspecified,,,,,Selectivity for Pneumocystis carinii DHFR over rat liver DHFR,Other,18605720.0,
1633,341478,6,2,,103164817,5578,Active,,,0.3,IC50,Inhibition of Mycobacterium avium DHFR using dihydrofolic acid substrate and NADPH cofactor,Confirmatory,18605720.0,
1634,341479,3,3,,103164817,5578,Unspecified,,,,,Selectivity for Mycobacterium avium DHFR over rat liver DHFR,Other,18605720.0,
1635,347377,9,5,,103164817,5578,Unspecified,81715208.0,,71.0,IC50,Inhibition of Bacillus anthracis recombinant DHFR expressed in mouse M15 cells assessed as rate of enzyme-dependent NADPH oxidation,Confirmatory,19007108.0,
1636,347378,9,5,,103164817,5578,Unspecified,118992.0,1719.0,120.0,IC50,Inhibition of human DHFR assessed as rate of enzyme-dependent NADPH oxidation,Confirmatory,19007108.0,
1637,347378,9,5,,103164817,5578,Unspecified,118992.0,573971.0,120.0,IC50,Inhibition of human DHFR assessed as rate of enzyme-dependent NADPH oxidation,Confirmatory,19007108.0,
1638,347379,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for human DHFR to IC50 for Bacillus anthracis recombinant DHFR,Other,19007108.0,
1639,361985,3,4,,103164817,5578,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method",Other,18666772.0,
1640,361986,3,4,,103164817,5578,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by shake flask method",Other,18666772.0,
1641,365323,4,3,,103164817,5578,Active,,,0.025,Ki,Inhibition of Pneumocystis jirovecii dihydrofolate reductase,Confirmatory,18771252.0,
1642,373986,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS3 transconjugant from Citrobacter freundii 64 by agar dilution method,Other,17724159.0,
1643,373987,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS4 transconjugant from Enterobacter cloacae 91 by agar dilution method,Other,17724159.0,
1644,374111,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant aac(6')-Ib-cr deficient Escherichia coli J53 qnrA1 bearing pHS5 transconjugant from Enterobacter cloacae 641 by agar dilution method,Other,17724159.0,
1645,374112,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant aac(6')-Ib-cr expressing Escherichia coli J53 qnrA1 bearing pHS6 transconjugant from Escherichia coli 650 by agar dilution method,Other,17724159.0,
1646,374113,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 by agar dilution method,Other,17724159.0,
1647,386623,4,8,,103164817,5578,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
1648,386625,9,5,,103164817,5578,Unspecified,313104181.0,6580.0,56.8,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
1649,390567,8,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Pneumocystis carinii dihydrofolate reductase,Confirmatory,18771252.0,
1650,390569,8,5,,103164817,5578,Unspecified,81871579.0,24312.0,133.0,IC50,Inhibition of rat liver dihydrofolate reductase,Confirmatory,18771252.0,
1651,390570,3,3,,103164817,5578,Unspecified,,,,,"Selectivity ratio, IC50 for rat liver dihydrofolate reductase to IC50 for Pneumocystis carinii dihydrofolate reductase",Other,18771252.0,
1652,390571,8,5,,103164817,5578,Active,729370.0,,2.7,IC50,Inhibition of Toxoplasma gondii dihydrofolate reductase,Confirmatory,18771252.0,
1653,390572,3,3,,103164817,5578,Unspecified,,,,,"Selectivity ratio, IC50 for rat liver dihydrofolate reductase to IC50 for Toxoplasma gondii dihydrofolate reductase",Other,18771252.0,
1654,391732,9,5,,103164817,5578,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human thymidylate synthase,Confirmatory,18800768.0,
1655,391733,10,4,,103164817,5578,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,18800768.0,
1656,391734,9,5,,103164817,5578,Unspecified,118992.0,1719.0,320.0,IC50,Inhibition of human recombinant DHFR,Confirmatory,18800768.0,
1657,391734,9,5,,103164817,5578,Unspecified,118992.0,573971.0,320.0,IC50,Inhibition of human recombinant DHFR,Confirmatory,18800768.0,
1658,391735,10,5,,103164817,5578,Inconclusive,729370.0,,,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,18800768.0,
1659,391736,9,5,,103164817,5578,Active,165971782.0,,0.01,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,18800768.0,
1660,391737,10,5,,103164817,5578,Active,729370.0,,6.8,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,18800768.0,
1661,391738,6,2,,103164817,5578,Unspecified,,,50.0,IC50,Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Toxoplasma gondii DHFR,Confirmatory,18800768.0,
1662,391741,3,9,,103164817,5578,Unspecified,118992.0,1719.0,,,Inhibition of human recombinant DHFR at >340 uM,Other,18800768.0,
1663,391741,3,9,,103164817,5578,Unspecified,118992.0,573971.0,,,Inhibition of human recombinant DHFR at >340 uM,Other,18800768.0,
1664,392155,6,2,,103164817,5578,Active,,,14.0,IC50,Inhibition of Cryptosporidium hominis DHFR,Confirmatory,19059777.0,
1665,404304,3,10,,103164817,5578,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
1666,408340,8,5,,103164817,5578,Unspecified,7531135.0,3757.0,239.88299999999998,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
1667,409950,3,9,,103164817,5578,Inactive,113978.0,4128.0,,,Inhibition of human brain MAOA,Other,18834112.0,
1668,409952,3,9,,103164817,5578,Inactive,113980.0,4129.0,,,Inhibition of human brain MAOB,Other,18834112.0,
1669,420367,7,2,,103164817,5578,Active,,,14.0,IC50,Antiparasitic activity against Toxoplasma gondii 2F tachyzoites infected in HFF assessed as parasite growth inhibition-related decrease in beta-galactosidase activity treated prior to infection measured after 5 days by spectrophotometry,Confirmatory,19618935.0,
1670,420368,8,1,,103164817,5578,Unspecified,,,320.0,TD50,Cytotoxicity against human HFF by spectrophotometry,Confirmatory,19618935.0,
1671,420369,3,3,,103164817,5578,Unspecified,,,,,"Therapeutic index, ratio of TD50 for human HFF to IC50 for Toxoplasma gondii 2F tachyzoites",Other,19618935.0,
1672,422632,9,5,,103164817,5578,Inconclusive,136611.0,7298.0,,IC50,Inhibition of human thymidylate synthase,Confirmatory,19719239.0,
1673,422633,9,4,,103164817,5578,Inconclusive,,,,IC50,Inhibition of Escherichia coli thymidylate synthase,Confirmatory,19719239.0,
1674,422634,10,5,,103164817,5578,Inconclusive,729370.0,,,IC50,Inhibition of Toxoplasma gondii thymidylate synthase,Confirmatory,19719239.0,
1675,422635,9,5,,103164817,5578,Unspecified,118992.0,1719.0,340.0,IC50,Inhibition of human recombinant dihydrofolate reductase,Confirmatory,19719239.0,
1676,422635,9,5,,103164817,5578,Unspecified,118992.0,573971.0,340.0,IC50,Inhibition of human recombinant dihydrofolate reductase,Confirmatory,19719239.0,
1677,422636,6,2,,103164817,5578,Active,,,0.01,IC50,Inhibition of Escherichia coli dihydrofolate reductase,Confirmatory,19719239.0,
1678,422637,10,5,,103164817,5578,Active,729370.0,,6.8,IC50,Inhibition of Toxoplasma gondii dihydrofolate reductase,Confirmatory,19719239.0,
1679,422638,3,4,,103164817,5578,Unspecified,,,,,Ratio of IC50 for human recombinant dihydrofolate reductase to IC50 for Toxoplasma gondii dihydrofolate reductase,Other,19719239.0,
1680,422641,3,9,,103164817,5578,Unspecified,118992.0,1719.0,,,Inhibition of human recombinant dihydrofolate reductase at 340 uM,Other,19719239.0,
1681,422641,3,9,,103164817,5578,Unspecified,118992.0,573971.0,,,Inhibition of human recombinant dihydrofolate reductase at 340 uM,Other,19719239.0,
1682,424866,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against wild type Salmonella enterica serovar Typhimurium ATCC 14028 by modified twofold broth microdilution method,Other,17938183.0,
1683,424867,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against bacterial sensory kinase PhoQ deficient Salmonella enterica serovar Typhimurium CS009 by modified twofold broth microdilution method,Other,17938183.0,
1684,425393,3,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against mucosa-associated Escherichia coli isolates isolated from patients with Crohn's disease by disk diffusion method,Other,18070962.0,
1685,425398,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate HM154 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1686,425399,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate HM580 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1687,425400,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1688,425401,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate HM615 isolated from colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1689,425402,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity Escherichia coli isolate HM413 isolated from ileo-colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1690,425403,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity Escherichia coli isolate HM419 isolated from ileo-colonic mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1691,425404,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate HM95 isolated from ileal mucosal biopsies of patient with Crohn's disease after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1692,425405,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against mucosa-associated Escherichia coli isolate HM428 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1693,425407,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against mucosa-associated Escherichia coli isolate HM456 isolated from patient with irritable bowel syndrome or sporadic polyps after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1694,425582,3,3,,103164817,5578,Active,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by Etest antibiotic concentration gradient method,Other,18070962.0,
1695,425583,6,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease,Other,18070962.0,
1696,425590,3,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease in mouse J774A1 cells assessed as intracellular killing of bacteria at 2.3 ug/ml after 3 hrs,Other,18070962.0,
1697,425596,3,3,,103164817,5578,Active,,,,,Antibacterial activity against extracellular Escherichia coli isolate HM605 isolated from colonic mucosal biopsies of patient with Crohn's disease at 0.01 to 10 ug/ml after 3 hrs,Other,18070962.0,
1698,425601,3,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM605 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax after 3 hrs,Other,18070962.0,
1699,425602,4,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate LF82 in mouse J774A1 cells isolated from chronic ileal lesions of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax after 3 hrs,Other,18070962.0,
1700,425603,3,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM580 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax after 3 hrs,Other,18070962.0,
1701,425604,3,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against gentamicin-treated internalized Escherichia coli isolate HM615 in mouse J774A1 cells isolated from colonic mucosal biopsies of patient with Crohn's disease assessed as intracellular killing of bacteria at 10% compound Cmax after 3 hrs,Other,18070962.0,
1702,425611,3,4,,103164817,5578,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells assessed as macrophage number at 2.3 ug/ml after 3 hrs by total cell protein assay,Other,18070962.0,
1703,425612,3,4,,103164817,5578,Unspecified,,,,,Cytotoxicity against mouse J774A1 cells assessed as release of adenylate kinase at 100 ug/ml after 3 hrs by total cell protein assay relative to control,Other,18070962.0,
1704,425621,7,2,,103164817,5578,Unspecified,,,,,Cmax in healthy human at 160 mg administered orally,Other,18070962.0,
1705,425652,7,2,,103164817,5578,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
1706,425653,7,2,,103164817,5578,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
1707,425737,7,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Bacillus anthracis Sterne after 16 hrs by modified alamar blue microdilution broth assay,Other,17875993.0,
1708,434955,1,2,,857743,5578,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1709,434959,1,1,,85788427,5578,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1710,434962,1,2,,857743,5578,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1711,434973,1,3,,50085866,5578,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1712,434989,1,1,,857743,5578,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1713,435003,1,3,,50085866,5578,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1714,435005,1,1,,857743,5578,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1715,435022,2,2,,50085866,5578,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1716,435030,1,2,,857743,5578,Active,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1717,435030,1,2,,857743,5578,Active,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1718,436917,10,2,,103164817,5578,Active,1169444.0,,42.0,IC50,Inhibition of Candida albicans DHFR expressed in Escherichia coli BL21 (DE3) assessed as rate of NADPH consumption using dihydrofolate as substrate,Confirmatory,19560363.0,
1719,436918,8,5,,103164817,5578,Unspecified,118992.0,1719.0,198.0,IC50,Inhibition of human DHFR assessed as rate of NADPH consumption using dihydrofolate as substrate,Confirmatory,19560363.0,
1720,436918,8,5,,103164817,5578,Unspecified,118992.0,573971.0,198.0,IC50,Inhibition of human DHFR assessed as rate of NADPH consumption using dihydrofolate as substrate,Confirmatory,19560363.0,
1721,436919,3,3,,103164817,5578,Unspecified,,,,,"Selectivity index, ratio of IC50 for human DHFR to IC50 for Candida albicans DHFR",Other,19560363.0,
1722,444050,7,1,,103164817,5578,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
1723,444051,6,2,,103164817,5578,Unspecified,,,,,Total clearance in human,Other,20070106.0,
1724,444052,6,2,,103164817,5578,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
1725,444053,6,2,,103164817,5578,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
1726,444054,6,1,,103164817,5578,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
1727,444055,3,3,,103164817,5578,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
1728,444056,3,3,,103164817,5578,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
1729,444057,3,3,,103164817,5578,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
1730,444058,6,2,,103164817,5578,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
1731,449728,1,2,,857743,5578,Active,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1732,449739,1,2,,857743,5578,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
1733,449762,1,2,,857743,5578,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1734,449763,1,3,,50085866,5578,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1735,449768,1,1,,857743,5578,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
1736,452315,8,5,,103164817,5578,Active,1706542.0,13361.0,0.5,Ki,Competitive inhibition of mouse DHFR by enzyme kinetics assay in presence of variable DHFA level,Confirmatory,19748785.0,
1737,452316,8,5,,103164817,5578,Active,118992.0,1719.0,4.9,Ki,Inhibition of human DHFR in presence of variable DHFA level by enzyme kinetics assay,Confirmatory,19748785.0,
1738,452316,8,5,,103164817,5578,Active,118992.0,573971.0,4.9,Ki,Inhibition of human DHFR in presence of variable DHFA level by enzyme kinetics assay,Confirmatory,19748785.0,
1739,452317,8,5,,103164817,5578,Active,81871579.0,24312.0,14.3,Ki,Inhibition of rat liver DHFR by enzyme kinetics assay in presence of variable DHFA level,Confirmatory,19748785.0,
1740,457190,8,5,,103164817,5578,Active,75426075.0,,0.3,IC50,Inhibition of Mycobacterium avium DHFR at 37 degC by spectrophotometry,Confirmatory,20056546.0,
1741,457202,8,5,,103164817,5578,Active,118998.0,,12.0,IC50,Inhibition of Pneumocystis carinii DHFR at 37 degC by spectrophotometry,Confirmatory,20056546.0,
1742,457205,8,5,,103164817,5578,Unspecified,81871579.0,24312.0,180.0,IC50,Inhibition of rat liver DHFR at 37 degC by spectrophotometry,Confirmatory,20056546.0,
1743,457207,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR,Other,20056546.0,
1744,457208,9,5,,103164817,5578,Active,729370.0,,2.8,IC50,Inhibition of Toxoplasma gondii DHFR at 37 degC by spectrophotometry,Confirmatory,20056546.0,
1745,457209,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR,Other,20056546.0,
1746,457210,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR,Other,20056546.0,
1747,463073,1,2,,857743,5578,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4),Screening,,
1748,463075,1,1,,857743,5578,Inactive,,,,,HTS to identify inhibitors of TNF-alpha Induced Cell Death in Jurkat FADD-/- Cells.,Screening,,
1749,463079,1,2,,857743,5578,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1750,463082,1,1,,857743,5578,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1751,463096,1,1,,50104512,5578,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1752,463097,1,1,,50104512,5578,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1753,463104,1,2,,50085866,5578,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1754,463106,1,2,,90340764,5578,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1755,463111,1,1,,857743,5578,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1756,463115,1,1,,857743,5578,Inactive,119622516.0,5045.0,,,High throughput fluorescence intensity-based biochemical assay to screen for small molecule inhibitors of Furin conducted by the Pittsburgh Molecular Library Screening Center.,Screening,,
1757,463141,1,2,,857743,5578,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1758,463165,1,1,,857743,5578,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1759,463187,1,1,,857743,5578,Inactive,,,,,384-well Z-Lyte format Hck-Nef inhibitor HTS run at the PMLSC,Screening,,
1760,463189,1,1,,53778377,5578,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1761,463190,1,2,,50085866,5578,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1762,463193,1,1,,857743,5578,Inactive,31563518.0,84557.0,,,High-content cell-based screening for modulators of autophagy,Screening,,
1763,463195,1,2,,50085866,5578,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1764,463210,1,2,,857743,5578,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1765,463212,1,1,,50085866,5578,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1766,463254,1,1,,857743,5578,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1767,467611,3,6,,103164817,5578,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
1768,467612,3,6,,103164817,5578,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
1769,467613,5,3,,103164817,5578,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
1770,470072,7,1,,103164817,5578,Inactive,,,,IC50,Inhibition of Escherichia coli HS294 ACCase,Confirmatory,19875284.0,
1771,470073,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli HS294,Other,19875284.0,
1772,470074,6,2,,103164817,5578,Unspecified,,,,,Selectivity ratio of MIC for Escherichia coli HS294 to IC50 for Escherichia coli HS294 ACCase,Other,19875284.0,
1773,476565,10,2,,103164817,5578,Unspecified,118992.0,1719.0,680.0,IC50,Inhibition of human DHFR,Confirmatory,20092323.0,
1774,476565,10,2,,103164817,5578,Unspecified,118992.0,573971.0,680.0,IC50,Inhibition of human DHFR,Confirmatory,20092323.0,
1775,476566,5,2,,103164817,5578,Active,,,0.02,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,20092323.0,
1776,476741,5,2,,103164817,5578,Active,,,2.9,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,20092323.0,
1777,476929,3,3,,103164817,5578,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
1778,477409,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus NCTC 8325 after 16 to 20 hrs by broth microdilution method,Other,20188576.0,
1779,477411,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against MBX-1090-resistant Staphylococcus aureus isolate d20A1 after 16 to 20 hrs by broth microdilution method,Other,20188576.0,
1780,480925,3,9,,103164817,5578,Active,118998.0,,,,Inhibition of Pneumocystis carinii DHFR by continuous spectrophotometric assay,Other,20363634.0,
1781,480926,3,9,,103164817,5578,Active,729370.0,,,,Inhibition of Toxoplasma gondii DHFR by continuous spectrophotometric assay,Other,20363634.0,
1782,480929,3,8,,103164817,5578,Active,,,,,Inhibition of Mycobacterium avium DHFR by continuous spectrophotometric assay,Other,20363634.0,
1783,480931,3,3,,103164817,5578,Active,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR,Other,20363634.0,
1784,480932,3,9,,103164817,5578,Unspecified,81871579.0,24312.0,,,Inhibition of rat liver DHFR by continuous spectrophotometric assay,Other,20363634.0,
1785,480934,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Toxoplasma gondii DHFR,Other,20363634.0,
1786,480935,3,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR,Other,20363634.0,
1787,481433,5,2,,103164817,5578,Active,,,46.0,IC50,Antiparasitic activity against Toxoplasma gondii 2F infected in HFF cells assessed as beta galactosidase activity after 5 days,Confirmatory,20373807.0,
1788,481434,4,1,,103164817,5578,Unspecified,,,320.0,TD50,Cytotoxicity against HFF after 5 days by Cell titer glo assay,Confirmatory,20373807.0,
1789,481435,3,4,,103164817,5578,Unspecified,,,,,"Therapeutic index, ratio of TD50 for HFF cells to IC50 for Toxoplasma gondii F2",Other,20373807.0,
1790,481439,3,4,,103164817,5578,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
1791,481442,3,6,,103164817,5578,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
1792,485270,1,1,,857743,5578,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1793,485272,1,1,,857743,5578,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1794,485273,2,1,,50085866,5578,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1795,485275,1,3,,857743,5578,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1796,485281,1,1,,857743,5578,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1797,485281,1,1,,11111924,5578,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1798,485290,1,1,,857743,5578,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1799,485290,1,1,,11111924,5578,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1800,485290,1,1,,11113621,5578,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1801,485290,1,1,,17389524,5578,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1802,485290,1,1,,26747124,5578,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1803,485290,1,1,,26751820,5578,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1804,485290,1,1,,50104512,5578,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1805,485294,1,1,,857743,5578,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1806,485295,1,2,,90340764,5578,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1807,485297,1,1,,857743,5578,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1808,485297,1,1,,90340764,5578,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1809,485298,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1810,485298,1,1,,90340764,5578,Inconclusive,,,4.6109,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1811,485313,1,2,,857743,5578,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1812,485313,1,2,,90340764,5578,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1813,485314,1,1,,857743,5578,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1814,485314,1,1,,50104512,5578,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1815,485317,1,2,,857743,5578,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1816,485341,1,1,,857743,5578,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1817,485342,1,2,,90340764,5578,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1818,485344,1,1,,857743,5578,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
1819,485345,1,2,,90340764,5578,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1820,485346,1,1,,50085866,5578,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1821,485346,1,1,,50085866,5578,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1822,485347,1,2,,857743,5578,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
1823,485349,1,1,,857743,5578,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1824,485350,1,2,,92124407,5578,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1825,485350,1,2,,92125161,5578,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1826,485353,2,1,,857743,5578,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1827,485358,1,1,,857743,5578,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
1828,485364,1,1,,857743,5578,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1829,485366,1,2,,90340764,5578,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1830,485367,1,2,,857743,5578,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1831,485368,1,2,,90340764,5578,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1832,488745,1,4,,85231275,5578,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1833,488752,1,4,,85231275,5578,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1834,488772,1,1,,90340764,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1835,488773,1,2,,90340764,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1836,488806,1,2,,857743,5578,Inactive,148539876.0,156.0,,,RNA aptamer-based validation for inhibitors of GRK2,Screening,,
1837,488816,1,1,,90340764,5578,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1838,488837,1,1,,857743,5578,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1839,488837,1,1,,90340764,5578,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1840,488839,1,1,,50085866,5578,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1841,488839,1,1,,50085866,5578,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1842,488847,1,3,,857743,5578,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1843,488862,1,1,,50085866,5578,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1844,488890,1,2,,857743,5578,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1845,488895,1,2,,50085866,5578,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1846,488896,1,1,,50085866,5578,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1847,488899,1,1,,50085866,5578,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1848,488922,1,2,,857743,5578,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1849,488942,1,1,,857743,5578,Active,15645703.0,899625.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
1850,488942,1,1,,857743,5578,Active,15646160.0,899738.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of AddAB recombination protein complex,Screening,,
1851,488949,1,2,,85231275,5578,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1852,488949,1,2,,90340764,5578,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1853,488953,1,1,,90340764,5578,Active,187960037.0,10951.0,0.006,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1854,488955,1,1,,857743,5578,Active,16130723.0,947287.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1855,488955,1,1,,857743,5578,Active,16130724.0,947286.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1856,488955,1,1,,857743,5578,Active,16130726.0,947294.0,,,Counterscreen for AddAB inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of RecBCD,Screening,,
1857,488956,1,1,,857743,5578,Active,,,,,Counterscreen for AddAB inhibitors: absorbance-based bacterial cell-based high throughput confirmation assay for inhibitors of bacterial viability,Screening,,
1858,488965,1,2,,50085866,5578,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1859,488966,1,1,,50085866,5578,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1860,488975,1,2,,857743,5578,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1861,488977,1,2,,857743,5578,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1862,488978,1,1,,90340764,5578,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1863,488979,1,1,,50104512,5578,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1864,488980,1,1,,85231275,5578,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1865,488981,1,1,,90340764,5578,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1866,488982,1,1,,90340764,5578,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1867,488983,1,1,,90340764,5578,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1868,489030,2,1,,50085866,5578,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1869,489031,2,1,,50085866,5578,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1870,492947,1,1,,857743,5578,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1871,492953,1,1,,50085866,5578,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1872,492956,1,1,,50085866,5578,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1873,492967,1,2,,92125161,5578,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1874,492967,1,2,,99301677,5578,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1875,492972,1,1,,50085866,5578,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1876,493005,1,1,,50085866,5578,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1877,493008,1,1,,50085866,5578,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1878,493008,1,1,,50085866,5578,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1879,493008,1,1,,50085866,5578,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1880,493008,1,1,,50085866,5578,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1881,493011,1,1,,50085866,5578,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1882,493012,1,1,,50085866,5578,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1883,493014,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1884,493027,1,2,,50085866,5578,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1885,493027,1,2,,50085866,5578,Inactive,223718203.0,5346.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-1 (PLIN1)",Screening,,
1886,493033,1,2,,92124407,5578,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1887,493033,1,2,,92125161,5578,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1888,493035,1,2,,50085866,5578,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1889,493035,1,2,,50085866,5578,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical high throughput validation assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1890,493036,1,2,,50085866,5578,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1891,493056,1,1,,857743,5578,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1892,493084,1,1,,857743,5578,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1893,493087,1,1,,50085866,5578,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1894,493091,1,1,,50085866,5578,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1895,493098,1,1,,50085866,5578,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1896,493106,1,1,,90340764,5578,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1897,493107,1,1,,90340764,5578,Inconclusive,116283940.0,79915.0,29.081,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1898,493127,1,1,,50104512,5578,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1899,493131,1,1,,50085866,5578,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1900,493140,1,1,,103913973,5578,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1901,493153,1,1,,90340764,5578,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1902,493153,1,1,,90340764,5578,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1903,493160,1,1,,50085866,5578,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1904,493162,1,2,,99301677,5578,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1905,493164,1,2,,90340764,5578,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1906,493164,1,2,,90340764,5578,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1907,493164,1,2,,90340764,5578,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1908,493187,1,2,,50085866,5578,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1909,493189,1,1,,50104512,5578,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1910,493244,1,1,,50085866,5578,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1911,493244,1,1,,50085866,5578,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1912,493244,1,1,,50085866,5578,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1913,493244,1,1,,50085866,5578,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1914,495629,2,3,,103164817,5578,Inactive,,,,,Antimicrobial activity against Pseudomonas luteola by disk diffusion method,Other,19884377.0,
1915,495748,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 25922 by Etest method,Other,19901088.0,
1916,495749,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Salmonella enterica serotype Virchow 3464b by Etest method,Other,19901088.0,
1917,495750,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J5 by Etest method,Other,19901088.0,
1918,495751,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow by Etest method,Other,19901088.0,
1919,495752,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime by Etest method,Other,19901088.0,
1920,495753,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J5 transconjugants expressing beta lactamase CTX-M-9 isolated from human flora associated C3H rat infected with Salmonella enterica serotype Virchow and treated with Cefixime-cluvulanic acid by Etest method,Other,19901088.0,
1921,496396,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against azide-resistant Escherichia coli J53 SXT1 transconjugant with qnrVC3 gene expressing Vibrio cholerae 59 strain,Other,19949057.0,
1922,496397,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against azide-resistant Escherichia coli J53 SXT2 transconjugant with qnrVC3 gene expressing Vibrio cholerae 59 strain,Other,19949057.0,
1923,496398,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against azide-resistant Escherichia coli J53 TET1 transconjugant with qnrVC3 gene expressing Vibrio cholerae 59 strain,Other,19949057.0,
1924,496399,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against azide-resistant Escherichia coli J53 TET2 transconjugant with qnrVC3 gene expressing Vibrio cholerae 59 strain,Other,19949057.0,
1925,496824,4,2,,103164817,5578,Unspecified,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
1926,496831,4,2,,103164817,5578,Active,,,4.0,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
1927,497005,4,2,,103164817,5578,Unspecified,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
1928,497717,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of IPTG-stimulated Escherichia coli K-12 folA at 16 fold MIC by microarray analysis,Other,19783991.0,
1929,497727,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of IPTG-stimulated Escherichia coli K-12 folA at 8 fold MIC by microarray analysis,Other,19783991.0,
1930,497887,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of IPTG-stimulated Escherichia coli K-12 folA at 4 fold MIC by microarray analysis,Other,19783991.0,
1931,497888,3,3,,103164817,5578,Active,,,,,Inhibition of IPTG-stimulated Escherichia coli K-12 rpSR at 4 fold MIC by microarray analysis,Other,19783991.0,
1932,500664,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of DHFR in Escherichia coli K-12 NCM3722 assessed as increase in oxidized folates level at 4 ug/ml by LC-MS/MS method,Other,18724364.0,
1933,500665,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of DHFR in Escherichia coli K-12 NCM3722 assessed as decrease in reduced folates level at 4 ug/ml by LC-MS/MS method,Other,18724364.0,
1934,500666,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of DHFR in Escherichia coli K-12 NCM3722 growing on filters on top of agarose medium support assessed as increase in oxidized folates level at 4 ug/ml by LC-MS/MS method,Other,18724364.0,
1935,500667,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of DHFR in Escherichia coli K-12 NCM3722 growing on filters on top of agarose medium support assessed as decrease in reduced folates level at 4 ug/ml by LC-MS/MS method,Other,18724364.0,
1936,500668,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of DHFR in Escherichia coli K-12 NCM3722 assessed as increase in reduced mono and glutamate folate species level at 4 ug/ml after 20 mins by LC-MS/MS method,Other,18724364.0,
1937,500669,3,8,,103164817,5578,Active,81175282.0,,,,Inhibition of DHFR in Escherichia coli K-12 NCM3722 assessed as impaired folylpoly-gamma-glutamate synthetase activity after 15 mins by [15N] flux profiling based LC-MS/MS method,Other,18724364.0,
1938,500670,3,3,,103164817,5578,Inactive,,,,,Inhibition of Escherichia coli K-12 recombinant His-tagged folylpoly-gamma-glutamate synthetase expressed in Escherichia coli BL21 at 200 uM LC-MS/MS method,Other,18724364.0,
1939,504326,1,2,,50085866,5578,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1940,504326,1,2,,50085866,5578,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1941,504327,1,1,,857743,5578,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1942,504327,1,1,,11111924,5578,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1943,504327,1,1,,90340764,5578,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1944,504329,1,1,,50085866,5578,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1945,504332,1,1,,857743,5578,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1946,504332,1,1,,11111924,5578,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1947,504332,1,1,,50104512,5578,Inactive,168985070.0,,10.0,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1948,504332,1,1,,90340764,5578,Inconclusive,168985070.0,,0.2818,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1949,504333,1,1,,857743,5578,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1950,504339,1,1,,50085866,5578,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1951,504357,1,1,,50085866,5578,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1952,504357,1,1,,50085866,5578,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1953,504364,1,1,,85231275,5578,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1954,504406,1,1,,857743,5578,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1955,504408,2,1,,857743,5578,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1956,504411,1,1,,50085866,5578,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1957,504414,1,1,,50085866,5578,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1958,504414,1,1,,50085866,5578,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1959,504423,1,1,,50085866,5578,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1960,504441,1,1,,50085866,5578,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1961,504444,1,1,,50085866,5578,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1962,504454,1,3,,50085866,5578,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1963,504462,1,1,,50085866,5578,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1964,504466,1,1,,857743,5578,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1965,504467,1,1,,857743,5578,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1966,504490,1,2,,50085866,5578,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1967,504523,1,1,,50085866,5578,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1968,504523,1,1,,50085866,5578,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1969,504536,1,1,,90340764,5578,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1970,504541,1,1,,857743,5578,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction for Validation Set,Screening,,
1971,504547,1,1,,90340764,5578,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1972,504548,1,2,,90340764,5578,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1973,504558,1,1,,50085866,5578,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1974,504577,2,2,,50085866,5578,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1975,504582,2,1,,50085866,5578,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1976,504594,1,1,,50085866,5578,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1977,504600,1,2,,857743,5578,Inactive,6325022.0,855842.0,,,Validation of HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1978,504621,1,1,,50085866,5578,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1979,504634,1,1,,50085866,5578,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1980,504648,1,1,,50085866,5578,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1981,504651,1,1,,857743,5578,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1982,504652,1,1,,857743,5578,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1983,504660,1,1,,857743,5578,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1984,504690,1,3,,50085866,5578,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1985,504692,2,2,,50085866,5578,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1986,504700,1,1,,50085866,5578,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1987,504700,1,1,,50085866,5578,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1988,504706,1,1,,857743,5578,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1989,504707,1,1,,50085866,5578,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1990,504707,1,1,,50085866,5578,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1991,504720,1,1,,50085866,5578,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1992,504734,1,1,,50085866,5578,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1993,504749,1,3,,17389524,5578,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1994,504749,1,3,,104171255,5578,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1995,504749,1,3,1.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1996,504749,1,3,2.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1997,504749,1,3,3.0,104171255,5578,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1998,504749,1,3,4.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1999,504749,1,3,5.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2000,504749,1,3,6.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2001,504749,1,3,7.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2002,504749,1,3,8.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2003,504749,1,3,9.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2004,504749,1,3,10.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2005,504749,1,3,11.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2006,504749,1,3,12.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2007,504749,1,3,13.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2008,504749,1,3,14.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2009,504749,1,3,15.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2010,504749,1,3,16.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2011,504749,1,3,17.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2012,504749,1,3,18.0,17389524,5578,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2013,504749,1,3,19.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2014,504749,1,3,20.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2015,504749,1,3,21.0,17389524,5578,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2016,504749,1,3,22.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2017,504749,1,3,23.0,104171255,5578,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2018,504749,1,3,24.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2019,504749,1,3,25.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2020,504749,1,3,26.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2021,504749,1,3,27.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2022,504749,1,3,28.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2023,504749,1,3,29.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2024,504749,1,3,30.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2025,504749,1,3,31.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2026,504749,1,3,32.0,17389524,5578,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2027,504749,1,3,33.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2028,504749,1,3,34.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2029,504749,1,3,35.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2030,504749,1,3,36.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2031,504749,1,3,37.0,17389524,5578,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2032,504749,1,3,38.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2033,504749,1,3,39.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2034,504749,1,3,40.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2035,504749,1,3,41.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2036,504749,1,3,42.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2037,504749,1,3,43.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2038,504749,1,3,44.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2039,504749,1,3,45.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2040,504749,1,3,46.0,17389524,5578,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2041,504749,1,3,47.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2042,504749,1,3,48.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2043,504749,1,3,49.0,17389524,5578,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2044,504749,1,3,50.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2045,504749,1,3,51.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2046,504749,1,3,52.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2047,504749,1,3,53.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2048,504749,1,3,54.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2049,504749,1,3,55.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2050,504749,1,3,56.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2051,504749,1,3,57.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2052,504749,1,3,58.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2053,504749,1,3,59.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2054,504749,1,3,60.0,104171255,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2055,504749,1,3,61.0,17389524,5578,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
2056,504766,2,1,,50085866,5578,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
2057,504770,1,2,,92124407,5578,Active,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
2058,504775,1,1,,50085866,5578,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
2059,504803,1,1,,50085866,5578,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
2060,504810,1,2,,857743,5578,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2061,504810,1,2,,90340764,5578,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2062,504812,1,2,,857743,5578,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2063,504812,1,2,,90340764,5578,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
2064,504821,1,1,,85231275,5578,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
2065,504832,1,1,,857743,5578,Inconclusive,,,1.4716,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2066,504832,1,1,,104171255,5578,Active,,,1.5101,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
2067,504834,1,1,,857743,5578,Inconclusive,,,18.526,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2068,504834,1,1,,104171255,5578,Active,,,2.1331,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
2069,504836,1,2,,90340764,5578,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
2070,504842,1,1,,857743,5578,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
2071,504845,1,1,,50085866,5578,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2072,504845,1,1,,90340764,5578,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
2073,504847,1,1,,11111924,5578,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2074,504847,1,1,,50085866,5578,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2075,504847,1,1,,90340764,5578,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2076,504847,1,1,,104171255,5578,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2077,504865,1,1,,11111924,5578,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2078,504865,1,1,,90340764,5578,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2079,504865,1,1,,104171255,5578,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2080,504884,1,2,,50085866,5578,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2081,504891,1,1,,50085866,5578,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2082,504894,1,1,,50085866,5578,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2083,504937,1,2,,50085866,5578,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2084,509630,5,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN4220 by broth microdilution method,Other,20008780.0,
2085,509631,5,4,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Staphylococcus aureus RN4220 transformant carrying plasmid pKKS25 and expressing erm(T), dfrK and tet(L) genes by broth microdilution method",Other,20008780.0,
2086,509632,5,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Staphylococcus aureus 25 transformant carrying plasmid pKKS25 and expressing erm(T), dfrKtet(L), tet(K), tet(M), mecA and blaZ genes by broth microdilution method",Other,20008780.0,
2087,519106,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli 10418 after 18 hrs by Etest method,Other,18180352.0,
2088,519107,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis B2 after 18 hrs by Etest method,Other,18180352.0,
2089,519108,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 44 mutant after 18 hrs by Etest method,Other,18180352.0,
2090,519109,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 48 mutant after 18 hrs by Etest method,Other,18180352.0,
2091,519110,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 55 mutant after 18 hrs by Etest method,Other,18180352.0,
2092,519111,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis NP14 after 18 hrs by Etest method,Other,18180352.0,
2093,519112,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 19 mutant after 18 hrs by Etest method,Other,18180352.0,
2094,519113,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 21 mutant after 18 hrs by Etest method,Other,18180352.0,
2095,519114,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 23 mutant after 18 hrs by Etest method,Other,18180352.0,
2096,519115,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis NP37 after 18 hrs by Etest method,Other,18180352.0,
2097,519117,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 29 mutant after 18 hrs by Etest method,Other,18180352.0,
2098,519118,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 31 mutant after 18 hrs by Etest method,Other,18180352.0,
2099,519119,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis NP43 after 18 hrs by Etest method,Other,18180352.0,
2100,519120,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 12 mutant after 18 hrs by Etest method,Other,18180352.0,
2101,519121,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 17 mutant after 18 hrs by Etest method,Other,18180352.0,
2102,519122,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis NP55 after 18 hrs by Etest method,Other,18180352.0,
2103,519123,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 35 mutant after 18 hrs by Etest method,Other,18180352.0,
2104,519124,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 40 mutant after 18 hrs by Etest method,Other,18180352.0,
2105,519125,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 42 mutant after 18 hrs by Etest method,Other,18180352.0,
2106,519205,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae by microdilution method,Other,18180358.0,
2107,519252,7,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus mirabilis M 26 mutant after 18 hrs by Etest method,Other,18180352.0,
2108,519734,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha with deltaampC by agar dilution method,Other,18316518.0,
2109,519737,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-1 by agar dilution method,Other,18316518.0,
2110,519740,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli DH5alpha expressing Klebsiella pneumoniae beta-lactamase SHV-72 by agar dilution method,Other,18316518.0,
2111,519743,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against Klebsiella pneumoniae INSRA1229 harboring SHV-72 Ile8Phe, Ala146Val, and Lys234Arg mutations by agar dilution method",Other,18316518.0,
2112,519833,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide,Other,18268083.0,
2113,519834,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method,Other,18268083.0,
2114,520081,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide,Other,18268083.0,
2115,520082,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against aheB deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method,Other,18268083.0,
2116,520083,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against aheB-deficient kanamycin-resistant Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring AheABC efflux pump by agar dilution method in presence of 64 mg/L efflux pump inhibitor phenylalanine-arginine-beta-naphthylamide,Other,18268083.0,
2117,520084,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method,Other,18268083.0,
2118,520085,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring plasmid pEX19Gm by agar dilution method,Other,18268083.0,
2119,520086,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AcrAB efflux pump by agar dilution method,Other,18268083.0,
2120,520087,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against acrAB-deficient Escherichia coli TG1 harboring AheABC efflux pump by agar dilution method,Other,18268083.0,
2121,520088,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Aeromonas hydrophila subsp. hydrophila ATCC 7966 harboring plasmid pEX19Gm by agar dilution method,Other,18268083.0,
2122,521220,3,3,,103164817,5578,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2123,521885,4,3,,103164817,5578,Active,,,2.6,IC50,Antiplasmodial activity against transgenic Plasmodium falciparum Dd2 pDT harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2124,521886,4,4,,103164817,5578,Unspecified,,,117.0,IC50,Antiplasmodial activity against transgenic Plasmodium falciparum HB3 pDT harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2125,521887,4,3,,103164817,5578,Unspecified,,,169.0,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2126,521888,4,2,,103164817,5578,Active,,,40.0,IC50,Antiplasmodial activity against Plasmodium falciparum W2 harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2127,521889,4,4,,103164817,5578,Unspecified,,,194.0,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2128,521890,4,4,,103164817,5578,Active,,,30.0,IC50,Antiplasmodial activity against Plasmodium falciparum D10 harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2129,521891,4,4,,103164817,5578,Unspecified,,,158.0,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2130,524593,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method,Other,20211897.0,
2131,524763,2,3,,103164817,5578,Active,,,2.032,IC50,Antiplasmodial activity against Plasmodium falciparum JC3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2132,524764,2,3,,103164817,5578,Active,,,48.18899999999999,IC50,Antiplasmodial activity against Plasmodium falciparum JF6 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2133,524765,2,3,,103164817,5578,Active,,,1.64,IC50,Antiplasmodial activity against Plasmodium falciparum JF11 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2134,524766,2,3,,103164817,5578,Active,,,3.3110000000000004,IC50,Antiplasmodial activity against Plasmodium falciparum XG10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2135,524767,2,3,,103164817,5578,Unspecified,,,50.695,IC50,Antiplasmodial activity against Plasmodium falciparum KC2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2136,524768,2,3,,103164817,5578,Unspecified,,,61.785,IC50,Antiplasmodial activity against Plasmodium falciparum WE2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2137,524773,2,3,,103164817,5578,Active,,,48.211000000000006,IC50,Antiplasmodial activity against Plasmodium falciparum DEV after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2138,524774,4,2,,103164817,5578,Active,,,4.1,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2139,524775,4,3,,103164817,5578,Active,,,2.8,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 harboring polymorphic DHFR after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2140,524790,7,2,,103164817,5578,Active,,,1.2589299999999999,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2141,524791,7,2,,103164817,5578,Active,,,36.531,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2142,524792,7,2,,103164817,5578,Active,,,3.16228,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2143,524794,7,1,,103164817,5578,Active,,,1.2589299999999999,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2144,524795,7,2,,103164817,5578,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2145,524797,2,3,,103164817,5578,Active,,,41.742,IC50,Antiplasmodial activity against Plasmodium falciparum KB8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2146,524798,2,3,,103164817,5578,Active,,,44.582,IC50,Antiplasmodial activity against Plasmodium falciparum KC5 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2147,524799,2,3,,103164817,5578,Active,,,39.806,IC50,Antiplasmodial activity against Plasmodium falciparum XD8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2148,524800,2,3,,103164817,5578,Active,,,43.831,IC50,Antiplasmodial activity against Plasmodium falciparum XB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2149,524801,2,3,,103164817,5578,Active,,,39.641999999999996,IC50,Antiplasmodial activity against Plasmodium falciparum JC9 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2150,524802,2,3,,103164817,5578,Active,,,2.481,IC50,Antiplasmodial activity against Plasmodium falciparum AUD after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2151,524803,2,3,,103164817,5578,Active,,,48.456,IC50,Antiplasmodial activity against Plasmodium falciparum AL2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2152,524804,2,3,,103164817,5578,Active,,,1.0959999999999999,IC50,Antiplasmodial activity against Plasmodium falciparum TF1 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2153,524805,2,3,,103164817,5578,Active,,,1.412,IC50,Antiplasmodial activity against Plasmodium falciparum KH7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2154,524806,2,3,,103164817,5578,Active,,,2.303,IC50,Antiplasmodial activity against Plasmodium falciparum NIC after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2155,524807,2,3,,103164817,5578,Active,,,40.053000000000004,IC50,Antiplasmodial activity against Plasmodium falciparum JB12 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2156,524808,2,3,,103164817,5578,Active,,,29.851999999999997,IC50,Antiplasmodial activity against Plasmodium falciparum D2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2157,524809,2,3,,103164817,5578,Active,,,0.855,IC50,Antiplasmodial activity against Plasmodium falciparum XE7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2158,524810,2,3,,103164817,5578,Active,,,24.165,IC50,Antiplasmodial activity against Plasmodium falciparum LC12 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2159,524811,2,3,,103164817,5578,Active,,,1.5030000000000001,IC50,Antiplasmodial activity against Plasmodium falciparum JH6 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2160,524812,2,3,,103164817,5578,Active,,,1.183,IC50,Antiplasmodial activity against Plasmodium falciparum LA10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2161,524813,2,3,,103164817,5578,Active,,,2.108,IC50,Antiplasmodial activity against Plasmodium falciparum KA6 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2162,524814,2,3,,103164817,5578,Active,,,2.0709999999999997,IC50,Antiplasmodial activity against Plasmodium falciparum JON after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2163,524815,2,3,,103164817,5578,Active,,,39.605,IC50,Antiplasmodial activity against Plasmodium falciparum NF10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2164,524816,2,3,,103164817,5578,Active,,,2.155,IC50,Antiplasmodial activity against Plasmodium falciparum QF5 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2165,524817,2,3,,103164817,5578,Active,,,2.657,IC50,Antiplasmodial activity against Plasmodium falciparum WF12 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2166,524818,2,3,,103164817,5578,Active,,,2.273,IC50,Antiplasmodial activity against Plasmodium falciparum XF12 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2167,524819,2,3,,103164817,5578,Unspecified,,,59.746,IC50,Antiplasmodial activity against Plasmodium falciparum DAN after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2168,524820,2,3,,103164817,5578,Unspecified,,,70.393,IC50,Antiplasmodial activity against Plasmodium falciparum JB8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2169,524821,2,3,,103164817,5578,Active,,,32.669000000000004,IC50,Antiplasmodial activity against Plasmodium falciparum WC4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2170,525040,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against fluoroquinolone-susceptible Escherichia coli PS5 harboring GyrA S83L mutant gene by Etest,Other,20008776.0,
2171,525041,5,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against fluoroquinolone-resistant Escherichia coli NorE5 harboring GyrA S83L mutant, ParC S80R mutant, truncated SoxR and constitutively active SoxS by Etest",Other,20008776.0,
2172,527081,6,7,,103164817,5578,Unspecified,81715208.0,,71.4,IC50,Inhibition of wild type Bacillus anthracis recombinant DHFR,Confirmatory,20882962.0,
2173,527082,4,3,,103164817,5578,Active,,,,IC50,Inhibition of Bacillus anthracis recombinant DHFR F96I mutant,Confirmatory,20882962.0,
2174,527083,2,4,,103164817,5578,Unspecified,,,,,Selectivity ratio of Ki for wild type Bacillus anthracis recombinant DHFR to Ki for Bacillus anthracis recombinant DHFR F96I mutant,Other,20882962.0,
2175,527084,4,3,,103164817,5578,Active,,,,IC50,Inhibition of Bacillus anthracis recombinant DHFR Y102F mutant,Confirmatory,20882962.0,
2176,527085,2,4,,103164817,5578,Unspecified,,,,,Selectivity ratio of Ki for wild type Bacillus anthracis recombinant DHFR to Ki for Bacillus anthracis recombinant DHFR Y102F mutant,Other,20882962.0,
2177,529456,4,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest",Other,18519712.0,
2178,529457,4,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest",Other,18519712.0,
2179,530345,5,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method",Other,18644958.0,
2180,530346,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method,Other,18644958.0,
2181,530347,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method,Other,18644958.0,
2182,530348,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method,Other,18644958.0,
2183,530349,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method,Other,18644958.0,
2184,530350,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method,Other,18644958.0,
2185,530531,2,4,,103164817,5578,Unspecified,,,,,Induction of Ppbp2::lacZ gene expression in Staphylococcus aureus SH1000 at 1 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control,Other,18541730.0,
2186,530540,2,4,,103164817,5578,Unspecified,,,,,Induction of PvraSr::lacZ gene expression in Staphylococcus aureus SH1000 at 1 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control,Other,18541730.0,
2187,530549,2,4,,103164817,5578,Unspecified,,,,,Induction of PtcaA::lacZ gene expression in Staphylococcus aureus SH1000 at 1 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control,Other,18541730.0,
2188,530752,2,4,,103164817,5578,Unspecified,,,,,Induction of PlytR::lacZ gene expression in Staphylococcus aureus SH1000 at 1 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control,Other,18541730.0,
2189,530761,2,4,,103164817,5578,Unspecified,,,,,Induction of PsgtB::lacZ gene expression in Staphylococcus aureus SH1000 at 1 ug/ml after 2 hrs by beta-galactosidase reporter gene assay relative to untreated control,Other,18541730.0,
2190,530769,5,2,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against beta-lactamase producing Staphylococcus aureus SH1000,Other,18541730.0,
2191,533659,5,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN4220,Other,18838584.0,
2192,533660,5,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid VGA,Other,18838584.0,
2193,533661,5,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid CU1,Other,18838584.0,
2194,533662,5,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN4220 harboring vgaAv positive plasmid CU1,Other,18838584.0,
2195,533663,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN1024,Other,18838584.0,
2196,533664,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN1024-tms,Other,18838584.0,
2197,533665,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 29213,Other,18838584.0,
2198,534106,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pasteurella multocida AL435 after 24 hrs by broth dilution method,Other,18725450.0,
2199,534107,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against TolC deficient Pasteurella multocida pm0527 after 24 hrs by broth dilution method,Other,18725450.0,
2200,534108,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pasteurella multocida pm0527 after 24 hrs by broth dilution method,Other,18725450.0,
2201,534109,1,3,,103164817,5578,Unspecified,,,,,Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm0527,Other,18725450.0,
2202,534110,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against TolC deficient Pasteurella multocida pm1980 after 24 hrs by broth dilution method,Other,18725450.0,
2203,534111,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pasteurella multocida pm1980 after 24 hrs by broth dilution method,Other,18725450.0,
2204,534112,1,3,,103164817,5578,Unspecified,,,,,Ratio of MIC for Pasteurella multocida AL435 to MIC for TolC deficient Pasteurella multocida pm1980,Other,18725450.0,
2205,540209,4,3,,103164817,5578,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2206,540210,4,3,,103164817,5578,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2207,540211,2,5,,103164817,5578,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2208,540212,4,3,,103164817,5578,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2209,540213,4,3,,103164817,5578,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2210,540253,1,1,,50085866,5578,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2211,540253,1,1,,50085866,5578,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2212,540253,1,1,,50085866,5578,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2213,540256,1,2,,50104512,5578,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2214,540256,1,2,,90340764,5578,Inconclusive,,,1.8349,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2215,540263,1,1,,50085866,5578,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2216,540263,1,1,,50085866,5578,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2217,540267,1,1,,50085866,5578,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2218,540275,1,1,,857743,5578,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2219,540276,1,2,,857743,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2220,540276,1,2,,11111923,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2221,540276,1,2,,11111924,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2222,540276,1,2,,11113621,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2223,540276,1,2,,17389524,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2224,540276,1,2,,26747124,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2225,540276,1,2,,26747125,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2226,540276,1,2,,26751820,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2227,540276,1,2,,50085866,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2228,540276,1,2,,50104512,5578,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2229,540276,1,2,,50104513,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2230,540276,1,2,,85231275,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2231,540276,1,2,,90340764,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2232,540276,1,2,,104171255,5578,Inconclusive,420597.0,,0.8196,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2233,540277,1,1,,857743,5578,Inconclusive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2234,540295,1,1,,50085866,5578,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2235,540299,1,2,,92124407,5578,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2236,540299,1,2,,92125161,5578,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2237,540303,1,1,,50085866,5578,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2238,540303,1,1,,50085866,5578,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2239,540303,1,1,,50085866,5578,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2240,540308,1,1,,50085866,5578,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2241,540317,1,1,,50085866,5578,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2242,540336,1,1,,50085866,5578,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2243,540336,1,1,,50085866,5578,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2244,540364,1,2,,50085866,5578,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2245,541855,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 29522 by microdilution assay,Other,19029319.0,
2246,541856,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against florfenicol-resistant Edwardsiella ictaluri M07-1 by microdilution assay,Other,19029319.0,
2247,541857,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli ATCC 29522 carrying Edwardsiella ictaluri pM07-1 by microdilution assay,Other,19029319.0,
2248,542420,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter sp. N2 isolate C439 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2249,542735,5,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Klebsiella pneumoniae D10 expressing aac(6')-Ib-cr, qnrB4, CTX-M-1G and DHA-1 genes by agar dilution method",Other,18936192.0,
2250,542737,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Klebsiella pneumoniae D24 expressing aac(6')-Ib-cr and CTX-M-9G genes by agar dilution method,Other,18936192.0,
2251,542742,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Citrobacter freundii D26 expressing qnrB6 and CTX-M-9G genes by agar dilution method,Other,18936192.0,
2252,542759,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli Du19 expressing qnrB6 and CTX-M-9G genes by agar dilution method,Other,18936192.0,
2253,542766,5,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Escherichia coli PA11 expressing aac(6')-Ib-cr, qnrS1 and qepA genes by agar dilution method",Other,18936192.0,
2254,542768,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 by agar dilution method,Other,18936192.0,
2255,542769,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 transformed with pHND1 carrying DHA-1 gene by agar dilution method,Other,18936192.0,
2256,542770,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 transformed with pHND2 carrying qnrB6 and CTX-M-9G genes by agar dilution method,Other,18936192.0,
2257,542771,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 transformed with pHND3 carrying qnrB6 gene by agar dilution method,Other,18936192.0,
2258,542772,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 transformed with pHNDU1 carrying qnrB6 gene by agar dilution method,Other,18936192.0,
2259,542773,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 transformed with pHNPA1 carrying qnrB6 gene by agar dilution method,Other,18936192.0,
2260,543065,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus ST398,Other,19015335.0,
2261,543102,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Pseudomonas lini isolate C701 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2262,543232,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli JM109 expressing Bgl2,Other,19015335.0,
2263,543233,2,3,,103164817,5578,Unspecified,,,,,Ratio of MIC for Escherichia coli JM109 expressing Bgl2 to MIC for wild type Escherichia coli JM109,Other,19015335.0,
2264,544007,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Bacillus sphaericus isolate C237 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2265,544008,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter lwoffii isolate C2 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2266,544019,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter lwoffii isolate C15 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2267,544020,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Psychrobacter ikaite isolate C20 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2268,544021,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Psychrobacter sp. DY9-2 isolate C711 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2269,544022,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Psychrobacter frigidicola isolate C712 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2270,544023,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Psychrobacter ikaite isolate C713 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2271,544024,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter calcoaceticus isolate C35 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2272,544025,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter calcoaceticus isolate C36 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2273,544026,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter lwoffii isolate C37 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2274,544027,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter rhizosphaerae isolate C44 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2275,544028,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Acinetobacter lwoffii isolate C141 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2276,544058,4,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Shigella flexneri isolate C506 harboring sul1 to sul3 genes assessed as antibiotic resistance breakpoint by agar dilution method,Other,19064898.0,
2277,546209,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus 2171 by broth microdilution method,Other,20498309.0,
2278,546624,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Virchow assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2279,546625,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Heidelberg assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2280,546626,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Heidelberg assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2281,547212,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio vulnificus assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2282,547213,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli by broth microdilution methods in presence of sulfamethoxazolee,Other,19114678.0,
2283,547214,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2284,547215,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2285,547216,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Typhimurium by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2286,547217,2,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Typhimurium assessed as percent susceptible isolates by broth microdilution methods in presence of sulfamethoxazolee,Other,19114678.0,
2287,547218,2,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Typhimurium assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2288,547219,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Enteritidis by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2289,547220,2,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Enteritidis assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2290,547221,2,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Enteritidis assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2291,547222,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Typhi by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2292,547223,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Paratyphi by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2293,547224,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Paratyphi assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2294,547225,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Paratyphi assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2295,547226,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Choleraesuis by broth microdilution method in presence of sulfamethoxazolee,Other,19114678.0,
2296,547227,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Choleraesuis assessed as percent susceptible isolates by broth microdilution methods in presence of sulfamethoxazolee,Other,19114678.0,
2297,547228,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Choleraesuis assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2298,547229,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Newport by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2299,547230,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Newport assessed as percent susceptible isolates by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2300,547231,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Newport assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2301,547232,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Virchow by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2302,547438,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Virchow assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2303,547439,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Heidelberg by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2304,547440,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella sonnei by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2305,547441,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella sonnei assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2306,547442,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella sonnei assessed as percent susceptible isolates assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2307,547443,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella flexneri by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2308,547444,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella flexneri assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2309,547445,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella flexneri assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2310,547446,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella boydii by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2311,547447,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella boydii assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2312,547448,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella boydii assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2313,547449,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella dysenteriae by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2314,547450,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella dysenteriae assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2315,547451,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella dysenteriae assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2316,547452,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Yersinia enterocolitica by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2317,547453,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Yersinia enterocolitica ssessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2318,547454,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Yersinia pseudotuberculosis by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2319,547455,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Yersinia pseudotuberculosis assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2320,547456,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Yersinia pseudotuberculosis assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2321,547457,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Yersinia enterocolitica assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2322,547458,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas hydrophila by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2323,547459,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas hydrophila assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2324,547460,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas hydrophila assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2325,547461,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas caviae by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2326,547462,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas caviae assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2327,547463,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas caviae assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2328,547464,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas sobria by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2329,547465,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas sobria assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2330,547466,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas sobria assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2331,547467,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas veronii by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2332,547468,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas veronii assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2333,547469,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Aeromonas veronii assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2334,547470,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Plesiomonas shigelloides by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2335,547471,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Plesiomonas shigelloides assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2336,547472,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Plesiomonas shigelloides assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2337,547473,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio cholerae by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2338,547474,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio cholerae assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2339,547475,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio cholerae assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2340,547476,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio parahaemolyticus by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2341,547477,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio parahaemolyticus assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2342,547478,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio parahaemolyticus assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2343,547479,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio alginolyticus by broth microdilution methods in presence of sulfamethoxazole,Other,19114678.0,
2344,547480,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio alginolyticus assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2345,547481,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio alginolyticus assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2346,547482,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio fluvialis by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2347,547483,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio fluvialis assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2348,547484,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio fluvialis assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2349,547485,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio vulnificus by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2350,547486,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio vulnificus assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2351,547487,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio sp. by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2352,547488,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio sp. assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2353,547489,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Vibrio sp. assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2354,547490,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Campylobacter jejuni by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2355,547491,6,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Campylobacter coli by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2356,547492,2,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Typhi assessed as percent susceptible isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2357,547493,2,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica serovar Typhi assessed as percent resistant isolates by broth microdilution method in presence of sulfamethoxazole,Other,19114678.0,
2358,555292,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-susceptible Staphylococcus aureus by agar dilution method,Other,19188385.0,
2359,555293,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus by agar dilution method,Other,19188385.0,
2360,555294,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Tmp-susceptible Staphylococcus aureus by agar dilution method,Other,19188385.0,
2361,555295,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Tmp-resistant Staphylococcus aureus by agar dilution method,Other,19188385.0,
2362,555296,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus aureus by agar dilution method,Other,19188385.0,
2363,555297,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus aureus by agar dilution method,Other,19188385.0,
2364,555298,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Tmp-susceptible coagulase-negative Staphylococcus aureus by agar dilution method,Other,19188385.0,
2365,555299,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Tmp-resistant coagulase-negative Staphylococcus aureus by agar dilution method,Other,19188385.0,
2366,555300,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth macrodilution method,Other,19188385.0,
2367,555301,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-susceptible Staphylococcus aureus 505 by broth macrodilution method,Other,19188385.0,
2368,555302,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by broth macrodilution method,Other,19188385.0,
2369,555303,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 145 by broth macrodilution method,Other,19188385.0,
2370,555304,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus 507 by broth macrodilution method,Other,19188385.0,
2371,555305,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 by broth macrodilution method,Other,19188385.0,
2372,555306,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis 051 by broth macrodilution method,Other,19188385.0,
2373,555307,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis 057 by broth macrodilution method,Other,19188385.0,
2374,555308,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 074 by broth macrodilution method,Other,19188385.0,
2375,555309,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 197 by broth macrodilution method,Other,19188385.0,
2376,555310,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 225 by broth macrodilution method,Other,19188385.0,
2377,555311,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 345 by broth macrodilution method,Other,19188385.0,
2378,555313,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 after 14 passages by agar dilution method,Other,19188385.0,
2379,555315,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-susceptible, vancomycin-intermediate Staphylococcus aureus 505 by broth macrodilution method",Other,19188385.0,
2380,555317,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-susceptible, vancomycin-intermediate Staphylococcus aureus 505 after 14 passages by agar dilution method",Other,19188385.0,
2381,555321,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 20 passages by agar dilution method,Other,19188385.0,
2382,555507,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis 197 after 50 passages by agar dilution method,Other,19188385.0,
2383,555737,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant and vancomycin-resistant Staphylococcus aureus VRS1 by agar dilution method,Other,19188385.0,
2384,555742,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-resistant, Linezolid non-susceptible coagulase-negative Staphylococcus epidermidis 345 by agar dilution method",Other,19188385.0,
2385,555743,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-resistant, vancomycin-intermediate coagulase-negative Staphylococcus epidermidis 225 by agar dilution method",Other,19188385.0,
2386,557795,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Proteus mirabilis 06-489 isolated from infected human urinary tract by CLSI agar dilution method,Other,19258263.0,
2387,557797,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 transconjugated with Proteus mirabilis pHS10 carrying qnrC gene by CLSI agar dilution method,Other,19258263.0,
2388,557799,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 by CLSI agar dilution method,Other,19258263.0,
2389,559547,3,2,,103164817,5578,Unspecified,,,101.75399999999999,IC50,"Antimalarial activity against pyrimethamine-resistant Plasmodium falciparum V1S expressing DHFR quadruple mutant with point mutations at codons 108, 51, 59 and 164 gene by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
2390,559548,2,4,,103164817,5578,Active,,,0.4067,IC50,Antimalarial activity against pyrimethamine-sensitive Plasmodium falciparum 3D7 expressing wild type DHFR by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
2391,559549,2,3,,103164817,5578,Active,,,29.656,IC50,Antimalarial activity against Plasmodium falciparum Kenyan isolates by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
2392,560247,5,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 by CLSI method,Other,19470508.0,
2393,560248,5,4,,103164817,5578,Unspecified,,,,,"Antibacterial activity against Staphylococcus aureus RN4220 harboring aadD, tet(L), dfrK and vga(C) gene by CLSI method",Other,19470508.0,
2394,560249,5,4,,103164817,5578,Unspecified,,,,,"Antibacterial activity against Staphylococcus aureus RN4220 harboring tet(L), dfrK gene by CLSI method",Other,19470508.0,
2395,560250,5,4,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus RN4220 harboring aadD and tet(L) gene by CLSI method,Other,19470508.0,
2396,560256,2,3,,103164817,5578,Active,,,9.3086,IC50,Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn and Cys59Arg or Ser108Asn and Asn51Ile double mutant by [3H]hypoxanthine incorporation assay,Confirmatory,19528269.0,
2397,560257,2,3,,103164817,5578,Active,,,33.655,IC50,"Antimalarial activity against Plasmodium falciparum Kenyan isolates expressing DHFR Ser108Asn, Asn51Ile and Cys59Arg triple mutant by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
2398,560258,3,2,,103164817,5578,Unspecified,,,154.736,IC50,"Antimalarial activity against Plasmodium falciparum isolate Kil-164 expressing DHFR Ser108Asn, Asn51Ile, Cys59Arg and Ile164Leu quadruple mutant by [3H]hypoxanthine incorporation assay",Confirmatory,19528269.0,
2399,561340,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus by CLSI broth microdilution method,Other,19289528.0,
2400,561341,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus by CLSI broth microdilution method,Other,19289528.0,
2401,561342,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A by CLSI broth microdilution method,Other,19289528.0,
2402,561513,6,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B by CLSI broth microdilution method,Other,19289528.0,
2403,561514,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis by CLSI broth microdilution method,Other,19289528.0,
2404,561515,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium by CLSI broth microdilution method,Other,19289528.0,
2405,561518,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 0.03 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2406,561519,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 0.06 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2407,561520,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 0.12 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2408,561521,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 0.25 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2409,561522,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 0.5 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2410,561523,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 1 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2411,561524,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 2 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2412,561525,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 4 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2413,561526,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2414,561527,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 16 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2415,561528,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 32 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2416,561529,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at 64 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2417,561530,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as inhibition of bacterial growth at >8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2418,561533,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 0.03 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2419,561534,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 0.06 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2420,561535,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 0.12 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2421,561536,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 0.25 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2422,561537,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 0.5 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2423,561538,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 1 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2424,561539,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 2 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2425,561540,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 4 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2426,561541,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2427,561542,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 16 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2428,561543,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 32 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2429,561544,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at 64 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2430,561545,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as inhibition of bacterial growth at >8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2431,561548,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 0.03 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2432,561549,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 0.06 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2433,561550,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 0.12 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2434,561551,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 0.25 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2435,561552,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 0.5 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2436,561553,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 1 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2437,561554,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 2 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2438,561555,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 4 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2439,561556,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2440,561557,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 16 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2441,561558,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 32 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2442,561559,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as inhibition of bacterial growth at 64 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2443,561562,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 0.03 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2444,561563,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 0.06 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2445,561564,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 0.12 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2446,561565,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 0.25 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2447,561566,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 0.5 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2448,561567,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 1 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2449,561568,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 2 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2450,561569,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 4 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2451,561718,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2452,561719,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 16 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2453,561720,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 32 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2454,561721,2,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as inhibition of bacterial growth at 64 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2455,561724,1,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Enterococcus faecium assessed as resistant isolates by CLSI broth microdilution method,Other,19289528.0,
2456,561725,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 0.03 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2457,561726,1,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Enterococcus faecalis assessed as resistant isolates by CLSI broth microdilution method,Other,19289528.0,
2458,561727,1,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Enterococcus faecium assessed as susceptible isolates by CLSI broth microdilution method,Other,19289528.0,
2459,561728,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 0.06 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2460,561729,1,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Enterococcus faecalis assessed as susceptible isolates by CLSI broth microdilution method,Other,19289528.0,
2461,561730,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 0.12 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2462,561731,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 0.25 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2463,561732,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 0.5 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2464,561733,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 1 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2465,561734,2,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as resistant isolates by CLSI broth microdilution method,Other,19289528.0,
2466,561735,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 2 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2467,561736,2,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group B assessed as susceptible isolates by CLSI broth microdilution method,Other,19289528.0,
2468,561737,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 4 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2469,561738,1,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as resistant isolates by CLSI broth microdilution method,Other,19289528.0,
2470,561739,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2471,561740,1,3,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Beta-hemolytic Streptococcus group A assessed as susceptible isolates by CLSI broth microdilution method,Other,19289528.0,
2472,561741,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 16 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2473,561742,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 32 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2474,561743,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at 64 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2475,561744,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis assessed as inhibition of bacterial growth at >8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2476,561745,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as susceptible isolates by CLSI broth microdilution method,Other,19289528.0,
2477,561747,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as resistant isolates by CLSI broth microdilution method,Other,19289528.0,
2478,561749,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 0.03 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2479,561750,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 0.06 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2480,561751,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 0.12 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2481,561752,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI broth microdilution method,Other,19289528.0,
2482,561753,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 0.25 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2483,561754,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 0.5 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2484,561755,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Methicillin-sensitive Staphylococcus aureus assessed as resistant isolates by CLSI broth microdilution method,Other,19289528.0,
2485,561756,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 1 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2486,561757,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 2 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2487,561758,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 4 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2488,561759,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2489,561760,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 16 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2490,561761,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 32 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2491,561762,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at 64 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2492,561763,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium assessed as inhibition of bacterial growth at >8 ug/ml by CLSI broth microdilution method,Other,19289528.0,
2493,561835,9,2,,103164817,5578,Unspecified,81715208.0,,77.0,IC50,Inhibition of Bacillus anthracis DHFR,Confirmatory,19364848.0,
2494,562614,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-sensitive Staphylococcus aureus by agar dilution method,Other,19738027.0,
2495,562615,1,3,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-sensitive Staphylococcus aureus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2496,562616,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus by agar dilution method,Other,19738027.0,
2497,562617,1,3,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2498,562618,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus by agar dilution method,Other,19738027.0,
2499,562619,1,3,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2500,562620,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by agar dilution method,Other,19738027.0,
2501,562621,1,3,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2502,562622,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Coagulase-negative Staphylococcus by agar dilution method,Other,19738027.0,
2503,562623,1,3,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Coagulase-negative Staphylococcus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2504,562624,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Group A Streptococcus by agar dilution method,Other,19738027.0,
2505,562625,1,3,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against Group A Streptococcus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2506,562626,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Group B Streptococcus by agar dilution method,Other,19738027.0,
2507,562627,2,3,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against Group B Streptococcus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2508,562628,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Group C Streptococcus by agar dilution method,Other,19738027.0,
2509,562629,2,3,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against Group C Streptococcus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2510,562630,6,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Group G Streptococcus by agar dilution method,Other,19738027.0,
2511,562631,2,3,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against Group G Streptococcus assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2512,562632,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Streptococcus pneumoniae by agar dilution method,Other,19738027.0,
2513,562633,1,3,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against Streptococcus pneumoniae assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2514,562634,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Corynebacterium spp. by agar dilution method,Other,19738027.0,
2515,562635,1,3,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against Corynebacterium spp. assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2516,562636,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Listeria monocytogenes by agar dilution method,Other,19738027.0,
2517,562637,1,3,,103164817,5578,Inconclusive,,,,,Antimicrobial activity against Listeria monocytogenes assessed as susceptible isolates by agar dilution method,Other,19738027.0,
2518,562638,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Streptococcus mitis by agar dilution method,Other,19738027.0,
2519,562809,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53,Other,19687243.0,
2520,562810,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 harboring pEK499 plasmid encoding CTX-M extended-spectrum beta-lactamases,Other,19687243.0,
2521,562811,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli J53 harboring pEK204 plasmid encoding CTX-M extended-spectrum beta-lactamases,Other,19687243.0,
2522,562812,5,3,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH5[alpha],Other,19687243.0,
2523,562813,5,3,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli DH5[alpha] harboring pEK516 plasmid encoding CTX-M extended-spectrum beta-lactamases,Other,19687243.0,
2524,565063,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-15 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2525,565064,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against SHV-12 ESBL producing Enterobacter cloacae assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2526,565065,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-14 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2527,565066,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-15 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2528,565067,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-15 and SHV-27 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2529,565068,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-15 and SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2530,565069,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against SHV-12 ESBL producing Escherichia coli assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2531,565070,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-14 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2532,565071,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-15 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2533,565072,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against SHV-12 ESBL producing Klebsiella pneumoniae assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2534,565073,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-14 ESBL producing Morganella morganii assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2535,565074,1,3,,103164817,5578,Unspecified,,,,,Antibacterial activity against CTX-M-14 ESBL producing Proteus mirabilis assessed as resistant isolates by disk diffusion method,Other,19721071.0,
2536,567091,2,6,,103164817,5578,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
2537,567317,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Proteus mirabilis TUM4660 by broth dilution method,Other,20566768.0,
2538,567318,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli TUM4670 by broth dilution method,Other,20566768.0,
2539,567319,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli TUM4672 by broth dilution method,Other,20566768.0,
2540,567320,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli ML4909 by broth dilution method,Other,20566768.0,
2541,567321,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Escherichia coli ML4901 by broth dilution method,Other,20566768.0,
2542,571305,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis,Other,19546364.0,
2543,571306,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis in presence of 50 ug/ml thymidine,Other,19546364.0,
2544,571307,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis in presence of 250 ug/ml thymidine,Other,19546364.0,
2545,571308,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium,Other,19546364.0,
2546,571309,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium in presence of 50 ug/ml thymidine,Other,19546364.0,
2547,571310,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecium in presence of 250 ug/ml thymidine,Other,19546364.0,
2548,571311,4,2,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Streptococcus pneumoniae,Other,19546364.0,
2549,571312,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae in presence of 50 ug/ml thymidine,Other,19546364.0,
2550,571313,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae in presence of 250 ug/ml thymidine,Other,19546364.0,
2551,571314,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Haemophilus influenzae,Other,19546364.0,
2552,571315,4,2,,103164817,5578,Inconclusive,,,,,Antibacterial activity against Haemophilus influenzae in presence of 50 ug/ml thymidine,Other,19546364.0,
2553,571316,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Haemophilus influenzae in presence of 250 ug/ml thymidine,Other,19546364.0,
2554,571317,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-resistant dfrE-positive and folA, dfrF-negative Enterococcus faecalis",Other,19546364.0,
2555,571318,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-sensitive folA, dfrF-negative Enterococcus faecalis harboring A5T, K88N, F102Y mutation in dfrE gene",Other,19546364.0,
2556,571319,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-sensitive dfrE, dfrF-positive and folA-negative Enterococcus faecalis",Other,19546364.0,
2557,571320,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-sensitive folA, dfrF-negative Enterococcus faecalis harboring K88N, A5T, H153R mutation in dfrE gene",Other,19546364.0,
2558,571321,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-resistant folA, dfrF-negative Enterococcus faecalis harboring K88N, A5T, H153R mutation in dfrE gene",Other,19546364.0,
2559,571322,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-sensitive dfrE, dfrF-negative and folA-positive Enterococcus faecium",Other,19546364.0,
2560,571323,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-sensitive dfrE, dfrF-negative Enterococcus faecium harboring M145I and R52H mutation in folA gene",Other,19546364.0,
2561,571324,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-sensitive dfrF-negative Enterococcus faecium harboring M145I mutation in folA and A5T, K88N mutation in dfrE genes",Other,19546364.0,
2562,571325,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-resistant dfrE, dfrF-negative and folA-positive Enterococcus faecium",Other,19546364.0,
2563,571326,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin-resistant dfrE-negative and folA, dfrF-positive Enterococcus faecium",Other,19546364.0,
2564,571327,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-sensitive dfrB-positive abd dfrA, dfrG-negative Staphylococcus aureus",Other,19546364.0,
2565,571328,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-resistant dfrA within SCCmec-N1, dfrA and dfrG -negative Staphylococcus aureus harboring F98Y mutation in dfrB gene",Other,19546364.0,
2566,571329,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-resistant dfrB, dfrA-positive and dfrA within SCCmec-N1, dfrG-negative Staphylococcus aureus",Other,19546364.0,
2567,571330,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-resistant dfrB, dfrG-positive and dfrA-negative Staphylococcus aureus",Other,19546364.0,
2568,571331,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-sensitive dfrC-positive and dfrA, dfrD-negative Staphylococcus epidermidis",Other,19546364.0,
2569,571332,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-sensitive dfrA, dfrD-negative Staphylococcus epidermidis harboring F98Y mutation in dfrC gene",Other,19546364.0,
2570,571333,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-sensitive dfrA-positive and dfrD-negative Staphylococcus epidermidis harboring F98Y mutation in dfrC gene,Other,19546364.0,
2571,571334,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-sensitive dfrC, dfrA-positive and dfrD-negative Staphylococcus epidermidis",Other,19546364.0,
2572,571335,4,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin-resistant dfrC, dfrA-positive and dfrA within SCCmec-N1, dfrD-negative Staphylococcus epidermidis",Other,19546364.0,
2573,571507,3,3,,103164817,5578,Active,,,0.055,IC50,Inhibition of Babesia gibsoni Dihydrofolate reductase-thymidylate synthase expressed in Escherichia coli BL21,Confirmatory,18794380.0,
2574,571510,3,3,,103164817,5578,Active,,,,,Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 20 uM by Giemsa staining based microscopy,Other,18794380.0,
2575,571511,1,3,,103164817,5578,Active,,,,,Antiparasitic activity against Babesia gibsoni infected in dog erythrocytes assessed as growth inhibition at 80 uM by Giemsa staining based microscopy,Other,18794380.0,
2576,571517,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin, vancomycin, trimethoprim-sensitive Staphylococcus aureus ATCC 29213 harboring dfrB gene",Other,19546364.0,
2577,571518,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin, trimethoprim-sensitive and methicillin-resistant Staphylococcus aureus ATCC 43300 harboring dfrB gene",Other,19546364.0,
2578,571519,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against vancomycin, trimethoprim, methicillin-resistant Staphylococcus aureus VRS1 harboring dfrA and dfrB genes",Other,19546364.0,
2579,571520,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin, vancomycin, trimethoprim-sensitive Staphylococcus epidermidis ATCC 14990 harboring dfrC gene",Other,19546364.0,
2580,571521,5,2,,103164817,5578,Unspecified,,,,,"Antibacterial activity against methicillin, vancomycin-sensitive and trimethoprim-resistant Staphylococcus epidermidis BAS000635 harboring dfrC and dfrA genes",Other,19546364.0,
2581,571522,2,4,,103164817,5578,Active,,,0.0257,IC50,Inhibition of trimethoprim-sensitive Staphylococcus aureus DfrB type dihydrofolate reductase,Confirmatory,19546364.0,
2582,571523,2,4,,103164817,5578,Active,,,10.243,IC50,Inhibition of trimethoprim-resistant Staphylococcus aureus DfrB type dihydrofolate reductase F98Y mutant,Confirmatory,19546364.0,
2583,571524,2,3,,103164817,5578,Active,,,32.997,IC50,Inhibition of trimethoprim-resistant Staphylococcus aureus Type S1 dihydrofolate reductase,Confirmatory,19546364.0,
2584,571525,2,9,,103164817,5578,Unspecified,118992.0,1719.0,,,Activity of human DHFR at 52 uM,Other,19546364.0,
2585,571525,2,9,,103164817,5578,Unspecified,118992.0,573971.0,,,Activity of human DHFR at 52 uM,Other,19546364.0,
2586,571540,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against trimethoprim-sensitive Staphylococcus aureus ATCC 29213,Other,19546364.0,
2587,571543,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against trimethoprim-sensitive Staphylococcus aureus ATCC 29213 infected in NMRI mouse model of septicemia,Other,19546364.0,
2588,571544,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against trimethoprim-resistant Staphylococcus aureus BAS003908,Other,19546364.0,
2589,571545,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against trimethoprim-resistant Staphylococcus aureus BAS003908 infected in NMRI mouse model of septicemia,Other,19546364.0,
2590,571882,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli KAM32 harboring plasmid pUC18 by CLSI broth microdilution method,Other,19770280.0,
2591,571884,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene by CLSI broth microdilution method,Other,19770280.0,
2592,572058,2,3,,103164817,5578,Unspecified,,,,,Ratio of MIC for Escherichia coli KAM32 harboring plasmid pUC18 to MIC for Escherichia coli KAM32 harboring recombinant plasmid pVBS1 encoding Acinetobacter baumannii abeS gene,Other,19770280.0,
2593,572059,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Acinetobacter baumannii AC0037 by CLSI broth microdilution method,Other,19770280.0,
2594,572060,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method,Other,19770280.0,
2595,572061,2,3,,103164817,5578,Unspecified,,,,,Ratio of MIC for Acinetobacter baumannii AC0037 to MIC for abeS-deficient Acinetobacter baumannii AC0037,Other,19770280.0,
2596,572062,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against abeS sigma abeS-deficient Acinetobacter baumannii AC0037 by CLSI broth microdilution method,Other,19770280.0,
2597,574545,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against community-associated methicillin-resistant Staphylococcus aureus USA300,Other,20713669.0,
2598,574546,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against community-associated methicillin-resistant Staphylococcus aureus Sanger 252,Other,20713669.0,
2599,575143,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolate NRS70 by broth microdilution method,Other,20606069.0,
2600,575144,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolate NRS1 by broth microdilution method,Other,20606069.0,
2601,575145,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolate NRS71 by broth microdilution method,Other,20606069.0,
2602,575146,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolate NRS123 by broth microdilution method,Other,20606069.0,
2603,575147,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-resistant Staphylococcus aureus VRS1 by broth microdilution method,Other,20606069.0,
2604,575148,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-resistant Staphylococcus aureus VRS2 by broth microdilution method,Other,20606069.0,
2605,575149,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-resistant Staphylococcus aureus VRS3 by broth microdilution method,Other,20606069.0,
2606,575150,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Francisella tularensis Schu4 by broth microdilution method,Other,20606069.0,
2607,575151,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Yersinia pestis CO92 by broth microdilution method,Other,20606069.0,
2608,575152,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Brucella abortus 2308 by broth microdilution method,Other,20606069.0,
2609,575153,5,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Bacillus anthracis Ames by broth microdilution method,Other,20606069.0,
2610,575154,5,7,,103164817,5578,Active,60392215.0,31214198.0,0.0144,IC50,Inhibition of Staphylococcus aureus wild type recombinant DHFR by MTS assay,Confirmatory,20606069.0,
2611,575155,2,3,,103164817,5578,Active,,,0.5397,IC50,Inhibition of Staphylococcus aureus DHFR F98Y mutant by MTS assay,Confirmatory,20606069.0,
2612,575156,2,3,,103164817,5578,Unspecified,,,,,Ratio of Ki for TMP-resistant Staphylococcus aureus DHFR to Ki for wild type Staphylococcus aureus DHFR,Other,20606069.0,
2613,575158,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 700802 by broth microdilution method,Other,20606069.0,
2614,575676,4,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Listeria monocytogenes isolated from humans harboring mutant dfrD gene,Other,20385859.0,
2615,576612,7,5,,103164817,5578,Unspecified,7531135.0,3757.0,239.88299999999998,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
2616,582763,1,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against eaeA positive verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates,Other,20733038.0,
2617,582764,1,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against eaeA negative verocytotoxin-producing non-O157 Escherichia coli isolates obtained from human assessed as percentage of resistant isolates,Other,20733038.0,
2618,584114,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method,Other,20855745.0,
2619,584115,5,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method,Other,20855745.0,
2620,584116,5,2,,103164817,5578,Unspecified,,,,,Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP72,Other,20855745.0,
2621,584121,5,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against methicillin-resistant Staphylococcus aureus ST398 isolate 11 containing apmA, erm(B), tet(L), tet(M), tet(K), dfrK, aadD, mecA, blaZ resistance genes by CLSI M31-A3 method",Other,20876371.0,
2622,584122,5,2,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus RN4220 by CLSI M31-A3 method,Other,20876371.0,
2623,584123,5,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against Staphylococcus aureus RN4220 carrying pAFS11-apmA, erm(B), tet(L), dfrK, aadD resistance genes by CLSI M31-A3 method",Other,20876371.0,
2624,586085,2,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from human assessed as percentage of resistant isolates by disk diffusion method,Other,20733038.0,
2625,586086,2,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against verocytotoxin-producing Escherichia coli isolate O157 obtained from animals and food assessed as percentage of resistant isolates by disk diffusion method,Other,20733038.0,
2626,588209,2,3,,103164817,5578,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2627,588210,2,4,,103164817,5578,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2628,588211,2,3,,103164817,5578,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2629,588212,2,3,,103164817,5578,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2630,588213,2,3,,103164817,5578,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2631,588220,2,3,,103164817,5578,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
2632,588334,1,1,,50085866,5578,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2633,588335,1,1,,50085866,5578,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2634,588342,1,1,,857743,5578,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2635,588349,1,1,,90340764,5578,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2636,588352,1,2,,50085866,5578,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2637,588354,1,1,,50085866,5578,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2638,588358,1,2,,50085866,5578,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2639,588368,1,2,,857743,5578,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies from validation set,Screening,,
2640,588378,1,1,,90340764,5578,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2641,588379,1,2,,124881730,5578,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
2642,588391,1,1,,50085866,5578,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2643,588405,1,1,,50085866,5578,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2644,588413,1,2,,50085866,5578,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2645,588436,1,1,,50085866,5578,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2646,588453,1,1,,50085866,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2647,588453,1,1,,85231275,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2648,588453,1,1,,90340764,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2649,588453,1,1,,124881736,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2650,588456,1,1,,50085866,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2651,588456,1,1,,90340764,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2652,588456,1,1,,124881736,5578,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2653,588458,1,1,,50085866,5578,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2654,588459,1,2,,857743,5578,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,16604538.0,
2655,588459,1,2,,857743,5578,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20035615.0,
2656,588459,1,2,,857743,5578,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set",Screening,20938917.0,
2657,588460,1,2,,857743,5578,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,16604538.0,
2658,588460,1,2,,857743,5578,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20035615.0,
2659,588460,1,2,,857743,5578,Inactive,,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set",Screening,20938917.0,
2660,588461,1,2,,857743,5578,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,16604538.0,
2661,588461,1,2,,857743,5578,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20035615.0,
2662,588461,1,2,,857743,5578,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set",Screening,20938917.0,
2663,588473,1,1,,50085866,5578,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2664,588473,1,1,,50085866,5578,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2665,588475,1,2,,50085866,5578,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2666,588475,1,2,,50085866,5578,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2667,588478,1,2,,124799530,5578,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2668,588489,1,1,,50085866,5578,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2669,588492,1,1,,50085866,5578,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2670,588493,1,2,,50085866,5578,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2671,588497,1,2,,50085866,5578,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2672,588497,1,2,,50085866,5578,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2673,588497,1,2,,50085866,5578,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2674,588499,1,3,,50085866,5578,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2675,588499,1,3,,50085866,5578,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2676,588499,1,3,,50085866,5578,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2677,588501,1,2,,50085866,5578,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2678,588501,1,2,,50085866,5578,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2679,588501,1,2,,50085866,5578,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2680,588506,1,2,,857743,5578,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors with Validation compound Set,Screening,,
2681,588511,1,2,,857743,5578,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2682,588513,1,1,,17389524,5578,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2683,588514,1,1,,17389524,5578,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2684,588515,1,1,,17389524,5578,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2685,588516,1,1,,17389524,5578,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2686,588519,1,2,,92124407,5578,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2687,588519,1,2,,92125161,5578,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2688,588526,1,1,,17389524,5578,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2689,588527,1,1,,17389524,5578,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2690,588532,1,1,,17389524,5578,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2691,588533,1,1,,17389524,5578,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2692,588534,1,1,,17389524,5578,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2693,588535,1,1,,17389524,5578,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2694,588536,1,1,,17389524,5578,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2695,588537,1,1,,17389524,5578,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2696,588541,1,1,,17389524,5578,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2697,588543,1,1,,17389524,5578,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2698,588544,1,1,,17389524,5578,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2699,588545,1,1,,17389524,5578,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2700,588546,1,1,,17389524,5578,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2701,588547,1,1,,17389524,5578,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2702,588549,1,1,,50085866,5578,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2703,588550,1,1,,857743,5578,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for Validation Compound Set,Screening,,
2704,588579,1,1,,11111924,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2705,588579,1,1,,50085866,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2706,588579,1,1,,90340764,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2707,588579,1,1,,104171255,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2708,588579,1,1,,124881730,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2709,588579,1,1,,124881732,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2710,588579,1,1,,124881734,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2711,588579,1,1,,124881736,5578,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2712,588590,1,1,,50085866,5578,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2713,588590,1,1,,50104512,5578,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2714,588590,1,1,,124881736,5578,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2715,588591,1,1,,50085866,5578,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2716,588591,1,1,,50104512,5578,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2717,588621,1,1,,50085866,5578,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2718,588627,1,1,,857743,5578,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2719,588664,1,2,,50085866,5578,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2720,588664,1,2,,50085866,5578,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2721,588674,1,2,,50085866,5578,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2722,588675,1,1,,857743,5578,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2723,588676,1,1,,857743,5578,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2724,588685,1,1,,857743,5578,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with Validation compound set,Screening,,
2725,588689,1,1,,50085866,5578,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2726,588692,2,1,,50085866,5578,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2727,588726,1,2,,50085866,5578,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2728,588727,1,1,,50085866,5578,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2729,588795,1,1,,50085866,5578,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2730,588795,1,1,,90340764,5578,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2731,588795,1,1,,124881736,5578,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2732,588814,1,3,,50085866,5578,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2733,588819,1,4,,50085866,5578,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2734,588834,2,1,,17389524,5578,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2735,588834,2,1,,50104512,5578,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2736,588850,1,1,,50085866,5578,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2737,588852,1,3,,50085866,5578,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2738,588855,1,1,,50085866,5578,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2739,588855,1,1,,124881736,5578,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2740,588856,1,1,,50085866,5578,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2741,588856,1,1,,124881736,5578,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2742,589043,1,11,,103164817,5578,Unspecified,117225.0,1558.0,,,"Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP2C8",Other,,
2743,592681,1,4,,103164817,5578,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
2744,602123,1,1,,50085866,5578,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2745,602141,1,1,,50085866,5578,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2746,602162,1,1,,50085866,5578,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2747,602163,1,1,,50085866,5578,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2748,602179,1,2,,50085866,5578,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2749,602229,1,1,,50085866,5578,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2750,602233,1,1,,50085866,5578,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2751,602244,1,2,,50085866,5578,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2752,602247,1,2,,50085866,5578,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2753,602248,1,2,,50085866,5578,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2754,602250,1,2,,50085866,5578,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2755,602252,1,1,,50085866,5578,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2756,602252,1,1,,50085866,5578,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2757,602261,1,1,,50085866,5578,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2758,602274,1,2,,50085866,5578,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2759,602281,1,1,,50085866,5578,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2760,602281,1,1,,50085866,5578,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2761,602310,1,2,,50085866,5578,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2762,602310,1,2,,124881736,5578,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2763,602313,1,1,,50085866,5578,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2764,602314,1,2,,92124407,5578,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2765,602314,1,2,,92125161,5578,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2766,602329,1,1,,50085866,5578,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2767,602332,1,1,,11111924,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2768,602332,1,1,,50085866,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2769,602332,1,1,,90340764,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2770,602332,1,1,,104171255,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2771,602332,1,1,,124881730,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2772,602332,1,1,,124881732,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2773,602332,1,1,,124881734,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2774,602332,1,1,,124881736,5578,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2775,602340,1,2,,50085866,5578,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2776,602342,2,1,,50085866,5578,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2777,602346,1,1,,50085866,5578,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2778,602363,1,1,,50085866,5578,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2779,602393,1,1,,50085866,5578,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2780,602396,1,2,,50085866,5578,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2781,602399,1,2,,50085866,5578,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2782,602405,1,1,,50085866,5578,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2783,602410,1,1,,50085866,5578,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2784,602429,1,1,,50085866,5578,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2785,602438,1,1,,50085866,5578,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2786,602440,1,1,,50085866,5578,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2787,602449,1,2,,50085866,5578,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2788,602481,1,1,,50085866,5578,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2789,614163,3,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus Smith ATCC 13709 by CLSI microdilution method,Other,21831637.0,
2790,614164,3,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus Smith ATCC 13709 in presence of 20% mouse serum by CLSI microdilution method,Other,21831637.0,
2791,614165,3,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 by CLSI microdilution method,Other,21831637.0,
2792,614166,3,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against ampicillin-resistant Haemophilus influenzae ATCC 49247 by CLSI microdilution method,Other,21831637.0,
2793,614167,3,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 35218 by CLSI microdilution method,Other,21831637.0,
2794,614168,5,5,,103164817,5578,Active,60392215.0,31214198.0,0.00124,Ki,Inhibition of Staphylococcus aureus DHFR assessed as oxidation of NADPH using dihydrofolate as substrate pre-incubated for 10 mins before substrate addition by spectrophotometry,Confirmatory,21831637.0,
2795,614169,2,2,,103164817,5578,Active,,,0.00018999999999999998,Ki,Inhibition of Haemophilus influenzae DHFR assessed as oxidation of NADPH using dihydrofolate as substrate pre-incubated for 10 mins before substrate addition by spectrophotometry,Confirmatory,21831637.0,
2796,614170,5,5,,103164817,5578,Active,118992.0,1719.0,19.07,Ki,Inhibition of human DHFR assessed as oxidation of NADPH using dihydrofolate as substrate pre-incubated for 10 mins before substrate addition by spectrophotometry,Confirmatory,21831637.0,
2797,614170,5,5,,103164817,5578,Active,118992.0,573971.0,19.07,Ki,Inhibition of human DHFR assessed as oxidation of NADPH using dihydrofolate as substrate pre-incubated for 10 mins before substrate addition by spectrophotometry,Confirmatory,21831637.0,
2798,614171,1,3,,103164817,5578,Unspecified,,,,,Ratio of Ki for human DHFR to Ki for Staphylococcus aureus DHFR,Other,21831637.0,
2799,614172,3,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against TMP-resistant Staphylococcus aureus harboring DHFR F99Y mutant by CLSI microdilution method,Other,21831637.0,
2800,614173,1,4,,103164817,5578,Active,,,0.09,Ki,Inhibition of TMP-resistant Staphylococcus aureus DHFR F99Y mutant assessed as oxidation of NADPH using dihydrofolate as substrate pre-incubated for 10 mins before substrate addition by spectrophotometry,Confirmatory,21831637.0,
2801,617102,6,5,,103164817,5578,Unspecified,118992.0,1719.0,100.0,IC50,Inhibition of human DHFR assessed as NADPH consumption for conversion of dihydrofolic acid to tetrahydrofolic acid after 6 mins every 5 sec by UV-Visible Spectrophotometer method,Confirmatory,21788136.0,
2802,617102,6,5,,103164817,5578,Unspecified,118992.0,573971.0,100.0,IC50,Inhibition of human DHFR assessed as NADPH consumption for conversion of dihydrofolic acid to tetrahydrofolic acid after 6 mins every 5 sec by UV-Visible Spectrophotometer method,Confirmatory,21788136.0,
2803,617103,1,4,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Staphylococcus aureus ATCC 6538p at 100 ug/disc after 18 to 24 hrs by paper disc agar diffusion assay relative to Cephaloridine,Other,21788136.0,
2804,617104,1,4,,103164817,5578,Inactive,,,,,Antimicrobial activity against Mycobacterium smegmatis ATCC 607 at 100 ug/disk after 18 to 24 hrs by paper disc agar diffusion assay relative to Streptomycin disk,Other,21788136.0,
2805,623870,1,1,,50085866,5578,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2806,623870,1,1,,50085866,5578,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2807,623877,1,1,,50085866,5578,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2808,623901,1,1,,50085866,5578,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2809,624030,1,2,,104171255,5578,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2810,624031,1,2,,104171255,5578,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2811,624032,1,2,,104171255,5578,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2812,624037,1,3,,50085866,5578,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2813,624038,1,3,,50085866,5578,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2814,624040,1,3,,50085866,5578,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2815,624044,1,2,,104171255,5578,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2816,624101,1,2,,85788427,5578,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2817,624125,1,4,,50085866,5578,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2818,624126,1,3,,50085866,5578,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2819,624127,1,2,,50085866,5578,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2820,624146,1,1,,90340764,5578,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2821,624147,1,1,,90340764,5578,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2822,624148,1,2,,90340764,5578,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2823,624149,1,1,,90340764,5578,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2824,624156,1,1,,85788427,5578,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
2825,624168,1,1,,50085866,5578,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2826,624169,1,1,,50085866,5578,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2827,624170,1,1,,50085866,5578,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2828,624170,1,1,,104171255,5578,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2829,624171,1,1,,50085866,5578,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2830,624172,1,1,,50085866,5578,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2831,624172,1,1,,104171255,5578,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2832,624173,1,3,,50085866,5578,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2833,624173,1,3,,104171255,5578,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2834,624178,1,1,,50085866,5578,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2835,624178,1,1,,124881736,5578,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2836,624202,1,1,,50085866,5578,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2837,624202,1,1,,124881736,5578,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2838,624204,1,2,,50085866,5578,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2839,624246,1,1,,50085866,5578,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2840,624256,1,2,,50085866,5578,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2841,624263,1,1,,50085866,5578,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2842,624263,1,1,,50085866,5578,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2843,624263,1,1,,124881736,5578,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2844,624263,1,1,,124881736,5578,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2845,624267,1,2,,50085866,5578,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2846,624267,1,2,,50085866,5578,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2847,624268,1,3,,50085866,5578,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2848,624288,1,1,,50085866,5578,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2849,624296,1,1,,17389524,5578,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2850,624296,1,1,,50085866,5578,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2851,624296,1,1,,104171255,5578,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2852,624297,1,1,,17389524,5578,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2853,624297,1,1,,50085866,5578,Inactive,7705682.0,51053.0,1.5849,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2854,624297,1,1,,104171255,5578,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2855,624304,1,2,,50085866,5578,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2856,624330,1,2,,50085866,5578,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2857,624349,1,2,,92124407,5578,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2858,624349,1,2,,92125161,5578,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2859,624349,1,2,,92307520,5578,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2860,624349,1,2,,92309070,5578,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2861,624349,1,2,,121362506,5578,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2862,624349,1,2,,121362832,5578,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2863,624352,1,1,,50085866,5578,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2864,624354,1,1,,50085866,5578,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2865,624377,1,1,,50085866,5578,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2866,624414,1,1,,50085866,5578,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2867,624414,1,1,,124881736,5578,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2868,624415,1,2,,50085866,5578,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2869,624416,1,1,,50085866,5578,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2870,624417,1,1,,50085866,5578,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2871,624418,1,1,,50085866,5578,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2872,624455,1,1,,90340764,5578,Inactive,299681.0,1812.0,0.0231,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2873,624463,1,1,,50085866,5578,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2874,624464,1,1,,50085866,5578,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2875,624465,1,1,,50085866,5578,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2876,624466,1,3,,50085866,5578,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2877,624467,1,1,,50085866,5578,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2878,624483,1,1,,50085866,5578,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2879,624622,3,1,,103164817,5578,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2880,624623,3,1,,103164817,5578,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
2881,624626,1,9,,103164817,5578,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2882,624628,1,9,,103164817,5578,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
2883,624629,1,9,,103164817,5578,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
2884,625279,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
2885,625280,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
2886,625281,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
2887,625282,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
2888,625283,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
2889,625284,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
2890,625285,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
2891,625286,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
2892,625287,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
2893,625288,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
2894,625289,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
2895,625290,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
2896,625291,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
2897,625292,1,3,,103164817,5578,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
2898,651550,1,1,,50085866,5578,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2899,651560,1,1,,50085866,5578,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2900,651572,1,2,,50085866,5578,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2901,651582,1,1,,50085866,5578,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2902,651602,1,1,,50085866,5578,Active,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2903,651602,1,1,,50085866,5578,Active,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2904,651602,1,1,,50085866,5578,Active,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2905,651631,4,1,,144203842,5578,Inconclusive,269849759.0,7157.0,2.371,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2906,651631,4,1,,144207355,5578,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2907,651632,4,1,,144203842,5578,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2908,651632,4,1,,144207355,5578,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2909,651633,4,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2910,651633,4,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2911,651634,4,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2912,651634,4,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2913,651635,1,3,,11111924,5578,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2914,651635,1,3,,50085866,5578,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2915,651635,1,3,,90340764,5578,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2916,651636,1,1,,50085866,5578,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2917,651640,1,1,,50085866,5578,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2918,651644,1,1,,50085866,5578,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2919,651647,1,1,,50085866,5578,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2920,651654,1,1,,50085866,5578,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2921,651658,1,1,,50085866,5578,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2922,651660,1,1,,50085866,5578,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors             Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2923,651661,2,1,,50085866,5578,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2924,651699,1,1,,50085866,5578,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2925,651699,1,1,,50085866,5578,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2926,651702,1,2,,50085866,5578,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2927,651704,2,1,,50085866,5578,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2928,651710,1,1,,50085866,5578,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2929,651711,2,1,,50085866,5578,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2930,651718,1,2,,50085866,5578,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2931,651724,1,1,,50085866,5578,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2932,651725,1,1,,50085866,5578,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2933,651741,1,1,,17389524,5578,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2934,651743,1,1,,17389524,5578,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2935,651749,1,1,,17389524,5578,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2936,651751,1,1,,17389524,5578,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2937,651754,1,1,,17389524,5578,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
2938,651755,1,1,,17389524,5578,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
2939,651757,1,1,,17389524,5578,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
2940,651758,1,1,,17389524,5578,Inconclusive,186368.0,3576.0,74.97800000000001,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
2941,651768,1,2,,50085866,5578,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
2942,651777,1,1,,17389524,5578,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
2943,651778,1,1,,17389524,5578,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
2944,651800,1,1,,50085866,5578,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
2945,651802,1,1,,17389524,5578,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2946,651819,1,1,,50085866,5578,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
2947,651820,1,1,,857743,5578,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2948,651820,1,1,,50085866,5578,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
2949,651821,2,4,,50085866,5578,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
2950,651828,1,2,,92309070,5578,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2951,651828,1,2,,121362068,5578,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2952,651828,1,2,,121362506,5578,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
2953,651838,1,1,,17389524,5578,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2954,651838,1,1,1.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2955,651838,1,1,2.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2956,651838,1,1,3.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2957,651838,1,1,4.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2958,651838,1,1,5.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2959,651838,1,1,6.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2960,651838,1,1,7.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2961,651838,1,1,8.0,17389524,5578,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
2962,651957,1,1,,50085866,5578,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
2963,651958,1,1,,50085866,5578,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
2964,651965,1,1,,50085866,5578,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2965,651965,1,1,,124881736,5578,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
2966,651982,1,1,,50085866,5578,Active,16130723.0,947287.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
2967,651982,1,1,,50085866,5578,Active,16130724.0,947286.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
2968,651982,1,1,,50085866,5578,Active,16130726.0,947294.0,,,Absorbance-based bacterial cell-based high throughput confirmation assay to identify inhibitors of RecBCD,Screening,,
2969,651983,1,1,,50085866,5578,Active,,,,,Counterscreen for inhibitors of RecBCD: Absorbance-based cell-based high throughput assay to identify inhibitors of bacterial viability,Screening,,
2970,651984,1,1,,50085866,5578,Active,15645703.0,899625.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2971,651984,1,1,,50085866,5578,Active,15646160.0,899738.0,,,Counterscreen for RECBCD inhibitors: absorbance-based high throughput cell-based assay to identify inhibitors of AddAB recombination protein complex,Screening,,
2972,651999,1,1,,50085866,5578,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
2973,652010,1,1,,50085866,5578,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
2974,652017,1,1,,50085866,5578,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
2975,652025,1,1,,50085866,5578,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
2976,652039,1,1,,50085866,5578,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
2977,652048,1,2,,50085866,5578,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2978,652048,1,2,,144203842,5578,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
2979,652051,1,1,,50085866,5578,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2980,652051,1,1,,144203842,5578,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
2981,652054,1,1,,50085866,5578,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
2982,652067,1,4,,50085866,5578,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
2983,652104,1,1,,50085866,5578,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
2984,652105,1,1,,50085866,5578,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
2985,652106,1,1,,50085866,5578,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2986,652106,1,1,,90340764,5578,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2987,652106,1,1,,124881736,5578,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
2988,652115,1,1,,50085866,5578,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
2989,652126,1,3,,50085866,5578,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
2990,652154,1,1,,50085866,5578,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2991,652162,2,1,,50085866,5578,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2992,652163,1,1,,50085866,5578,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2993,652197,1,1,,50085866,5578,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2994,652257,1,1,,50085866,5578,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
2995,653893,2,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against ciprofloxacin-, SXT-sensitive Escherichia coli ATCC 25922",Other,22406152.0,
2996,653894,2,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against ciprofloxacin-sensitive, SXT-resistant Klebsiella pneumoniae ATCC 700603",Other,22406152.0,
2997,653895,2,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against ciprofloxacin-sensitive, SXT-resistant Pseudomonas aeruginosa ATCC 10145",Other,22406152.0,
2998,653896,2,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against ciprofloxacin-, SXT-resistant Escherichia coli",Other,22406152.0,
2999,653897,2,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against ciprofloxacin-, SXT-sensitive Staphylococcus aureus ATCC 25923",Other,22406152.0,
3000,653898,2,2,,103164817,5578,Unspecified,,,,,"Antimicrobial activity against ciprofloxacin-sensitive, SXT-resistant Staphylococcus epidermidis NRS60",Other,22406152.0,
3001,653899,2,2,,103164817,5578,Inconclusive,,,,IC50,Inhibition of DNA supercoiling activity of Escherichia coli DNA gyrase after 1 hr by agarose gel electrophoresis,Confirmatory,22406152.0,
3002,653900,2,2,,103164817,5578,Inconclusive,,,,IC50,Inhibition of DNA decatenation activity of Escherichia coli DNA topoisomerase 4 after 1 hr by agarose gel electrophoresis,Confirmatory,22406152.0,
3003,653901,4,2,,103164817,5578,Active,,,0.12300000000000001,IC50,Inhibition of DHFR using dihydrofolate as substrate following 3 mins substrate preincubation measured after 3 mins by spectrophotometric analysis,Confirmatory,22406152.0,
3004,656690,2,1,,103164817,5578,Active,,,15.0,ID50,Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in human fibroblasts assessed as inhibition of replication of tachyzoites after 4 days by bacterial beta-galactosidase assay,Confirmatory,22425568.0,
3005,656691,2,1,,103164817,5578,Unspecified,,,500.0,TD50,Cytotoxicity against human fibroblasts assessed as cell viability by microplate reader,Confirmatory,22425568.0,
3006,656692,1,2,,103164817,5578,Unspecified,,,,,"Therapeutic index, ratio of TD50 for human fibroblast cell to ID 50 for Toxoplasma gondii ATCC 50839",Other,22425568.0,
3007,667502,1,3,,103164817,5578,Unspecified,,,,,"Selectivity index, ratio of binding affinity to human DHFR to binding affinity to Escherichia coli DHFR",Other,22424148.0,
3008,667503,1,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of Ki for chromosomal DHFR to Ki for R67 DHFR,Other,22424148.0,
3009,667504,1,3,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for chromosomal DHFR to IC50 for R67 DHFR,Other,22424148.0,
3010,671160,7,2,,103164817,5578,Unspecified,118992.0,1719.0,340.0,IC50,Inhibition of human DHFR,Confirmatory,22739090.0,
3011,671160,7,2,,103164817,5578,Unspecified,118992.0,573971.0,340.0,IC50,Inhibition of human DHFR,Confirmatory,22739090.0,
3012,671161,4,1,,103164817,5578,Active,,,0.01,IC50,Inhibition of Escherichia coli DHFR,Confirmatory,22739090.0,
3013,671162,7,2,,103164817,5578,Active,729370.0,,6.8,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,22739090.0,
3014,678712,1,8,,103164817,5578,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
3015,678713,1,8,,103164817,5578,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
3016,678714,1,8,,103164817,5578,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3017,678715,1,8,,103164817,5578,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3018,678716,1,8,,103164817,5578,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
3019,678717,1,8,,103164817,5578,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
3020,678721,1,5,,103164817,5578,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
3021,678722,1,5,,103164817,5578,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
3022,681121,1,8,,103164817,5578,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells,Other,11602674.0,
3023,681130,1,8,,103164817,5578,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,11602674.0,
3024,681132,1,8,,103164817,5578,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,11602674.0,
3025,681337,1,8,,103164817,5578,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: Western blot, HK-2 cells",Other,12387747.0,
3026,681385,1,8,,103164817,5578,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: RT-PCR in HK-2 cell,Other,12387747.0,
3027,686940,1,1,,50085866,5578,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
3028,686964,1,1,,50085866,5578,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
3029,686970,1,2,,50085866,5578,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
3030,686971,1,2,,50085866,5578,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
3031,686977,2,1,,49698744,5578,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
3032,686978,1,1,,50085866,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3033,686978,1,1,,124881730,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3034,686978,1,1,,124881732,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3035,686978,1,1,,124881736,5578,Inconclusive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3036,686978,1,1,,144203842,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3037,686979,1,1,,50085866,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3038,686979,1,1,,124881730,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3039,686979,1,1,,124881732,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3040,686979,1,1,,124881736,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3041,686979,1,1,,144203842,5578,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3042,686992,2,1,,50085866,5578,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3043,686996,1,1,,50085866,5578,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3044,687014,1,1,,50085866,5578,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3045,687016,1,1,,50085866,5578,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3046,687035,1,1,,163565225,5578,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3047,687037,1,3,,163565225,5578,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
3048,698877,2,2,,103164817,5578,Inactive,,,,GI50,Growth inhibition of human NCI60 cells at 10 uM incubated for 48 hrs by SRB assay,Confirmatory,22734697.0,
3049,699539,1,7,,103164817,5578,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
3050,699540,1,7,,103164817,5578,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3051,699541,1,7,,103164817,5578,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3052,720504,1,1,,50085866,5578,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
3053,720508,1,1,,50085866,5578,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3054,720509,1,1,,50085866,5578,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3055,720511,1,1,,50085866,5578,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
3056,720516,2,1,,144203842,5578,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3057,720516,2,1,,144207355,5578,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3058,720532,1,1,,11111924,5578,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3059,720532,1,1,,124881730,5578,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3060,720532,1,1,,124881732,5578,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3061,720532,1,1,,124881734,5578,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3062,720532,1,1,,144203842,5578,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3063,720533,1,1,,11111924,5578,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3064,720533,1,1,,124881730,5578,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3065,720533,1,1,,124881732,5578,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3066,720533,1,1,,124881734,5578,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3067,720533,1,1,,144203842,5578,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3068,720538,1,2,,90340764,5578,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
3069,720542,1,2,,50085866,5578,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
3070,720543,1,1,,50085866,5578,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
3071,720551,1,2,,50085866,5578,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
3072,720552,2,1,,144203842,5578,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3073,720552,2,1,,144207355,5578,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3074,720553,1,2,,50085866,5578,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
3075,720554,1,3,,121362506,5578,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
3076,720559,1,2,,90340764,5578,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
3077,720572,1,2,,90340764,5578,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
3078,720573,1,2,,90340764,5578,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
3079,720579,2,1,,50085866,5578,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3080,720579,2,1,,124881732,5578,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3081,720579,2,1,,124881736,5578,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3082,720580,1,1,,50085866,5578,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3083,720580,1,1,,124881732,5578,Inconclusive,222762.0,3707576.0,5.0119,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3084,720580,1,1,,124881736,5578,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3085,720582,1,1,,50085866,5578,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
3086,720596,1,1,,50085866,5578,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
3087,720634,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3088,720634,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3089,720635,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3090,720635,2,1,,144207355,5578,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3091,720636,1,1,,17389524,5578,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3092,720637,2,1,,144203842,5578,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3093,720637,2,1,,144207355,5578,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3094,720641,1,2,,92307520,5578,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3095,720641,1,2,,92309070,5578,Active,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3096,720647,1,2,,50085866,5578,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
3097,720648,1,1,,50085866,5578,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
3098,720652,1,1,,17389524,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3099,720653,1,1,,17389524,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3100,720659,1,1,,17389524,5578,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3101,720674,2,2,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3102,720674,2,2,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3103,720675,2,2,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3104,720675,2,2,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3105,720678,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3106,720678,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3107,720679,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3108,720679,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3109,720680,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3110,720680,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3111,720681,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3112,720681,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3113,720682,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3114,720682,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3115,720683,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3116,720683,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3117,720684,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3118,720684,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3119,720685,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3120,720685,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3121,720686,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3122,720686,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3123,720687,2,2,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3124,720687,2,2,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3125,720691,4,1,,144203842,5578,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3126,720691,4,1,,144207355,5578,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3127,720692,3,1,,144203842,5578,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3128,720692,3,1,,144207355,5578,Inconclusive,311348376.0,2908.0,12.2712,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3129,720693,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3130,720693,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3131,720700,1,4,,50085866,5578,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
3132,720702,1,1,,50085866,5578,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
3133,720704,1,4,,50085866,5578,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
3134,720706,1,2,,50085866,5578,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3135,720707,1,2,,50085866,5578,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3136,720708,1,2,,50085866,5578,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
3137,720709,1,2,,50085866,5578,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3138,720711,1,2,,50085866,5578,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
3139,720717,1,3,,92124407,5578,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3140,720717,1,3,,92125161,5578,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3141,720717,1,3,,92307520,5578,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3142,720717,1,3,,92309070,5578,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3143,720719,2,1,,144203842,5578,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3144,720719,2,1,,144207355,5578,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3145,720725,2,1,,144203842,5578,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3146,720725,2,1,,144207355,5578,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3147,722035,1,2,,103164817,5578,Unspecified,,,,,"Therapeutic index, ratio of TD50 for human foreskin fibroblast cells to ID 50 for Toxoplasma gondii",Other,23321561.0,
3148,722036,2,1,,103164817,5578,Unspecified,,,100.0,TD50,Cytotoxicity against human foreskin fibroblast cells by colorimetric method,Confirmatory,23321561.0,
3149,722037,2,1,,103164817,5578,Active,,,15.0,ID50,Antimicrobial activity against Toxoplasma gondii assessed as inhibition of growth measured after 5 days by beta-galactosidase assay,Confirmatory,23321561.0,
3150,743012,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3151,743012,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3152,743014,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3153,743014,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3154,743015,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3155,743015,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3156,743033,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3157,743033,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3158,743035,2,1,,144203842,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3159,743035,2,1,,144207355,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3160,743036,2,1,,144203842,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3161,743036,2,1,,144207355,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3162,743040,3,1,,144203842,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3163,743040,3,1,,144207355,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3164,743041,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3165,743041,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3166,743042,3,1,,144203842,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3167,743042,3,1,,144207355,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3168,743053,2,1,,144203842,5578,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3169,743053,2,1,,144207355,5578,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3170,743054,2,1,,144203842,5578,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3171,743054,2,1,,144207355,5578,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3172,743063,2,1,,144203842,5578,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3173,743063,2,1,,144207355,5578,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3174,743064,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3175,743064,3,1,,144207355,5578,Inconclusive,,,30.5444,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3176,743065,3,1,,144203842,5578,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3177,743065,3,1,,144207355,5578,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3178,743066,3,1,,144203842,5578,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3179,743066,3,1,,144207355,5578,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3180,743067,2,1,,144203842,5578,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3181,743067,2,1,,144207355,5578,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3182,743069,2,1,,144203842,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3183,743069,2,1,,144207355,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3184,743074,2,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3185,743074,2,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3186,743075,2,1,,144203842,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3187,743075,2,1,,144207355,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3188,743077,2,1,,144203842,5578,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3189,743077,2,1,,144207355,5578,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3190,743078,2,1,,144203842,5578,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3191,743078,2,1,,144207355,5578,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3192,743079,3,1,,144203842,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3193,743079,3,1,,144207355,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3194,743080,3,1,,144203842,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3195,743080,3,1,,144207355,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3196,743081,3,1,,144203842,5578,Inconclusive,,,0.3349,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3197,743081,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3198,743083,3,1,,144203842,5578,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3199,743083,3,1,,144207355,5578,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3200,743084,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3201,743084,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3202,743085,3,1,,144203842,5578,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3203,743085,3,1,,144207355,5578,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3204,743086,3,1,,144203842,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3205,743086,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3206,743091,2,1,,144203842,5578,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3207,743091,2,1,,144207355,5578,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3208,743094,3,1,,144203842,5578,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3209,743094,3,1,,144207355,5578,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3210,743122,2,1,,144203842,5578,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3211,743122,2,1,,144207355,5578,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3212,743126,1,1,,50085866,5578,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3213,743139,2,1,,144203842,5578,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3214,743139,2,1,,144207355,5578,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3215,743140,2,1,,144203842,5578,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3216,743140,2,1,,144207355,5578,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3217,743191,3,1,,144207355,5578,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3218,743191,3,1,,170464633,5578,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3219,743194,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3220,743194,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3221,743199,2,1,,144207355,5578,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3222,743199,2,1,,170464633,5578,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3223,743202,4,1,,144207355,5578,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3224,743202,4,1,,170464633,5578,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3225,743203,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3226,743203,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3227,743205,1,1,,90340764,5578,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3228,743205,1,1,,90340764,5578,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3229,743206,1,1,,90340764,5578,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3230,743206,1,1,,90340764,5578,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3231,743207,1,1,,90340764,5578,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3232,743207,1,1,,90340764,5578,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3233,743209,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3234,743209,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3235,743210,4,1,,144207355,5578,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3236,743210,4,1,,170464633,5578,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3237,743211,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3238,743211,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3239,743212,3,1,,144207355,5578,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3240,743212,3,1,,170464633,5578,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3241,743213,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3242,743213,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3243,743215,3,1,,144207355,5578,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3244,743215,3,1,,170464633,5578,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3245,743217,3,1,,144207355,5578,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3246,743217,3,1,,170464633,5578,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3247,743218,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3248,743218,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3249,743219,3,1,,144207355,5578,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3250,743219,3,1,,170464633,5578,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3251,743220,3,1,,144207355,5578,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3252,743220,3,1,,170464633,5578,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3253,743221,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3254,743221,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3255,743222,3,1,,144207355,5578,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3256,743222,3,1,,170464633,5578,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3257,743223,3,1,,144207355,5578,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3258,743223,3,1,,170464633,5578,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3259,743224,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3260,743224,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3261,743225,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3262,743225,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3263,743226,2,1,,144207355,5578,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3264,743226,2,1,,170464633,5578,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3265,743227,2,1,,144207355,5578,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3266,743227,2,1,,170464633,5578,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3267,743228,3,1,,144207355,5578,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3268,743228,3,1,,170464633,5578,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3269,743238,1,1,,50085866,5578,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3270,743239,2,1,,144207355,5578,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3271,743239,2,1,,170464633,5578,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3272,743240,2,1,,144207355,5578,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3273,743240,2,1,,170464633,5578,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3274,743241,2,1,,144207355,5578,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3275,743241,2,1,,170464633,5578,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3276,743242,2,1,,144207355,5578,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3277,743242,2,1,,170464633,5578,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3278,743244,1,1,,90340764,5578,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3279,743244,1,1,,144203842,5578,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3280,743247,1,2,,50085866,5578,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3281,743255,1,1,,50085866,5578,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3282,743266,1,2,,50085866,5578,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3283,743268,1,1,,172080606,5578,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
3284,743269,1,1,,50085866,5578,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3285,743269,1,1,,50085866,5578,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3286,743270,1,1,,172080606,5578,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3287,743271,1,1,,172080606,5578,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
3288,743272,1,1,,172080606,5578,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
3289,743279,1,2,,50085866,5578,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3290,743287,1,1,,50085866,5578,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
3291,743288,1,1,,17389524,5578,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3292,743292,1,1,,17389524,5578,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3293,743322,2,1,,174316130,5578,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3294,743323,2,1,,174316130,5578,Inactive,,,9.4329,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3295,743324,2,1,,174316130,5578,Inactive,,,,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3296,743325,2,1,,174316130,5578,Active,,,4.2135,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3297,743326,2,1,,174316130,5578,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3298,743327,2,1,,174316130,5578,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3299,743397,1,1,,50085866,5578,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3300,743398,1,1,,50085866,5578,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3301,743656,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against Escherichia coli EB2120 conditional lolA strain with lolA deletion and complementing copy placed at araBAD locus at 1 to 256 ug/mL after 18 hrs in presence of 0.00002 to 0.2% of arabinose,Other,23473681.0,
3302,747607,1,1,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Pneumocystis carinii DHFR,Other,23627352.0,
3303,747608,1,1,,103164817,5578,Active,,,0.0015,IC50,Inhibition of Mycobacterium avium DHFR,Confirmatory,23627352.0,
3304,747609,1,1,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for rat liver DHFR to IC50 for Mycobacterium avium DHFR,Other,23627352.0,
3305,747610,2,3,,103164817,5578,Active,118998.0,,12.5,IC50,Inhibition of Pneumocystis carinii DHFR,Confirmatory,23627352.0,
3306,747611,2,3,,103164817,5578,Unspecified,81871579.0,24312.0,180.0,IC50,Inhibition of rat liver DHFR,Confirmatory,23627352.0,
3307,747612,1,1,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Pneumocystis jirovecii recombinant DHFR,Other,23627352.0,
3308,747613,1,1,,103164817,5578,Active,,,0.12,IC50,Inhibition of Pneumocystis jirovecii recombinant DHFR,Confirmatory,23627352.0,
3309,747614,2,3,,103164817,5578,Active,118992.0,1719.0,32.2,IC50,Inhibition of human recombinant DHFR,Confirmatory,,
3310,747614,2,3,,103164817,5578,Active,118992.0,573971.0,32.2,IC50,Inhibition of human recombinant DHFR,Confirmatory,,
3311,977599,1,1,,103164817,5578,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3312,977602,1,2,,103164817,5578,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
3313,977608,3,1,,170482414,5578,Active,228312079.0,,77200.0,IC50,Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB,Other,19364848.0,
3314,977610,3,1,,170483356,5578,Active,347948500.0,,0.617,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,21684339.0,
3315,977610,3,1,,170484073,5578,Active,347948627.0,,0.593,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,21684339.0,
3316,977611,3,1,,170481435,5578,Active,225733917.0,28380994.0,0.43,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,19280600.0,
3317,977611,3,1,,208013454,5578,Active,,,1.43,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,24210757.0,
3318,1053175,2,1,,178126539,5578,Active,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
3319,1053197,1,1,,50085866,5578,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
3320,1059658,1,1,,103164817,5578,Unspecified,,,,,Selectivity ratio of IC50 for human DHFR to IC50 for Toxoplasma gondii DHFR,Other,24470841.0,
3321,1059659,1,1,,103164817,5578,Active,,,2.7,IC50,Inhibition of Toxoplasma gondii DHFR,Confirmatory,24470841.0,
3322,1074564,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3323,1074571,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC BAA-255 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3324,1074572,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 700904 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3325,1074573,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 700676 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3326,1074574,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 700677 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3327,1074575,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 700675 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3328,1074576,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 51916 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3329,1074577,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 700671 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3330,1074578,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 700669 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3331,1074579,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 700674 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3332,1074580,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3333,1074582,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against TMP-resistant Staphylococcus aureus expressing DHFR F99Y mutant after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3334,1074583,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 13709 after 18 to 24 hrs by alamar Blue assay in presence of 20% heat inactivated mouse serum,Other,24428639.0,
3335,1074584,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 13709 after 18 to 24 hrs by alamar Blue assay,Other,24428639.0,
3336,1074585,1,1,,103164817,5578,Unspecified,,,,,Selectivity ratio of Ki for human DHFR to Ki for Staphylococcus aureus DHFR,Other,24428639.0,
3337,1074586,2,3,,103164817,5578,Active,118992.0,1719.0,19.07,Ki,Inhibition of human DHFR using dihydrofolate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis in presence of NADPH,Confirmatory,24428639.0,
3338,1074586,2,3,,103164817,5578,Active,118992.0,573971.0,19.07,Ki,Inhibition of human DHFR using dihydrofolate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis in presence of NADPH,Confirmatory,24428639.0,
3339,1074587,2,3,,103164817,5578,Active,60392215.0,28380994.0,0.0012,Ki,Inhibition of Staphylococcus aureus DHFR using dihydrofolate as substrate preincubated for 10 mins followed by substrate addition by spectrophotometric analysis in presence of NADPH,Confirmatory,24428639.0,
3340,1079931,1,1,,103164817,5578,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
3341,1079932,1,1,,103164817,5578,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
3342,1079933,1,1,,103164817,5578,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
3343,1079934,1,1,,103164817,5578,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
3344,1079935,1,1,,103164817,5578,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
3345,1079936,1,1,,103164817,5578,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
3346,1079937,1,1,,103164817,5578,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
3347,1079938,1,1,,103164817,5578,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
3348,1079939,1,1,,103164817,5578,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
3349,1079940,1,1,,103164817,5578,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
3350,1079941,1,1,,103164817,5578,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
3351,1079942,1,1,,103164817,5578,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
3352,1079943,1,1,,103164817,5578,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
3353,1079944,1,1,,103164817,5578,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
3354,1079945,1,1,,103164817,5578,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
3355,1079946,1,1,,103164817,5578,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
3356,1079947,1,1,,103164817,5578,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
3357,1079948,1,1,,103164817,5578,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
3358,1079949,1,1,,103164817,5578,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
3359,1084654,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida parapsilosis NRRL Y-12969 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3360,1084655,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida zeylanoides NRRL Y-1774 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3361,1084656,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Pichia kudriavzevii NRRL Y-7179 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3362,1084657,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida tropicalis NRRL Y-12968 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3363,1084658,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Cyberlindnera jadinii NRRL Y-900 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3364,1084659,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida glabrata clinical isolate after 24 to 48 hr by CLSI broth microdilution method,Other,,
3365,1084660,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida glabrata ATCC 36583 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3366,1084661,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida albicans clinical isolate after 24 to 48 hr by CLSI broth microdilution method,Other,,
3367,1084662,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida albicans NRRL Y-27077 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3368,1084663,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3369,1084664,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3370,1084665,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3371,1084666,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Salmonella enterica subsp. enterica serovar Typhimurium NRRL B-4420 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3372,1084667,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Proteus vulgaris NRLL B-123 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3373,1084668,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3374,1084669,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 35218 after 24 to 48 hr by CLSI broth microdilution method,Other,,
3375,1091955,1,2,,103164817,5578,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
3376,1091956,1,1,,103164817,5578,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
3377,1091957,1,1,,103164817,5578,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
3378,1091958,2,1,,103164817,5578,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
3379,1094318,2,3,,103164817,5578,Unspecified,118992.0,1719.0,890.0,IC50,Inhibition of Homo sapiens (human) dihydrofolate reductase using dihydrofolate as substrate incubated for 5 min prior to substrate addition by spectrophotometric assay,Confirmatory,,
3380,1094318,2,3,,103164817,5578,Unspecified,118992.0,573971.0,890.0,IC50,Inhibition of Homo sapiens (human) dihydrofolate reductase using dihydrofolate as substrate incubated for 5 min prior to substrate addition by spectrophotometric assay,Confirmatory,,
3381,1094319,2,3,,103164817,5578,Active,74766996.0,,4.0,IC50,Inhibition of Cryptosporidium parvum recombinant DHFR using dihydrofolate as substrate incubated for 5 min prior to substrate addition by spectrophotometric assay,Confirmatory,,
3382,1106508,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3383,1106509,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 11778 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3384,1106510,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3385,1106511,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3386,1106512,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 90028 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3387,1106514,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3388,1106515,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3389,1106516,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae ATCC 13883 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3390,1106517,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterobacter aerogenes ATCC 13048 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3391,1106518,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pseudomonas fluorescens ATCC 49838 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3392,1106519,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 12228 at 30 ug/disk after 18 to 24 hr by disk diffusion method,Other,,
3393,1106531,1,2,,103164817,5578,Unspecified,,,,,Antifungal activity against Candida albicans ATCC 90028 after 18 to 24 hr by broth microdilution method,Other,,
3394,1106532,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 18 to 24 hr by broth microdilution method,Other,,
3395,1106533,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hr by broth microdilution method,Other,,
3396,1106534,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 18 to 24 hr by broth microdilution method,Other,,
3397,1106535,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pseudomonas fluorescens ATCC 49838 after 18 to 24 hr by broth microdilution method,Other,,
3398,1106536,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterobacter aerogenes ATCC 13048 after 18 to 24 hr by broth microdilution method,Other,,
3399,1106537,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus epidermidis ATCC 12228 after 18 to 24 hr by broth microdilution method,Other,,
3400,1106538,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Bacillus subtilis ATCC 6633 after 18 to 24 hr by broth microdilution method,Other,,
3401,1106539,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Enterococcus faecalis ATCC 29212 after 18 to 24 hr by broth microdilution method,Other,,
3402,1106540,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Bacillus cereus ATCC 11778 after 18 to 24 hr by broth microdilution method,Other,,
3403,1106541,1,2,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus ATCC 25923 after 18 to 24 hr by broth microdilution method,Other,,
3404,1117298,1,2,,170464633,5578,Inactive,,,1.4125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
3405,1117301,1,2,,170464633,5578,Inactive,,,7.9433,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
3406,1117302,1,2,,170464633,5578,Inactive,,,3.5481,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
3407,1117303,1,2,,170464633,5578,Inactive,,,8.92,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
3408,1117304,1,2,,170464633,5578,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
3409,1117305,1,2,,170464633,5578,Unspecified,,,,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
3410,1117310,1,1,,170464633,5578,Inactive,,,1.41254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
3411,1117311,1,1,,170464633,5578,Inactive,,,7.943280000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
3412,1117312,1,1,,170464633,5578,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
3413,1117314,1,1,,170464633,5578,Inactive,,,,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
3414,1117315,1,1,,170464633,5578,Inactive,,,3.5481300000000005,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
3415,1117318,1,1,,170464633,5578,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
3416,1117319,1,2,,857743,5578,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3417,1117319,1,2,,857743,5578,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
3418,1117326,1,1,,170464633,5578,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
3419,1117329,1,1,,170464633,5578,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
3420,1117336,1,1,,170464633,5578,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
3421,1117340,1,1,,170464633,5578,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
3422,1117341,1,1,,170464633,5578,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
3423,1117342,1,1,,170464633,5578,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
3424,1117343,1,1,,170464633,5578,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
3425,1117346,1,1,,170464633,5578,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
3426,1117358,1,2,,857743,5578,Inactive,,,,CC50,A cell based assay for assessing vero cell cytotoxicity of Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G,Confirmatory,,
3427,1117361,1,1,,857743,5578,Inactive,9629358.0,155871.0,,Average IC50,An HIV-1 Tat-TAR Fluorescence Polarization (FP) Counter Screen to evaluate Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G,Confirmatory,,
3428,1117362,1,2,,857743,5578,Inactive,1389744.0,,,Average IC50,A TR-FRET Counter Screen assay to evaluate Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G,Confirmatory,,
3429,1121843,1,1,,103164817,5578,Unspecified,,,77.0,IC50,Inhibition of Bacillus anthracis DHFR,Confirmatory,,
3430,1121844,3,2,,103164817,5578,Active,1169444.0,,41.0,IC50,Inhibition of Candida albicans DHFR,Confirmatory,,
3431,1121845,3,1,,103164817,5578,Active,,,7.0,IC50,Inhibition of Candida glabrata DHFR,Confirmatory,,
3432,1121846,1,1,,103164817,5578,Active,,,14.0,IC50,Inhibition of Cryptosporidium hominis DHFR,Confirmatory,,
3433,1121847,1,3,,103164817,5578,Active,60392215.0,28380994.0,0.023,IC50,Inhibition of methicillin-resistant Staphylococcus aureus DHFR,Confirmatory,,
3434,1121848,1,1,,103164817,5578,Active,,,1.7,IC50,Inhibition of methicillin-resistant Staphylococcus aureus DHFR F98Y mutant,Confirmatory,,
3435,1121849,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus,Other,,
3436,1121850,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Bactrim-resistant Staphylococcus aureus,Other,,
3437,1121851,1,1,,103164817,5578,Unspecified,,,,,Ratio of IC50 for methicillin-resistant Staphylococcus aureus DHFR F98Y mutant to IC50 for methicillin-resistant Staphylococcus aureus DHFR,Other,,
3438,1124510,1,3,,103164817,5578,Unspecified,109940075.0,508809.0,,,Inhibition of bovine liver dihydrofolate reductase using dihydrofolic acid as substrate,Other,458817.0,
3439,1134796,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus faecalis MGH2 assessed as growth inhibition by Gradient plate test,Other,97382.0,
3440,1134797,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus UC-76 assessed as growth inhibition by Gradient plate test,Other,97382.0,
3441,1134798,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against drug-resistant Staphylococcus aureus S18713 assessed as growth inhibition by Gradient plate test,Other,97382.0,
3442,1134799,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against Pseudomonas aeruginosa 28 by Gradient plate test,Other,97382.0,
3443,1134800,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against Escherichia coli Vogel by Gradient plate test,Other,97382.0,
3444,1134801,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against Shigella sonnei C-10 by Gradient plate test,Other,97382.0,
3445,1135029,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus faecalis MGH-2 assessed as growth inhibition,Other,117107.0,
3446,1135030,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus UC-76 assessed as growth inhibition,Other,117107.0,
3447,1135031,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus S18713 assessed as growth inhibition,Other,117107.0,
3448,1135032,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa 28 assessed as growth inhibition,Other,117107.0,
3449,1135033,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli Vogel assessed as growth inhibition,Other,117107.0,
3450,1135034,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella sonnei C-10 assessed as growth inhibition,Other,117107.0,
3451,1135035,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition,Other,117107.0,
3452,1143953,1,1,,103164817,5578,Unspecified,,,,,Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as daily dose required to suppression of 90% parasite infection administered with diet for 6 days,Other,102792.0,
3453,1143954,1,1,,103164817,5578,Unspecified,,,,,Ratio of quinine hydrochloride SD90 to compound SD90 for trophozoite-induced Plasmodium berghei infected in mouse assessed as daily dose required to suppression of 90% parasite infection administered with diet for 6 days,Other,102792.0,
3454,1144021,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Streptococcus faecalis MGH-2 by gradient plate test,Other,102792.0,
3455,1144022,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Staphylococcus aureus UC-96 by gradient plate test,Other,102792.0,
3456,1144023,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against drug-resistant Staphylococcus aureus S18713 by gradient plate test,Other,102792.0,
3457,1144024,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Pseudomonas aeruginosa 28 by gradient plate test,Other,102792.0,
3458,1144025,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Escherichia coli Vogel by gradient plate test,Other,102792.0,
3459,1144026,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Shigella sonnei C-10 by gradient plate test,Other,102792.0,
3460,1144027,1,1,,103164817,5578,Unspecified,,,,,Antibacterial activity against Mycobacterium tuberculosis H37Ra by gradient plate test,Other,102792.0,
3461,1145671,1,1,,103164817,5578,Active,,,0.08,IC50,Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth,Confirmatory,137981.0,
3462,1145672,1,1,,103164817,5578,Active,,,1.2,IC50,Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth,Confirmatory,137981.0,
3463,1145673,1,1,,103164817,5578,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 to IC50 for sensitive Streptococcus faecium ATCC 8043",Other,137981.0,
3464,1145674,1,1,,103164817,5578,Active,,,0.19,IC50,Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction,Confirmatory,137981.0,
3465,1145675,1,1,,103164817,5578,Active,,,0.017,IC50,Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth,Confirmatory,137981.0,
3466,1145676,1,1,,103164817,5578,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 to IC50 for sensitive Lactobacillus casei ATCC 7469",Other,137981.0,
3467,1145677,1,1,,103164817,5578,Active,,,11.7,IC50,Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction,Confirmatory,137981.0,
3468,1145678,1,1,,103164817,5578,Unspecified,,,67.5,IC50,Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth,Confirmatory,137981.0,
3469,1145679,1,1,,103164817,5578,Unspecified,,,,,"Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 to IC50 for sensitive Pediococcus cerevisiae ATCC 808",Other,137981.0,
3470,1145680,1,1,,103164817,5578,Active,,,0.4,IC50,Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth,Confirmatory,137981.0,
3471,1145681,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid,Other,137981.0,
3472,1145682,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid,Other,137981.0,
3473,1145683,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid,Other,137981.0,
3474,1145684,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid,Other,137981.0,
3475,1145685,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid,Other,137981.0,
3476,1145686,1,1,,103164817,5578,Inactive,,,,,Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid,Other,137981.0,
3477,1145687,1,1,,103164817,5578,Active,,,,,Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth in presence of p-aminobenzoic acid,Other,137981.0,
3478,1145688,1,1,,103164817,5578,Unspecified,,,,,Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time,Other,137981.0,
3479,1145689,1,1,,103164817,5578,Unspecified,,,,,Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days,Other,137981.0,
3480,1146765,1,1,,103164817,5578,Unspecified,,,,IC50,Inhibition of Escherichia coli dihydrofolate reductase,Confirmatory,319234.0,
3481,1146766,1,3,,103164817,5578,Unspecified,60392215.0,28380994.0,,,Inhibition of Staphylococcus aureus dihydrofolate reductase,Other,319234.0,
3482,1146767,1,1,,103164817,5578,Unspecified,,,,,Inhibition of Proteus vulgaris dihydrofolate reductase,Other,319234.0,
3483,1146768,1,3,,103164817,5578,Unspecified,118992.0,1719.0,,,Inhibition of human liver dihydrofolate reductase,Other,319234.0,
3484,1146768,1,3,,103164817,5578,Unspecified,118992.0,573971.0,,,Inhibition of human liver dihydrofolate reductase,Other,319234.0,
3485,1146769,1,3,,103164817,5578,Unspecified,81871579.0,24312.0,,,Inhibition of rat liver dihydrofolate reductase,Other,319234.0,
3486,1159386,1,2,,103164817,5578,Unspecified,,,,,ASTRAZENECA: Most basic pKa value (pKa B1) determined by absorption and potentiometric titration using standard methodology from Sirius Analytical. Experimental range Bases: >= 2.,Other,,
3487,1159387,1,2,,103164817,5578,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
3488,1159389,1,2,,103164817,5578,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
3489,1159394,1,2,,103164817,5578,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
3490,1159509,1,1,,144207355,5578,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3491,1159509,1,1,,170464633,5578,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
3492,1159515,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3493,1159515,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
3494,1159516,1,1,,144207355,5578,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3495,1159516,1,1,,170464633,5578,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
3496,1159517,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3497,1159517,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
3498,1159518,1,1,,144207355,5578,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3499,1159518,1,1,,170464633,5578,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
3500,1159519,1,1,,144207355,5578,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3501,1159519,1,1,,170464633,5578,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
3502,1159520,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3503,1159520,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3504,1159521,1,1,,144207355,5578,Inconclusive,15928672.0,19885.0,0.0609,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3505,1159521,1,1,,170464633,5578,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3506,1159523,1,1,,144207355,5578,Inconclusive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3507,1159523,1,1,,170464633,5578,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
3508,1159524,1,1,,50085866,5578,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3509,1159524,1,1,,124881730,5578,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3510,1159524,1,1,,124881732,5578,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
3511,1159525,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3512,1159525,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
3513,1159526,1,1,,144207355,5578,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3514,1159526,1,1,,170464633,5578,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
3515,1159527,1,1,,144207355,5578,Inconclusive,325495497.0,6256.0,17.3335,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3516,1159527,1,1,,170464633,5578,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
3517,1159528,1,1,,144207355,5578,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3518,1159528,1,1,,170464633,5578,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
3519,1159529,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3520,1159529,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
3521,1159531,1,1,,144207355,5578,Active,325495497.0,6256.0,29.0995,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3522,1159531,1,1,,170464633,5578,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
3523,1159550,3,1,,252401908,5578,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
3524,1159551,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3525,1159551,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
3526,1159552,1,1,,144207355,5578,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3527,1159552,1,1,,170464633,5578,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3528,1159553,2,1,,144207355,5578,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3529,1159553,2,1,,170464633,5578,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
3530,1159555,1,1,,144207355,5578,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3531,1159555,1,1,,170464633,5578,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
3532,1159580,2,1,,268734744,5578,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3533,1159580,2,1,,273003048,5578,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
3534,1159583,2,1,,178126539,5578,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
3535,1159585,1,2,,307068470,5578,Inactive,124801388.0,812762.0,,CDPK1_IC50_uM,Biochemical screen of P. falciparum CDPK1,Confirmatory,26934697.0,
3536,1159586,1,2,,307068470,5578,Inactive,124513486.0,813740.0,,PK6_IC50_uM,Biochemical screen of P. falciparum PK6,Confirmatory,26934697.0,
3537,1159587,1,2,,307068470,5578,Inactive,124801229.0,812721.0,,PK7_IC50_uM,Biochemical screen of P. falciparum PK7,Confirmatory,26934697.0,
3538,1159588,1,2,,307068470,5578,Inactive,124511890.0,2655116.0,,CDPK4_IC50_uM,Biochemical screen of P. falciparum CDPK4,Confirmatory,26934697.0,
3539,1159589,1,2,,307068470,5578,Inactive,124803797.0,810694.0,,,Biochemical screen of P. falciparum MAPK2,Other,26934697.0,
3540,1159606,1,1,,50085866,5578,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
3541,1159607,2,1,,312309736,5578,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
3542,1159614,1,2,,170464633,5578,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
3543,1159620,1,1,,103164817,5578,Active,,,,,Summary of drug indications.,Other,,
3544,1172026,1,1,,103164817,5578,Unspecified,,,,,Antimicrobial activity against Bacillus anthracis assessed as growth inhibition measured as turbidity,Other,25435253.0,
3545,1172027,1,1,,103164817,5578,Unspecified,,,77.233,Ki,Binding affinity to Bacillus anthracis DHFR assessed as tetrahydrofolate production,Confirmatory,25435253.0,
3546,1179551,1,2,,103164817,5578,Active,118992.0,1719.0,6e-06,Ki,Binding affinity to DHFR (unknown origin) by NMR analysis,Confirmatory,24913411.0,
3547,1179551,1,2,,103164817,5578,Active,118992.0,573971.0,6e-06,Ki,Binding affinity to DHFR (unknown origin) by NMR analysis,Confirmatory,24913411.0,
3548,1188645,1,1,,103164817,5578,Unspecified,,,,IC50,Antiparasitic activity against Toxoplasma gondii infected in human foreskin fibroblasts assessed as tachyzoite growth inhibition after 5 days by colorimetric assay,Confirmatory,25140751.0,
3549,1188646,1,1,,103164817,5578,Unspecified,,,320.0,TD50,Cytotoxicity against human foreskin fibroblasts after 5 days by colorimetric assay,Confirmatory,25140751.0,
3550,1188649,1,1,,103164817,5578,Active,,,,,Antiparasitic activity against Toxoplasma gondii infected in human foreskin fibroblasts assessed as inhibition of replication measured as decrease in the number of tachyzoites in vacuole at 10 uM after 24 hrs by fluorescence assay,Other,25140751.0,
3551,1188651,1,1,,103164817,5578,Unspecified,,,,,"Therapeutic index, ratio of TD50 for human foreskin fibroblasts to IC50 for Toxoplasma gondii infected in human foreskin fibroblasts",Other,25140751.0,
3552,1196722,1,1,,103164817,5578,Unspecified,,,,,Antiparasitic activity against promastigote form of Leishmania mexicana MHOM/BZ/61/M379 at 100 uM after 24 hrs by haemocytometer,Other,25576738.0,
3553,1196723,1,1,,103164817,5578,Unspecified,,,100.0,IC50,Antiparasitic activity against promastigote form of Leishmania mexicana MHOM/BZ/61/M379 after 24 hrs by haemocytometer,Confirmatory,25576738.0,
3554,1196724,1,1,,103164817,5578,Inconclusive,,,,,Solubility of the compound in phosphate buffered saline at pH 7.4 by UV spectrophotometry,Other,25576738.0,
3555,1196727,1,1,,103164817,5578,Unspecified,,,,,Inhibition of Leishmania mexicana MHOM/BZ/61/M379 DHFR assessed as survival at 100 uM after 1 hr,Other,25576738.0,
3556,1196728,1,1,,103164817,5578,Unspecified,,,,,Inhibition of Leishmania mexicana MHOM/BZ/61/M379 DHFR assessed as parasite survival at 100 uM after 1 hr in presence of 100 uM folic acid,Other,25576738.0,
3557,1210069,1,2,,103164817,5578,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
3558,1221956,1,1,,103164817,5578,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3559,1221957,1,1,,103164817,5578,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3560,1221958,1,1,,103164817,5578,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
3561,1221960,1,1,,103164817,5578,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3562,1221961,1,1,,103164817,5578,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3563,1221962,1,1,,103164817,5578,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3564,1221963,1,1,,103164817,5578,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3565,1221964,1,1,,103164817,5578,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3566,1221965,1,1,,103164817,5578,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
3567,1221982,1,1,,103164817,5578,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
3568,1224818,1,1,,312345394,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
3569,1224819,1,1,,312345394,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3570,1224820,1,1,,312345394,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
3571,1224821,1,1,,312345394,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3572,1224822,1,1,,312345394,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
3573,1224823,1,1,,312345394,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
3574,1224834,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3575,1224834,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
3576,1224835,1,1,,144207355,5578,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3577,1224835,1,1,,170464633,5578,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
3578,1224836,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3579,1224836,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3580,1224837,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3581,1224837,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3582,1224838,1,1,,144207355,5578,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3583,1224838,1,1,,170464633,5578,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3584,1224839,1,1,,144207355,5578,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3585,1224839,1,1,,170464633,5578,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3586,1224840,3,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3587,1224840,3,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3588,1224841,3,1,,144207355,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3589,1224841,3,1,,170464633,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3590,1224842,3,1,,144207355,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3591,1224842,3,1,,170464633,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3592,1224843,1,1,,144207355,5578,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3593,1224843,1,1,,170464633,5578,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3594,1224844,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3595,1224844,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3596,1224845,1,1,,144207355,5578,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3597,1224845,1,1,,170464633,5578,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3598,1224846,1,1,,144207355,5578,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3599,1224846,1,1,,170464633,5578,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3600,1224847,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3601,1224847,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3602,1224848,3,1,,144207355,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3603,1224848,3,1,,170464633,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3604,1224849,3,1,,144207355,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3605,1224849,3,1,,170464633,5578,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3606,1224857,2,1,,170464633,5578,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3607,1224857,2,1,,312345394,5578,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3608,1224859,2,1,,90340764,5578,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3609,1224859,2,1,,170464633,5578,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3610,1224863,1,1,,176484496,5578,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3611,1224863,1,1,,316919924,5578,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3612,1224864,1,2,,316935303,5578,Inactive,,,,,HCS microscopy assay (F508del-CFTR),Screening,27732613.0,
3613,1224865,1,2,,50085866,5578,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3614,1224867,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3615,1224867,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3616,1224868,1,1,,144207355,5578,Inconclusive,,,48.8524,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3617,1224868,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3618,1224869,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3619,1224869,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3620,1224870,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3621,1224870,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3622,1224871,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3623,1224871,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3624,1224872,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3625,1224872,1,1,,170464633,5578,Inconclusive,,,6.007000000000001,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3626,1224873,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3627,1224873,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3628,1224874,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3629,1224874,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3630,1224875,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3631,1224875,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3632,1224876,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3633,1224876,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3634,1224877,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3635,1224877,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3636,1224878,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3637,1224878,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3638,1224879,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3639,1224879,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3640,1224880,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3641,1224880,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3642,1224881,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3643,1224881,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3644,1224882,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3645,1224882,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3646,1224883,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3647,1224883,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3648,1224884,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3649,1224884,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3650,1224885,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3651,1224885,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3652,1224886,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3653,1224886,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3654,1224887,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3655,1224887,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3656,1224888,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3657,1224888,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3658,1224889,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3659,1224889,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3660,1224890,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3661,1224890,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3662,1224892,1,1,,144207355,5578,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3663,1224892,1,1,,170464633,5578,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3664,1224893,1,1,,144207355,5578,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3665,1224893,1,1,,170464633,5578,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3666,1224894,1,1,,144207355,5578,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3667,1224894,1,1,,170464633,5578,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3668,1224895,1,1,,144207355,5578,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3669,1224895,1,1,,170464633,5578,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3670,1224896,1,1,,144207355,5578,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3671,1224896,1,1,,170464633,5578,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3672,1224905,2,1,,92309070,5578,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3673,1224905,2,1,,92309070,5578,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3674,1224905,2,1,,121362068,5578,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3675,1224905,2,1,,121362068,5578,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3676,1259241,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3677,1259241,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3678,1259242,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3679,1259242,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3680,1259243,1,1,,144207355,5578,Inactive,124375976.0,367.0,10.8376,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3681,1259243,1,1,,170464633,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3682,1259244,1,1,,144207355,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3683,1259244,1,1,,170464633,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3684,1259247,1,1,,144207355,5578,Inconclusive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3685,1259247,1,1,,170464633,5578,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3686,1259248,1,1,,144207355,5578,Inconclusive,348019627.0,2099.0,48.4096,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3687,1259248,1,1,,170464633,5578,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3688,1259309,1,1,,178126539,5578,Active,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3689,1259310,1,1,,104169981,5578,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3690,1259310,1,1,,321942605,5578,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3691,1259310,1,1,,332949315,5578,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3692,1259310,1,1,,332949802,5578,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3693,1259310,1,1,,332949871,5578,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3694,1259311,1,1,,178126539,5578,Active,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3695,1259313,1,1,,50085866,5578,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3696,1259318,1,1,,50085866,5578,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3697,1259325,1,2,,336954038,5578,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3698,1259344,1,1,,144203842,5578,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3699,1259354,1,1,,348438299,5578,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
3700,1259355,1,1,,17389524,5578,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3701,1259356,1,1,,144203842,5578,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3702,1259364,1,1,,144207355,5578,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3703,1259364,1,1,,170464633,5578,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3704,1259365,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3705,1259365,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3706,1259366,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3707,1259366,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3708,1259367,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3709,1259367,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3710,1259368,1,1,,144207355,5578,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3711,1259368,1,1,,170464633,5578,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3712,1259369,1,1,,144207355,5578,Inconclusive,109731339.0,2737.0,15.3085,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3713,1259369,1,1,,170464633,5578,Inactive,109731339.0,2737.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3714,1259370,2,2,,124638149,5578,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3715,1259370,2,2,,124638149,5578,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3716,1259370,2,2,,124638149,5578,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
3717,1259377,1,1,,144207355,5578,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3718,1259377,1,1,,170464633,5578,Inconclusive,54288833.0,2100.0,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3719,1259378,1,1,,144207355,5578,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3720,1259378,1,1,,170464633,5578,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3721,1259379,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3722,1259379,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3723,1259380,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3724,1259380,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3725,1259381,1,1,,144207355,5578,Active,124375976.0,367.0,9.658999999999999,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3726,1259381,1,1,,170464633,5578,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3727,1259382,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3728,1259382,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3729,1259383,1,1,,144207355,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3730,1259383,1,1,,170464633,5578,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3731,1259384,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3732,1259384,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3733,1259385,1,1,,144207355,5578,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3734,1259385,1,1,,170464633,5578,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3735,1259386,1,1,,144207355,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3736,1259386,1,1,,170464633,5578,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3737,1259387,1,1,,144207355,5578,Inconclusive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3738,1259387,1,1,,170464633,5578,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3739,1259388,1,1,,144207355,5578,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3740,1259388,1,1,,170464633,5578,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3741,1259389,1,1,,124638149,5578,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
3742,1259390,1,1,,144207355,5578,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3743,1259390,1,1,,170464633,5578,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3744,1259391,1,1,,144207355,5578,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3745,1259391,1,1,,170464633,5578,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3746,1259392,1,1,,144207355,5578,Active,109731339.0,2737.0,17.1764,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3747,1259392,1,1,,170464633,5578,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3748,1259393,1,1,,144207355,5578,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3749,1259393,1,1,,170464633,5578,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3750,1259394,1,1,,144207355,5578,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3751,1259394,1,1,,170464633,5578,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3752,1259395,1,1,,144207355,5578,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3753,1259395,1,1,,170464633,5578,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3754,1259396,1,1,,144207355,5578,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3755,1259396,1,1,,170464633,5578,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3756,1259400,1,1,,170464633,5578,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3757,1259401,1,1,,144207355,5578,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3758,1259401,1,1,,170464633,5578,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3759,1259402,1,1,,144207355,5578,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3760,1259402,1,1,,170464633,5578,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3761,1259403,1,1,,144207355,5578,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3762,1259403,1,1,,170464633,5578,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3763,1259404,1,1,,144207355,5578,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3764,1259404,1,1,,170464633,5578,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3765,1259406,1,1,,363920353,5578,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3766,1259406,1,1,1.0,363920353,5578,Inactive,26638650.0,3778.0,0.00407191,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3767,1259406,1,1,2.0,363920353,5578,Inactive,4758626.0,3779.0,0.0570229,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3768,1259406,1,1,3.0,363920353,5578,Inactive,5031823.0,10242.0,-0.0234827,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3769,1259406,1,1,4.0,363920353,5578,Inactive,26051275.0,27345.0,0.0143315,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3770,1259406,1,1,5.0,363920353,5578,Inactive,160410009.0,389816.0,-0.00393423,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3771,1259406,1,1,6.0,363920353,5578,Inactive,26638650.0,3778.0,0.00151305,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3772,1259406,1,1,7.0,363920353,5578,Inactive,4758626.0,3779.0,-0.050962,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3773,1259406,1,1,8.0,363920353,5578,Inactive,5031823.0,10242.0,-0.032125,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3774,1259406,1,1,9.0,363920353,5578,Inactive,26051275.0,27345.0,0.00256344,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3775,1259406,1,1,10.0,363920353,5578,Inactive,5031823.0,10242.0,0.00875768,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3776,1259407,1,1,,363900360,5578,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3777,1259408,1,1,,363895874,5578,Active,,,,,GENE-TOX mutagenicity studies,Other,,
3778,1259413,1,2,,104169981,5578,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
3779,1259415,1,1,,50085866,5578,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3780,1259416,1,2,,857743,5578,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3781,1259416,1,2,,340080720,5578,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3782,1259421,1,1,,340080720,5578,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3783,1259423,1,2,,354767547,5578,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3784,1259423,1,2,,354810323,5578,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3785,1259423,1,2,,354978391,5578,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
3786,1259423,1,2,,355025653,5578,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
